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[I] 
 
Abstract 
 
Arthrogryposis, renal dysfunction and cholestasis (ARC) syndrome is a severe multisystem 
disorder caused by mutations in VPS33B and VIPAR. A splice site mutation, VPS33B 
c.1225+5 G>C, was identified in a patient with attenuated ARC phenotype. Modelling of this 
mutation and missense mutations indicated that VPS33B-VIPAR interaction and co-
localisation at recycling-endosome like structures is necessary for their function.  
Development of a murine ARC model began with ubiquitous removal of Vps33b, and in 
parallel, its homologue Vps33a. Both resulted in embryonic lethality between E7.5 and E8.5. 
A good ARC phenocopy was obtained the liver specific Vps33b knockout, Vps33bfl/fl-
AlpfCre. Bile acid levels were increased in comparison to control and the apical proteins CEA 
and BSEP were mislocalised, with the distribution similar to that in ARC livers. In contrast, a 
Vps33bfl/fl-Pf4Cre mouse did not result in a good ARC platelet phenocopy, with α-granules 
found present. They did however present with a mild platelet phenotype, with defects in stable 
aggregate formation under shear conditions and deficiencies in the α-granule proteins VWF 
and PF4, giving possible insights into the bleeding diathesis in patients.  
In conclusion, this work has produced suitable ARC models for further study of Vps33b 
function and provides a platform for the future development of gene therapy and drug 
treatments. 
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CHAPTER 1 - INTRODUCTION 
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1.1 ARC syndrome 
Arthrogryposis, Renal dysfunction and Cholestasis (ARC) syndrome (MIM 208085) is an 
autosomal recessive multisystem disorder caused by mutations in VPS33B (Vacuolar Protein 
Sorting-associated protein 33B) and VIPAR (VPS33B Interacting Protein, Apical-basolateral 
polarity Regulator)(Gissen et al. 2004)(Cullinane et al. 2010). The first cases of ARC 
syndrome were reported in 1973 and 1979 by Lutz-Richner and Landolt, and Nezelof et al. 
(Lutz-Richner & Landolt 1973)(Nezelof et al. 1979). ARC syndrome patients 
characteristically present with neonatal cholestatic jaundice, renal tubular acidosis, variable 
degree of joint contractures and a severe failure to thrive (Gissen et al. 2006). Most patients 
fail to survive past the first year of life despite medical intervention as a result of recurrent 
infections leading to dehydration and acidosis (Abu-Sa’da et al. 2005). Other features include 
ichthyosis- dry scaly or flaky skin, a platelet α-granule storage defect (Deal et al. 1990) and 
mild dysmorphic features such as large hands, low set ears and sloping forehead. Corpus 
callosum dysgenesis (at least 20%), cardiac defects and deafness have also been reported 
(Gissen et al. 2006).  
 
1.2 VPS33B and VIPAR 
Mutations in VPS33B and VIPAR have been found to be causative for ARC syndrome (Gissen 
et al. 2004)(Cullinane et al. 2010). VPS33B is a 617 amino acid protein containing a Sec1-
like domain spanning the entire protein (Carim et al. 2000).  It is a member of the 
Sec1/Munc18 (SM) family of proteins, which are known to directly interact with SNAREs 
(Soluble NSF Attachment protein Receptors) and aid SNARE complex formation leading to 
tethering and fusion of organellar membranes (Gallwitz & Reinhard Jahn 2003). 
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VIPAR has 2 protein coding sequences within the Consensus CoDing Sequences (CCDS) 
database (http://www.ncbi.nlm.nih.gov/CCDS/CcdsBrowse), resulting in proteins of 480 or 
493 amino acids in size, and contains a golgin A5 domain in the C-terminal domain identified 
using the Pfam database. Golgins were originally identified as golgi-localised proteins 
(Fritzler et al. 1993) which contain a shared rod-like motif containing long coiled-coil regions 
(Burkhard et al. 2001). They are responsible for structural support of the golgi cisternae and 
have also been shown to be involved in membrane tethering (Barr & Short 2003). They are 
proposed to allow the movement of vesicles through the golgi by a series of tethering and 
release events (Sinka et al. 2008). They carry out this function by interacting with Rabs 
(Hayes et al. 2009)(Yu & Hughson 2010), small GTPases involved in intracellular trafficking, 
discussed in section 1.6.5. 
In ARC syndrome it has been found that apical proteins in polarised epithelial cells, such as 
Bile Salt Exporter Pump (BSEP) and CarcinoEmbryonic Antigen (CEA) within hepatocytes, 
are mislocalised (Gissen et al. 2004)(Cullinane et al. 2010). Additionally, further defects 
involved in cell polarity have been identified. In order to understand why in ARC syndrome a 
deficiency in VPS33B or VIPAR may cause the phenotype observed, and how it is the hope 
to determine this by developing a model organism, cell polarity and protein trafficking must 
first be understood. 
	  
1.3 Cell polarity 
Cell polarity is the ability of cells to maintain an asymmetric distribution of molecules in 
order to confine specific activities to distinct areas of the cell (Carmosino et al. 2010). For 
example, in the liver it is necessary for hepatocytes to be polarised in order to produce and 
excrete bile. The apical membrane forms the bile canaliculi and is modified specifically for 
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bile constituent excretion. The lateral surfaces contact one another forming junctional 
complexes (adherens and tight) to provide a barrier between the blood and bile, and the basal 
membrane contacts the blood for uptake of many different molecules such as cholesterol, 
removal of which is required to prevent accumulation of cholesterol in the body and to 
produce bile. 
Within polarised cells there exists two planes of polarisation (figure 1.1), planar cell polarity 
(Axelrod 2009) not discussed here, and perpendicular to this, apical-basolateral polarity. 
There are complex mechanisms responsible for establishment of apical-basolateral cell 
polarity, and many layers of regulation are required. Proteins must be correctly targeted to the 
relevant membrane within specific vesicles, the membrane domains must be defined in order 
for the vesicles to reach their destination, and extrinsic cues must be received in order for the 
cell to be orientated in the correct manner (Mellman & Nelson 2008).  
 
1.4 Protein Transport 
Transport of proteins through the epithelial cell requires careful regulation in order for the cell 
to function correctly and maintain apical-basolateral polarity. Major breakthroughs in protein 
transport were made by George E. Palade for which he received a Nobel Prize in 1974 (Palade 
1975). The aim of his work was to identify and discern the function of the tiny structures 
within cells. Palade developed an in vivo autoradiographic technique suitable for electron 
microscopy (EM) (Caro & Palade 1964). The synthesis, intracellular transport, storage and 
secretion of proteins in the guinea pig was studied by injecting a DL-leucine-4,5-H3 label, 
which was integrated into newly synthesised proteins. By fixing the pancreas at time-points  
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Figure 1.1 Planes of polarisation and an overview of protein trafficking in polarised 
epithelial cells  
There exists 2 planes of polarisation within an epithelial cell, planar and apical-basolateral 
polarity.  
Newly synthesised proteins undergo folding in the endoplasmic reticulum (ER), and are 
transported to the trans-Golgi network (TGN) where post-translational modifications occur. 
From the TGN proteins may be trafficked directly to apical and basolateral surfaces (blue 
arrows), sorted to the correct membrane in common recycling endosomes (CRE), or undergo 
transcytosis from the basolateral to apical surfaces (purple arrows). Proteins destined for 
degradation traffic through early and late endosomes (EE and LE) to the lysosomes (Lys) 
Adapted from (Schuck & Simons 2004) 
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ranging from 5 minutes to 15 hours, protein progression through the pancreatic exocrine cells 
was observed. This work led to a model of the secretory process, which holds strong today. 
Along with work from other groups organelles and vesicles involved in protein transport 
within polarised cell have been characterised (figure 1.1).   
 
1.5 Protein Sorting 
Within cells there are 3 major sites of protein sorting: the golgi, endosomes and the plasma 
membrane (PM)(Mellman & Nelson 2008). Intermediate vesicles which allow transport 
between these structures are formed by Coatomer Protein Complex-I (COPI) and Coatomer 
Protein Complex-II (COPII) originally identified in yeast, responsible for golgi-ER and ER-
golgi transport respectively (Novick et al. 1980)(Hosobuchi et al. 1992)(Lee et al. 2004). 
Additionally, the Adaptor Protein (AP)-clathrin complexes, first identified in 1969 in guinea 
pig brain synaptosomes (Kanaseki & Kadota 1969), are a major component of protein sorting 
responsible for transport between golgi, endosomes and plasma membrane. These coat 
proteins are recruited to the donor membrane, select specific cargo for the vesicle and form a 
scaffold which allows the vesicles to bud from the donor membrane, the coat is then shed 
(Robinson 2004). The complexes are ubiquitous to all cells, however polarised cells have 
further adapted to allow sorting of proteins to different membrane domains. One adaptor 
protein, AP-1B, identified within polarised cells is definitively involved in the sorting of 
proteins to the basolateral membrane (Ohno et al. 1999).  
AP-complexes are heterotetramers and together with other proteins recognise and bind 
specific protein motifs allowing the sorting and correct targeting of proteins. There have been 
4 AP-complexes identified to date, AP-1 to AP-4.  AP complexes 1-4 are composed of 2 large  
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subunits (γ, α, δ, and ε respectively) and β1-4, a medium-sized µ subunit and a small σ subunit 
(Robinson & Bonifacino 2001). The AP complex subunits are collectively known as adaptins. 
The µ adaptin subunits promote protein sorting by binding to tyrosine-based or di-leucine 
based peptide sorting motifs (Nakatsu & Ohno 2003).  
AP-1B an epithelial cell-specific variant of AP-1 contains a µ1B subunit in the place of the 
ubiquitous µ1A subunit. In the first study carried out to determine the role of AP-1B, porcine 
kidney epithelial (LLC-PK1) cells were used as they do not express the subunit µ1B (Fölsch 
et al. 1999). It was found that Low Density Lipoprotein Receptor (LDLR) was localised in the 
apical membrane in these cells but in the basolateral membrane in Madin Darby Canine 
Kidney (MDCK) cells. When µ1B was stably introduced into the LLC-PK1 cells, LDLR 
localisation was then restricted to the basolateral membrane. The same observation was made 
with the transferrin receptor, another basolateral PM protein, indicating that AP-1B plays a 
critical role in the targeting of proteins to the basolateral membrane (Fölsch et al. 1999). An 
AP-1B deficient mouse was created by the knockout of Ap1m2. This mouse developed 
spontaneous chronic colitis and was found to have defects in trafficking of cytokine receptors 
in the gut epithelial cells, with them being mistargeted to the apical instead of the basolateral 
membrane (Takahashi et al. 2011), thus supporting results from studies using cell lines. 
Hepatocytes do not express the epithelial specific variant of AP-1 in higher mammals, instead 
appearing to sort their proteins at multivesicular bodies and the basolateral membrane rather 
than the TGN, adding an extra layer of complexity to the understanding of apical-basolateral 
polarity establishment and maintenance (Matter & Mellman 1994)(Ohno et al. 1999).  
Mutations in AP-3 have been found to cause Hermansky Pudlak Syndrome (HPS), a rare 
autosomal recessive disorder characterised by oculocutaneous albinism and bleeding problems 
due to a dense granule storage disease (Dell’Angelica et al. 1999) discussed in section 1.11.3. 
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AP-3 has also been found to interact with HOmotypic Protein Sorting (HOPS) complex 
proteins in yeast (Angers & Merz 2009). There is ongoing debate as to whether VPS33B and 
VIPAR, deficiencies of which cause ARC syndrome, form part of the mammalian equivalent 
of the HOPS complex, discussed in section 1.6.2 and 1.9, which has also been shown to 
interact with AP-3 (Zlatic et al. 2011).  
 
1.5.1 Basolateral sorting motifs 
In 1986, Mostov et al. found that by deleting a motif on polymeric immunoglobulin-A 
receptor, the basolateral protein was mislocalised to the apical membrane (Mostov et al. 
1986). Subsequently, in 1991 they found that if this motif was transferred to apically localised 
proteins they would be mislocalised to the basolateral membrane (Casanova et al. 1991). 
Specific basolateral motifs were eventually identified and were found to be very similar to 
endocytic motifs (Weisz & Rodriguez-Boulan 2009). Motifs recognised by clathrin adapters 
and AP-complexes include tyrosine, leucine or di-leucine based sorting motifs found on 
cytoplasmically exposed regions (Fölsch et al. 2009). Basolateral sorting signals are normally 
dominant over apical sorting signals (Matter & Mellman 1994), therefore in most cases a 
basolateral signal must be absent in order for proteins to be trafficked apically. 
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1.5.2 Apical sorting motifs 
Apical sorting is complex and has proven more difficult to elucidate than basolateral sorting. 
Proteins are either trafficked directly (vectorial route) to the apical membrane (Weisz & 
Rodriguez-Boulan 2009), or indirectly via the basolateral membrane (transcytotic route) 
(Bonilha et al. 1997). Apical sorting signals may be contained within any of the domains of 
the protein; cytoplasmic, membrane or luminal domains and the sorting signal within the 
protein is contributed to by the lipid, carbohydrate or protein components (Fölsch et al. 2009). 
Examples of known apical sorting signals include O- and N- glycans, which are added post-
translationally to the extracellular domains of proteins. They are important in targeting of 
these proteins to the apical membrane (Vagin et al. 2009). For example, the removal of N-
glycans from BSEP significantly decreased its abundance within the apical membrane 
(Mochizuki et al. 2007). Also, the addition of N-glycans to endoplasmic reticulum (ER)- or 
basolaterally-localised proteins was shown to redistribute the modified proteins to the apical 
membrane (Vagin et al. 2009).  A second group of apical targeting signals first characterised 
in the 1980’s by Ferguson and Williams (Ferguson & Williams 1988) is the 
GlycosylPhosphatidyl-Inositol (GPI) anchor. It is a post-translational modification, located at 
the C-terminus of proteins (Paulick & Bertozzi 2008). This modification anchors proteins to 
the outer leaflet of the plasma membrane, and since many GPI-anchored proteins are apically 
located it has been proposed as an apical-targeting signal.  Addition of this modification onto 
secreted proteins resulted in an apical localisation (Lisanti et al. 1989). 
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1.5.3 PDZ motif 
In addition to apical and basolateral sorting signals contained within proteins, there are also 
components which allow retention within the membrane. PDZ proteins (their name deriving 
from the first three proteins in which this domain was identified; postsynaptic density protein 
PSD-95/SAP-90, Disc-large DLG and zona occludens ZO-1 (Kennedy 1995)) anchored at the 
target membrane contain PDZ domains. These domains recognise 5 amino acid motifs usually 
found at the C-terminus of proteins destined for the apical or basolateral membrane (Brône & 
Eggermont 2005). Interaction of the PDZ protein with the 5 amino acid motif allows the 
trafficked protein to be retained at the target membrane. PDZ proteins may be specifically 
located at the apical or basolateral membrane, for example the PDZ protein, Na+/H+ 
exchanger regulatory factors-1 (NHERF-1), is located at the apical brush-border of epithelial 
cells and affects membrane expression and localisation of its interacting proteins including a 
wide range of ion channels and transporters such as Npt2 (Brône & Eggermont 2005). In 
NHERF-1-/- mice, Npt2, normally apically located in renal proximal tubule cells, is instead 
found in intracellular vesicles reducing expression in the membrane resulting in a phosphate 
wasting phenotype (Shenolikar et al. 2002).  
 
1.6 Fusion of vesicles to the correct membrane 
Sorting of apical and basolateral membrane proteins into vesicles at the TGN and the 
recycling endosome is the first step necessary to get proteins to their target membrane. The 
vesicles must be coupled to a movement mechanism, to physically transport them to their 
target membrane. In addition to this they require fusion machinery at the membrane to allow 
them to dock and fuse at the correct location. Movement is mediated by the cytoskeleton and 
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motors. Docking and fusion is mediated by tethering factors, Soluble NSF Attachment protein 
(SNAP) REceptors, SNAREs, small Rab GTPases and Sec1/Munc18 family members. 
 
1.6.1 Transport of vesicles – cytoskeleton and motor proteins 
In order to be transported throughout the cell, vesicles must rely on motor proteins to tether 
them to and transport them along the microtubules and actin filaments. In 1994 it was 
demonstrated that microtubule motors were required for both apical and basolateral transport 
within MDCK cells (Lafont et al. 1994). Previous to this it was believed that transport to the 
basolateral membranes occurred by diffusion and was microtubule and actin independent 
(Rindler et al. 1987). Cells were treated with a drug that causes depolymerisation of 
microtubules, Nocodazole, and apical and basolateral trafficking was measured by monitoring 
levels of Hemagglutinin and vesicular stomatitis virus G-protein (VSV-G) respectively. 
Transport of both was blocked by Nocodazole treatment.  
The majority of microtubules (MTs) form small oligomers (nucleate) and then rapidly extend 
from microtubule organising centres (MTOCs) and centrosomes. In non-polarised cells such 
as fibroblasts they remain anchored here (Mellman & Nelson 2008). In epithelial cells 
however, most MTs align along the apical-basolateral axis of the cell, with the slow-growing 
minus end towards the apical domain, and the fast growing plus-end towards the basolateral 
(Müsch 2004). Microtubule-based transport to both the apical and basolateral membranes is 
dependent on different motors. Kinesins typically traffic towards the fast-growing plus-end at 
the basolateral membrane, and dyneins towards the minus-end and thus target the apical 
membrane (Li & Gundersen 2008). For example, transport of rhodopsin-bearing vesicles in 
photoreceptors within the eye utilises a dynein light-chain, Tctex-1, which interacts with the 
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C-terminus of the transmembrane protein rhodopsin for trafficking to the apical membrane 
(Tai et al. 1999). 
Actin filaments have also been implicated in vesicle movement, but are shorter than 
microtubules. They are composed of G-actin monomers which polymerise in a polarised 
manner, with growth more rapid at the plus-end (Li & Gundersen 2008).  Myosins are 
involved in vesicle trafficking along actin filaments through their tail domains, and Myosin I, 
II, V and VI are the most important in trafficking within polarised epithelial cells (Durrbach et 
al. 2000)(Au et al. 2007)(Müller et al. 2008). Myosin II regulatory light chain for example 
was identified in a yeast two-hybrid screen of rat liver as a binding partner for BSEP, 
MultiDrug Resistance protein 1 (MDR1) and MultiDrug Resistance protein 2 (MDR2)– 
proteins found in the apical membrane of hepatocytes (Chan et al. 2005). It was shown that by 
blocking myosinII with Blebbistatin, a compound that stabilises myosinII in an actin detached 
state, newly synthesised BSEP appearance at the apical surface was significantly impaired, 
suggesting that myosinII is required for its trafficking to the apical membrane. 
Filamentous actin forms a sheet underneath the plasma membrane in eukaryotic cells, known 
as the actin cortex, and is dense enough to restrict vesicles from the plasma membrane. 
Capture of microtubules at the cortex, referred to as cortical capture, results in the 
stabilisation of microtubules (Li & Gundersen 2008). Proteins are present at this juncture 
which link microtubules and actin to allow vesicle transfer from one to the other and 
subsequent transport to the PM (Watanabe et al. 2004). Proteins involved include plus-end-
tracking protein (+TIPs) proteins which bind to the + ends of microtubules such as CAP-GLY 
domain containing linker protein 170 (CLIP-170), and proteins associated with the actin 
cortex such as IQ motif containing GTPase activating protein (IQGAP), an essential protein 
for cytoskeleton reorganisation (Briggs & Sacks 2003). IQGAP1 interacts directly with 
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Adenomatous Polyposis Coli (APC) linking it to the actin cortex, and together they are 
required for the formation of a complex with CLIP-170. CLIP-170 is a +TIP, and interaction 
with IQGAP1 allows the capture of microtubules providing a link between the cortical actin 
and microtubules.  
Once vesicles have been transported to the correct destination the next important step is for 
the recognition of cargo at the recipient end. A multitude of different factors are involved, 
beginning with tethering factors.  
 
1.6.2 Tethering factors 
Before vesicles come into contact with their target membrane and undergo SNARE mediated 
fusion, tethering factors may act as an initial connection and act as facilitators of membrane 
recognition (Sztul & Lupashin 2006). In vitro reconstitution of SNARE-mediated vesicle 
fusion is slow (Ohya et al. 2009) and SNARE complex assembly has been shown to be  
accelerated by tethering factors (Shorter et al. 2002). This may be due to some vesicles 
arriving with their coats intact possibly obscuring SNAREs and therefore requiring another 
mode for tethering (Zink et al. 2009). Tethers are able to interact with Rab GTPases to capture 
vesicles before SNARE action (Behnia & Munro 2005). Tethering factors fall into 2 
categories: long coiled-coil tethers and multiprotein complexes (Yu & Hughson 2010).  
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Figure 1.2 The location of tethering complexes in eukaryotic cells 
The location of multisubunit tethering complexes involved in vesicle trafficking are shown. 
CORVET- class C core vacuole/endosome tethering complex, GARP - Golgi-associated 
retrograde protein complex, HOPS- homotypic fusion and vacuole protein sorting (or class C 
vacuolar protein sorting) complex, TRAPP- transport protein particle. 
Adapted from (Yu & Hughson 2010)  
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Coiled-coil tethers, including golgins, are characterised by long regions of homodimeric, 
parallel coiled-coil motifs forming long, extended rod-like structures (Burkhard et al. 2001). 
This structure allows coiled-coil tethers to bridge the gap between membranes, and their role 
is demonstrated by the p115 and cis-Golgi matrix protein (GM130) model. In vitro and in 
vivo studies suggest a critical role for P115 in tethering or fusion (Waters et al. 
1992)(Seemann et al. 2000)(Yu & Hughson 2010). It resides on COPI vesicles and binds 
GM130 found on cis-golgi (Sönnichsen et al. 1998). It is proposed that p115 binds GM130, 
linking COPI vesicles to golgi elements in order to facilitate fusion (Sztul & Lupashin 2006).  
Blocking P115 or GM130 function resulted in defective trafficking of VSV-G from ER to 
golgi (Seemann et al. 2000). 
Tethering multiprotein complexes act at specific locations (Figure 1.2), for example the 
HOmotypic fusion and vacuole Protein Sorting (HOPS) and Class C core vacuole/endosome 
tethering (CORVET) complexes in yeast act at the vacuole and endosomes respectively. The 
core protein components of these complexes were first identified due to a loss of vacuole in 
yeast (Raymond et al. 1992)(Wada et al. 1992) and these complexes are essential for the 
biogenesis and maturation of late endosomes and vacuoles (Nickerson et al. 2009). Through 
in vitro reconstitution of proteolysosomes resembling vacuoles, it has been shown that HOPS 
is required for tethering and fusion of these vesicles, its action dependent on the presence of a 
combination of Ypt7- a Rab GTPase and SNARE proteins (Wickner 2010).  
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In yeast, HOPS and CORVET complexes contain a common set of 4 class C Vps genes 
originally identified in yeast mutants without vacuoles, Vps11, Vps16, Vps18 and Vps33 
(Raymond et al. 1992)(Wada et al. 1992). These complexes are of particular interest as 
VPS33B and VIPAR are homologues of yeast Vps33 and Vps16 respectively, core 
components of HOPS and CORVET complexes. In yeast, the HOPS and CORVET 
complexes are well defined, each complex contains 2 additional proteins, Vps39 and Vps41 in 
the HOPS complex and Vps3 and Vps8 in the CORVET complex (Seals et al. 
2000)(Peplowska et al. 2007). The organisation of proteins within the HOPS complex in yeast 
has been investigated and its predicted composition detailed (Figure 1.3A)(Ostrowicz et al. 
2010)(Plemel et al. 2011). Peplowska et al. have found that the HOPS and CORVET 
complexes are able to convert into one another via intermediates of these complexes in a 
directed manner, and thus suggests a link to organelle identity and Rab GTPase switching 
(Figure 1.3B)(Peplowska et al. 2007). In metazoans the HOPS complex is less well defined, 
and an equivalent to the CORVET complex is yet to be reported. In metazoans there are 2 
homologues of the yeast HOPS and CORVET core protein Vps33 which in humans share 
51% similarity, designated VPS33A and VPS33B (Gissen et al. 2005). Vps33a and Vps33b 
animal models, discussed in section 1.9, have presented different phenotypes with protein 
function shown to be non-redundant thus implying they are required at different trafficking 
steps. Yeast Vps16 also contains 2 homologues in metazoans, in humans known as VPS16 
and a more distant homologue VIPAR. It has been found in Drosophila (Pulipparacharuvil et 
al. 2005) and human embryonic kidney (HEK293) cells (Cullinane et al. 2010) that Vps33a 
interacts with Vps16a and not Vps16b, and Vps33b interacts with Vps16b (VIPAR in 
humans) but not Vps16a. In C. elegans,this was found not to be the case as Spe-39 was found 
to interact with both Vps33b and Vps33a (Zhu et al. 2009). The interactions of these proteins  
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Figure 1.3 Predicted CORVET and HOPS subunit composition and HOPS switching 
A. Predicted HOPS and CORVET subunit interactions determined by a combination of 
co-immunoprecipitation and  yeast-2-hybrid experiments. Adapted from (Ostrowicz et 
al. 2010)(Plemel et al. 2011) 
B. A model for the conversion of the multisubunit complexes HOPS and CORVET and 
their intermediates, iHOPS and iCORVET suggesting that these complexes are 
dynamic.  Adapted from (Peplowska et al. 2007) 
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with other HOPS and CORVET complex proteins remains poorly defined, however in 
Drosophila it was found that Vps33a interacts with a homologue of Vps18, Dor, suggesting 
that Vps33a might form part of the metazoan HOPS complex (Sevrioukov et al. 1999). 
 
1.6.3 SNARES 
In the 1980’s Novick and Schekman identified the first SNARE proteins: Sec17, Sec 20 and 
Sec22, using temperature sensitive Saccharomyces cerevisiae trafficking mutants (Novick et 
al. 1980). SNAREs are a superfamily consisting of 36 members in humans and 25 in yeast 
(Jahn & Scheller 2006). SNARE proteins contain a conserved motif of 60-70 amino acids 
made up of heptad repeats (Kloepper et al. 2007). These motifs form coiled-coils of 4 α-
helices and are classified according to which conserved amino acid they have within the 
central ‘0’ layer, either 1 of 3 glutamine residues (Qa-, Qb- or Qc-) or an arginine residue (R-) 
(Bock et al. 2001). Q-SNAREs are predominantly found on the target membrane and thus 
used to be known as t-SNAREs, R-SNAREs on the vesicle and were otherwise known as v-
SNAREs. One of each of the 4 classifications of SNARE are required to form a hetero-
oligomeric trans-SNAREpin which provides the energy to allow fusion of vesicles (Figure 
1.4A) (Südhof & Rothman 2009). One SNARE complex has been shown to be sufficient for 
membrane fusion (van den Bogaart et al. 2010) In 1996 it was found that N-ethylmaleimide 
Sensitive Fusion (NSF) protein and Soluble NSF Attachment Protein (αSNAP) were required 
for recycling of SNAREs, allowing dissociation of SNAREpins thus priming SNAREs for the 
next round of binding, but were not required for docking or fusion (Mayer et al. 1996). In 
1993, Sollner and Rothman introduced the SNARE hypothesis suggesting that SNAREs were 
sufficient to confer specific binding (Söllner et al. 1993). However, it was subsequently found 
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in a series of studies that binding of vesicles was much more promiscuous and other factors 
must be involved (Waters & Hughson 2000).  
Specific apical and basolateral localisation of Q-SNAREs are critical for polarity. Syntaxin 3 
is found on the apical membrane and syntaxin 4 on the basolateral membrane in all cell types 
(Low et al. 1996) (Weimbs et al. 1997). When syntaxin 3 was mislocalised by altering its 
apical targeting FMDE motif (named after the first 4 amino acids) in the N-terminal domain, 
it was found that syntaxin 3 was localised in both the apical and basolateral membranes in 
MDCK cells (Sharma et al. 2006). As a result of this, p75, an apical membrane protein was 
found in the basolateral membrane of mutants, indicating that syntaxin 3 allows the p75-
positive vesicle to become fusion competent. Overall epithelial polarity was also affected and 
this was tested by monitoring trans-epithelial electrical resistance (TEER) - a measure of tight 
junction reformation after reintroduction of calcium to cells growing in calcium free media. 
The TEER peak, an indication of tight junction formation, was delayed by approximately 10 
hours. Wild type MDCK cells grown in 3D culture form cysts, with the apical membrane 
facing a single lumen. In syntaxin3 knockdown cells, tight junctions could not be detected and 
a lumen did not form giving a tumour-like structure. This indicates that syntaxin3 plays an 
important role in apical-basolateral polarity and SNAREs may contribute to fusion specificity 
(Sharma et al. 2006). 
 
1.6.4 SM proteins 
VPS33B is a member of the Sec1/Munc18 (SM) family of which there are seven SM family 
proteins in vertebrates. Their structure is highly conserved, consisting of 3 domains making 
an arched shape protein with a cavity on one side and a groove on the other, both of which 
have been implicated in SNARE interaction (Misura et al. 2000). SM proteins have been 
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shown to bind individual Q-SNAREs, for example when bound to its cognate SM protein 
Tlg2p adopts a closed conformation preventing SNAREpin formation (Furgason et al. 2009), 
suggesting a negative regulatory role for SM proteins.  However it has also been shown that 
SM proteins are as important as SNAREs in membrane fusion events with deletion of 
Munc18-1 blocking exocytosis at synapses (Verhage et al. 2000) and has more severe 
consequences than deleting its interacting SNAREs, synaptobrevin or SNAP-25. This 
suggests that the role of SM proteins is not purely inhibitory but that they also have an 
important stimulatory role.  This is confirmed by many studies including a multitude of 
different organisms showing that a loss of function of SM proteins leads to an accumulation 
of vesicles (Novick & Schekman 1979)(Hosono et al. 1992)(Harrison et al. 1994). SM 
proteins have been found to interact via their N-terminus with an N-terminal peptide sequence 
within syntaxins (Yamaguchi et al. 2002). In this way the SM proteins are able to bind to the 
open conformation of the syntaxin but leave the arch-shaped part of the protein to bind to the 
SNAREpin (figure1.4B) (Dulubova et al. 2007). 
Studies in S. cerevisae indicate that the role of SM proteins in vesicle fusion go further than 
SNAREpin formation. A wide range of sec1 mutants were constructed using site-directed 
mutagenesis and random mutations (Hashizume et al. 2009). The mutants could be separated 
into 2 groups depending on their phenotype. Group 1 mutants did not form SNARE 
complexes or fuse suggesting a role for Sec1p in vesicle docking and SNAREpin formation. 
The second group were able to dock and form SNAREpins, however the vesicles could not 
fuse, suggesting a role for SM proteins in vesicle fusion. Supporting findings were made 
when Vps33p in yeast was found to be required for pore opening, the last stage of vesicle 
fusion, after the hemifusion of vesicle membranes (Pieren et al. 2010). Vacuoles isolated from 
yeast were found to maintain 70% of the lipid mixing activity but only 6% of content mixing  
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Figure 1.4 SNAREpin formation and SM binding models 
A. 3 Q-SNAREs on a target membrane come into contact with an R-SNARE on a vesicle. 
The vesicle is able to dock through loose interaction of the Q-SNAREs with the R-
SNARE. These are then able to ‘zip-up’ to form a tight SNARE-pin, and mixing of the 
membranes- ‘hemifusion’, and pore opening- ‘fusion’ may then occur. Adapted from 
(Jahn & Scheller 2006). 
B. SM proteins have been found to bind Q-SNAREs in an open conformation thought to 
aid SNAREpin formation or less commonly in a closed conformation.  SM proteins 
also bind the SNAREpin. Adapted from (Südhof & Rothman 2009) 
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ability when Vps33p was inactive indicative of a pore opening defect. 
 
1.6.5 Rab proteins 
There are over 60 Rab genes in the human genome, they are members of the Ras superfamily 
of GTPases and are conserved in all eukaryotes. Some Rabs are ubiquitously expressed 
whereas others are tissue specific, such as Rab17 in epithelia (Stenmark & Olkkonen 2001). 
Rabs are located in the cytoplasm or on cytoplasmic face of specific intracellular membranes 
allowing them to carry out their functions. Rabs specifically involved in maintenance of 
apical-basolateral polarity are Rab11a, Rab11b, Rab25 and Rab8a (Casanova et al. 
1999)(Wang et al. 2000)(Roland et al. 2011) . Rab11a is known to function at the apical 
recycling endosome and investigations using cell lines found that in Rab11a GTP deficient 
mutants, basolateral trafficking is not affected but apical recycling and transcytosis of IgA is 
(Casanova et al. 1999).  
Rab localisation is influenced by their state, they cycle between a guanosine triphosphate 
(GTP) bound or guanine diphosphate (GDP) bound conformation, with the GTP bound being 
considered ‘active’. GDP/GTP exchange factors (GEFs) mediate the exchange of GDP to 
GTP on the Rab (Stenmark & Olkkonen 2001). 
In its GTP bound state Rabs are able to bind their effectors. Rabs perform their function by 
recruiting a variety of different effectors at different stages in membrane transport. They have 
roles in cargo selection, vesicle transport, tethering and fusion (Hutagalung &  Novick 2011). 
Rab9 can recruit cargo through its effector TIP47. When TIP47 is directly bound to Rab9-
GTP, TIP47 has increased affinity for its cargo, mannose-6-phosphate receptors (M6PR). 
TIP47 directly links M6PR and Rab9, allowing Rab9 to direct the M6PR receptors from 
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endosomes to the TGN (Carroll et al. 2001). Trafficking of vesicles via Rab effectors is due to 
Rabs ability to interact with motor proteins that act on microtubules. Rab11 for example 
recruits myosinVb through its effector FIP2, allowing regulation of plasma membrane 
recycling (Hales et al. 2002). Rabs are also involved in SNARE mediated vesicle fusion by 
interaction with effectors that influence SNARE function, for example by interaction with 
tethers, SM proteins or directly with the SNAREs themselves (Hutagalung & Novick 2011). 
One such example is the interaction of the yeast Rab Ypt7p and tethering complex HOPS 
during vacuole formation  (Seals et al. 2000). Reconstitution of HOPS-directed fusion of 
proteoliposomes by Wickner and colleagues (Stroupe et al. 2006)(Mima et al. 2008)(Stroupe 
et al. 2009)(Wickner 2010) found that the fusion of vesicles was dependent on the presence of 
the HOPS complex. Ypt7p was shown to be essential for reconstituted fusion under 
conditions when HOPS could not bind to membrane lipids, for example when Vps41p was 
phosphorylated (Hickey et al. 2009). This suggests the key role for Ypt7 is to bind HOPS to 
the vesicle membrane. They also found that the HOPS complex and the yeast Rab, Ypt7, were 
not sufficient for stable tethering but also required 3 of the 4 SNARE proteins. Upon trans-
SNARE formation HOPS prevents the disassembly of trans-SNARE complexes and allows 
membrane fusion (Xu et al 2010).  
Sorting and targeting of proteins to the apical and basolateral membranes, and fusion of the 
transport vesicles at the correct membrane is important in maintaining apical-basolateral 
polarity. The complexes and structures which define these domains also need to be 
understood to give an overview of apical-basolateral polarity.  
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1.7 Apical junctional complexes 
In ARC syndrome, defects in junctions joining epithelial cells have been identified (Cullinane 
et al. 2010). Epithelial cells are polarised cells and provide tissues with selective barrier 
against the external environment. They perform this function by contacting neighbouring cells 
via tight junctions and adherens junctions collectively known as apical junctional complexes 
(AJC).   
1.7.1 Tight junctions 
Tight junctions (TJ) are present at the most apical part of the AJC and were first observed by 
Farquhar and Palade in 1963 (Farquhar & Palade 1963). The tight junction forms a 
continuous belt separating the apical and basolateral membrane domains (Förster 2008). TJs 
are composed of three transmembrane proteins which form part of the tight junction, 
occludin, claudins and junctional adhesion molecules (JAMs)(figure 1.5)(Aktories & Barbieri 
2005). Occludin and claudins homodimerise to form tight cell-cell contacts, thus allowing TJs 
to fulfil their role. 
Tight junctions have 3 functions; to form a tight seal between epithelial cells and therefore 
block the movement of ions through the paracellular space, regulate the diffusion of solutes 
with size and charge selectivity through the paracellular space thus providing a ‘gate’ function 
(Powell 1981) and provide a 'fence' which separates and prevents the mixing of apical and 
basolateral membrane components. Purification of TJ-enriched membrane from rodent livers 
allowed the identification of the first TJ-associated protein Zona Occludins-1 (ZO-1) 
(Stevenson et al. 1986). ZO-1 is one of the cytoplasmic adapter proteins, including ZO-2 and 
ZO-3 responsible for linking the tight junction transmembrane proteins to the actin 
cytoskeleton, thought to be key for its ‘fence’ function (Förster 2008).     
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Claudins are tetraspanning membrane proteins and there are multiple subtypes, 24 in humans 
and mouse have been identified to date, and different epithelial cells have different 
combinations of these claudins (Förster 2008). Mouse models have been used to further 
elucidate the requirements of these different claudins, and is good example of how genetically 
modified mice have been used to understand protein function in multicellular organisms 
(Gupta & Ryan 2010).  For example, claudin-1 knockout mice died at birth due to a skin 
barrier defect with water loss, indicating that claudin-1 is important for skin integrity (Furuse 
et al. 2002). This is supported by  patients with mutations in Claudin-1 presenting with 
neonatal ichthyosis and sclerosing cholangitis (Hadj-Rabia et al. 2004). 
 
1.7.2 Adherens junctions 
Adherens junctions (AJ) are a defining feature of epithelial sheets (Fristrom 1988) and are 
found basolaterally to the TJ, just below the apical surface (Wang &  Margolis 2007). They 
are composed of members of the cadherin superfamily, E-cadherin in the case of epithelial 
cells, which are membrane spanning proteins that interact with the cadherins on neighbouring 
cells. Cadherins transdimerise in a calcium dependent manner and form weak homophilic 
cell-cell contacts (Baum & Georgiou 2011). In this way they are able to form a tight adhesive 
belt around the cell. The cytoplasmic tail of cadherins connects to multiple intracellular 
proteins allowing wide reaching functions (Hartsock & Nelson 2008). These proteins include 
members of the catenin superfamily which make up the adherens junction and include p120-, 
α- and β-catenin (Harris & Tepass 2010). Roles of the adherens junctions include cell-cell 
adhesion, attachment to and regulation of the actin cytoskeleton, intracellular signalling and 
transcriptional regulation (Hartsock & Nelson 2008). 
[26] 
 
E-cadherin is a key protein in epithelial cells, with it being required for morphogenesis, 
epithelial function and as a tumour suppressor (Lock & Stow 2005). Its localisation is 
dynamic and it is trafficked to the AJ via Rab11 positive endosomes (Le et al. 1999)(Lock & 
Stow 2005). In one study depleting E-cadherin resulted in defective TJ formation, but found 
that maintenance of the TJ was not affected (Capaldo & Macara 2007).  
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Figure 1.5 Molecular composition of tight and adherens junctions 
Three transmembrane proteins make up the tight junction, the claudins, occludin and JAM-1 
which seal the space between cells preventing paracellular diffusion. These proteins connect 
to the actin cytoskeleton via ZO-1 and ZO-2. Adherens junctions found just below the tight 
junctions consist of the transmembrane protein cadherin which transdimerise to form a tight 
belt around the cell. These proteins interact with the actin cytoskeleton via α- and β-catenins. 
Adapted from (Förster 2008).  
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1.8 The AJC and epithelial polarisation in ARC syndrome 
ARC syndrome has been associated with abnormalities in polarised epithelial cells 
particularly in the liver and kidney (Cullinane et al. 2010). Mislocalisation of apical 
membrane proteins to the cytoplasm or basolateral membrane, for example Carcinoembryonic 
antigen (CEA) and Bile Salt Exporter Pump (BSEP), has been found in hepatocytes and renal 
tubular cells in VPS33B and VIPAR deficient patients (Gissen et al. 2004)(Cullinane et al. 
2010). Other apical proteins such as MRP2 remain correctly localised. Investigations using 
Vps33b- and Vipar-deficient mouse inner medullary collecting duct (mIMCD-3) cells by 
Cullinane et al. confirmed the mislocalisation of apical proteins (Cullinane et al. 2010). When 
Vipar- and Vps33b-deficient mIMCD-3 cells were transfected with an apical p75 
neurotrophin receptor protein it was found that p75 was mislocalised to the basolateral 
membrane. In addition, if protein synthesis was blocked in the mIMCD knockdown cells, 
levels of p75 on the membrane dropped suggesting that for some reason the stability of p75 is 
reduced. As VPS33B and VIPAR form a complex, shown to partially co-localise with Rab11a 
– a marker for apical recycling endosomes. It was proposed that defective recycling of p75 is 
responsible for the reduction of its level at the membrane. 
In both Vps33b- and Vipar-deficient mIMCD-3 cells, Cullinane et al. found that apical 
junctional complexes (AJC) were disrupted, with tight junctions showing reduced complexity 
by freeze-fracture electron microscopy (Cullinane et al. 2010). Epithelial cell polarity is 
characterised by the presence of AJCs and when these are disrupted epithelial polarity is lost 
(Etienne-Manneville 2008). AJC proteins were abnormally expressed in the knockdown cells 
with E-cadherin and Claudin-1 levels at the AJC being reduced. Disruption of the AJC led to 
loss of a columnar appearance of cells to a more flattened appearance. In addition, mIMCD-3 
cells no longer grew in a uniformed monolayer but instead grew in multi-layered structures. It 
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was suggested that this might be due to a loss in the knockdown cells of contact-inhibition 
(Cullinane et al. 2010). Contact inhibition is required for cells growing in a monolayer to 
become quiescent when they reach confluence to prevent overgrowth and it has been 
suggested in several studies that E-cadherin adhesion is required for this growth inhibition in 
epithelial cells (Takahashi & Suzuki 1996)(Croix et al. 1998). 
The ability of epithelia to form lumina is a central architectural characteristic of most organs 
(Schlüter & Margolis 2009). Simple assays modelling cyst and tube formation can be used to 
assess the ability of epithelial cells to polarise. In a cyst formation assay, cells are embedded 
in extracellular matrix (ECM) where the cells polarise resulting in the formation of a large 
hollow lumen (Schlüter & Margolis 2009). It has been found that lumen formation is related 
to apical membrane biogenesis (Lubarsky & Krasnow 2003). Defects in polarity can result in 
multiple-lumen or no-lumen phenotypes. Epithelial cells grown in 3D collagen gel can also 
form tubules when cells extend out from a cyst, repolarise and form a lumen connecting to the 
cyst (Leung-Hagesteijn et al. 2005). Vps33b- and Vipar-knockdown cells were unable to form 
tubular structures in gels (Cullinane et al. 2010). Together this data suggests that VPS33B and 
VIPAR are involved in the establishment and maintenance of apical-basolateral polarity in 
epithelial cells. 
In the case of ARC syndrome, a complex multisystem disorder in which apical-basolateral 
polarity is defective, model organisms would be useful to learn more about the function of 
VPS33B and VIPAR in cellular trafficking and organ development and function. 
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1.9 Animal models of Vipar, Vps33b and its homologue Vps33a 
In metazoans there are 2 homologues of the yeast vacuolar protein-sorting protein Vps33p, 
Vps33a and Vps33b (Pevsner et al. 1996). Human VPS33B and VIPAR share 31% identity 
and 51% similarity, with an insertion of 31aa which is present in VPS33B but not VPS33A 
(Gissen et al. 2005). Mutations in VPS33B have been found in patients with ARC syndrome. 
Although VPS33A has been suggested as a candidate gene for Hermansky Pudlak Syndrome, 
no mutations have been identified in human VPS33A (Suzuki et al. 2003). VIPAR is a distant 
homologue of yeast vps16, mutations in which also result in ARC syndrome (Cullinane et al. 
2010). Studies using model organisms have been undertaken in order to try and delineate the 
roles of these proteins and determine whether in metazoans these form part of an equivalent 
HOPS or CORVET complex. The models used so far will be discussed. 
In Saccharomyces cerevisiae, genetic screens identified 41 Vacuolar Protein Sorting (VPS) 
genes involved in delivery of cargo to the yeast vacuole (Novick et al. 1980).  Cells with a 
deletion of the VPS genes Vps33, Vps18, Vps11 or Vps16 (Woolford et al. 1990)(Preston et al. 
1991)(Horazdovsky & Emr 1993) caused a severe ‘no vacuole’ phenotype, and were named 
Vps Class C genes. In addition to the ‘no vacuole’ phenotype, deletion of Vps33 revealed 
defects in fusion events at the late endosome (Subramanian et al. 2004). In yeast, Vps33p and 
Vps16 are core components of the HOPS complex and CORVET complex along with the 
remaining 2 class C VPS proteins Vps18 and Vps11, which act at the vacuole and endosomes 
respectively (Peplowska et al. 2007). 
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1.9.1 VPS33A models 
Drosophila - In Drosophila carnation has been identified as the homologue of human 
VPS33A. Studies have looked at the role of the protein product of car, Car/Vps33A, in 
Drosophila (Sevrioukov et al. 1999)(Akbar et al. 2009). A mutation in car which led to an 
almost complete deletion of the Vps33A protein resulted in lethality at the second instar stage 
(larval stage in development of Drosophila). This indicates Vps33A is important for larval 
development of the fly (Akbar et al. 2009). Due to lethality, knockout of Vps33A was 
restricted to the eye. Car was shown to be necessary for biogenesis of pigment granules, a 
lysosome-related organelle within the eye (Akbar et al. 2009). Loss of Vps33A also resulted 
in defective delivery of endosomal contents to lysosomes. As a consequence, endocytosed 
receptors and ligands accumulated in late endosomes. It was found dVps33b could not rescue 
the car phenotype indicating that Vps33A and Vps33B are not redundant in Drosophila. 
It was demonstrated by Sevrioukov et al. that Vps33A interacts with Deep-orange (Dor) a 
homologue of the yeast core HOPS complex protein, Vps18 (Sevrioukov et al. 1999).  The 
HOPS complex in yeast is required for the fusion of autophagosomes with vacuoles in yeast 
(Rieder & Emr 1997). Accumulation of autophagosome-like organelles was observed in car 
mutants supporting a role for Vps33A in autophagosome-lysosome fusion in Drosophila. 
Degeneration of the photoreceptor neurons was detected which is an important observation as 
neurodegeneration is a common result of lysosome dysfunction (Akbar et al. 2009).  
Mouse - The first mammalian mutation to be identified in Vps33a was a spontaneous 
missense mutation p.Asp251Glu in the buff  mouse (Suzuki et al. 2003). Reduced coat-colour 
pigmentation due to reduced size and number of melanosomes and a dense granule platelet 
defect was detected. In contrast to the dense granule defect seen in buff platelets, ARC 
patients with mutations in VPS33B have a platelet α-granule biogenesis disorder (Lo et al. 
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2005). Lysosomal function in the buff mouse initially was thought to be unaffected. However, 
in a study on bladder urothelium it was found that there was a defect in the endocytic 
degradation of uroplakin (Guo et al. 2009). The fusion of uroplakin-degrading multi-vesicular 
bodies to lysosomes was defective, indicating that Vps33a may play a role in this fusion 
event. Standardised behavioural tests were carried out on the buff mouse and significant motor 
deficits were found in tests such as grip strength and righting reflex, worsening with age 
(Chintala et al. 2009). A progressive loss of Purkinje cells was found, suggesting a role for 
Vps33a in maintenance but not formation of Purkinje cells. In conclusion, it appears that 
Vps33a in the mouse is required for the formation of melanosomes (Suzuki et al. 2003), the 
maintenance of Purkinje cells (Chintala et al. 2009) and may act in the endocytic degradation 
pathway (Akbar et al. 2009).  
 
1.9.2 VPS33B and VIPAR models 
C. elegans – In 2009, Zhu et al. published work using C. elegans and RNAi experiments to 
investigate the function of SPErmatogenesis defective protein 39 (SPE-39)(VIPAR 
homologue)(Zhu et al. 2009). Previously it had been found that in C. elegans spermatogenesis 
is defective in spe-39 mutant (Zhu & L’Hernault 2003).  It was confirmed that this phenotype 
was also observed when knocking down expression of Vps33b but not Vps33a by RNAi. 
Defective cell division and membranous organelle defects were observed. Processing of 
internalised yolk proteins and degradation of endocytosed substrates in oocytes and 
coelomocytes (macrophage-like scavengers) respectively, were also found to be defective in 
C. elegans suggesting a function for SPE-39 in endosomal/lysosomal trafficking pathways 
(Zhu et al. 2009). An interaction between SPE-39 and both VPS33A and VPS33B was 
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reported by Zhu et al. an interaction not observed in Drosophila or HEK293 cells 
(Pulipparacharuvil et al. 2005)(Zhu et al. 2009)(Cullinane et al. 2010).   
Drosophila – Pulipparacharuvil et al. 2005 found that dVps33A interacts with dVps16A, and 
dVps33b interacts with dVps16b (now known as full-of-bacteria – a homologue of human 
VIPAR)(Pulipparacharuvil et al. 2005). An investigation of the full-of-bacteria (fob) gene has 
recently been reported in Drosophila.  In this homozygous fob null allele, a defect in 
phagosome fusion with lysosomes was reported in hemocytes (fly macrophages) when 
challenged with non-pathogenic bacteria (Akbar et al. 2011).  The same was observed with a 
Vps33b knockdown by RNAi, suggesting the 2 proteins work together in this process. The 
endocytic trafficking of ligands was unaffected unlike the car mutant. Starvation induced 
autophagy that requires fusion with lysosomes was also not affected suggesting a very 
specific role for fob and dVps33b in phagosome-lysosome fusion. VPS33B in humans has 
also been shown necessary for phagosome-lysosome fusion in macrophages and that the M. 
Tuberculosis protein PtpA inhibits this fusion by dephosphorylating VPS33B (Bach et al. 
2008). 
Zebrafish – Zebrafish morpholinos have been used to further investigate the role of Vps33b 
and Vipar in development. Abnormal liver biliary tract development with a reduced number 
of terminal branches was observed in zebrafish larvae after treatment with morpholino 
oligonucleotides used to knock down expression of both Vps33b and Vipar (Matthews et al. 
2005)(Cullinane et al. 2010). Bile excretion was reduced when monitored by using PED6, a 
compound that becomes fluorescent after cleavage by a phospholipase enzyme in the liver 
cells, and then is excreted as part of bile into the hepatobiliary ductal system (Matthews et al. 
2005). Keratin immunostaining was also abnormal consistent with the abnormal development 
of terminal biliary ductules. Cytoplasmic vesicles were present within Vps33b deficient 
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biliary epithelial cells, suggesting the defect in biliary tract development may be due to a 
defect in vesicle sorting (Matthews et al. 2005). 
No Vps33b or Vipar mouse models have yet been reported. In this thesis, the development of 
mouse models of Vps33a and Vps33b deficiencies are described. These mouse models were 
created in order to investigate the function of the two genes within the mammalian system. 
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Table 1.1 Summary of Vps33a, Vps33b and Vipar model organisms 
The method of production, model organism used and phenotype observed is listed. 
 
Disrupted gene  Organism Phenotype 
vps33 
treatment with the mutagenic 
agent, ethyl methanesulfonate 
Yeast • 'no vacuole' phenotype 
• Defective endosomal fusion 
carnation (Vps33a) 
null allele using P element 
Drosophila • Lethal at second instar stage 
• defective biogenesis of pigment granules in 
the eye 
• accumulation of autophagosomes (defective 
fusion with lysosomes) 
Vps33a,  
spontaneous mutation 
 
buff mouse • Reduced size and number of melanosomes 
• dense granule defect in platelets 
• defective fusion of uroplakin-degrading 
multi-vesicular bodies to lysosomes  
Vps33b 
RNAi 
Nematode,  
C. elegans 
• Defective spermatogenesis – associated with 
defects in formation of membranous 
organelles 
Vps33b 
RNAi 
Drosophila • Defective fusion of phagosomes with 
lysosomes 
Vps33b 
Morpholino 
Zebrafish • abnormal biliary tract development 
• Reduced bile excretion 
Vps16 
treatment with the mutagenic 
agent, ethyl methanesulfonate 
Yeast • ‘no vacuole’ phenotype 
spe-39 (VIPAR) 
induced mutation due to treatment 
with the mutagenic agent ethyl 
methanesulfonate or ultraviolet 
irradiation 
Nematode,  
C. elegans 
• Defective fusion of membranous organelles 
required for sperm function 
• Defective clearance of endocytosed 
substrates in macrophage-like cells and 
oocytes 
fob (VIPAR) 
targeted mutagenesis using ends-
out homologous recombination 
Drosophila • Defective fusion of phagosomes with 
lysosomes 
Vipar 
morpholino 
Zebrafish • abnormal biliary tract development and 
accumulation of vesicles in biliary epithelial 
cells 
• Reduced bile excretion 
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1.10 The Liver 
Cholestasis is a cardinal feature of ARC syndrome, and is due to a defect in bile export- a 
function of the primary liver cell, the hepatocyte. The liver is the largest visceral organ in 
mammals, and is composed of 7 distinct cell types including: hepatocytes, sinusoidal 
endothelial cells, kupffer cells, hepatic stellate cells, biliary epithelial cells, pit (natural killer) 
cells and hepatic dendritic cells (Ishibashi et al. 2009). It carries out a great many functions 
including bile synthesis, glycogen storage, plasma protein synthesis and hormone production. 
It also extracts and metabolises multiple nutrients, xenobiotics and old cells brought in from 
the gastrointestinal tract via portal circulation.  
Hepatocytes, otherwise known as liver parenchymal cells, are large polygonal cells that make 
up 80% of the mass/volume of the liver and compose 60% of all cell content within this organ 
(Tanaka et al. 2011). Hepatocytes are polarised cells, with the apical membrane modified 
specifically for bile constituent excretion into the bile canaliculi (Nicolaou et al. 2012), and 
the basolateral surfaces which consist of 2 parts: the membrane where hepatocytes contact one 
another, forming junctional complexes (adherens, tight and gap) to provide a barrier between 
the blood and bile, and the membrane which contacts the blood forming spaces known as 
sinusoids (Figure 1.6A). Hepatocytes are not simple bipolar cells such as the proximal tubule 
kidney epithelial cells. They do not have a singular apical-basolateral polarity but instead 
have a punctate plasma membrane (figure 1.6A) (Wilton & Matthews 1996), which allows the 
formation of a large branched network of bile canaliculi.  
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Figure 1.6 Hepatocytes 
A. Hepatocyte polarity - hepatocytes are not simple bipolar cells but instead have multiple 
apical surfaces which allow the formation of a large branched network of bile canaliculi 
B. Transporters found in the apical and basolateral membranes of hepatocytes and their 
substrates. Arrows indicate the direction of transport. In the basolateral membrane - 
Sodium/Taurocholate Co-transporting Peptide (NTCP), Organic Anion Transporting 
Polypeptide (OATP) Organic Cation Transporter (OCT1). Efflux pumps in the basolateral 
membrane include Multidrug Resistance-associated Protein 3 and 4 (MRP3, MRP4). Apical 
(canalicular) efflux pumps of the hepatocyte comprise bile-salt export pump (BSEP), 
Multidrug resistance-associated protein 2, and MultiDrug Resistance protein 1 and 3 (MRP2, 
MDR1 and MDR3), and phospholipid-transporting ATPase IC (ATP8B1). Adapted from 
(Giacomini et al. 2010). 
[38] 
 
A major role of hepatocytes is to produce bile, which is secreted via the biliary duct system 
into the intestine for the emulsification of fats. In addition it is an important route for 
elimination of drugs, toxins and metabolic products such as cholesterol and bilirubin (Trauner 
& Boyer 2003). Bile canaliculi are the terminal ductules of the intrahepatic biliary tree, and 
are found at the apical surface of the hepatocytes where bile is secreted. These canaliculi join 
to form the Canals of Hering which are lined with cholangiocytes – cells which alter the 
constituents of the primary canalicular bile, then bile ductules, intrahepatic bile ducts and 
finally the common bile duct, where the bile exits the liver for storage in the gall bladder 
before release into the small intestine (Arias et al. 2009).  Many of the organic constituents of 
bile such as bile acids are reabsorbed (up to 95%) in the small intestine and then taken back to 
the liver in the portal vein. Bile salts are then reabsorbed at the basolateral side of the 
hepatocytes, allowing the circulation and reuse of these bile constituents. This is known as 
enterohepatic circulation (Hofmann 1999). 
 
1.10.1 The importance of hepatocyte polarity in liver development/function 
Apical junctional complexes in hepatocytes demarcate the bile canaliculi, they form a barrier 
between the blood and bile allowing the maintenance of concentration gradients between the 
two (Boyer 1980) and act as a physical barrier to separate the apical and basolateral domains 
in order to allow polarisation of hepatocytes (Son et al. 2009).  In zebrafish hepatocyte 
polarisation coincides with development of the vasculature and biliary tree, suggesting 
hepatocyte polarisation may be required for the formation of these structures during liver 
development (Sakaguchi et al. 2008). It has also been shown that disruption of apical 
trafficking of ABC transporters in hepatocytes results in a failure of bile canalicular to form in 
rat hepatoma/human fibroblast hybrid (WIF-B9) cells, a polarised hepatic epithelial cell line 
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(Wakabayashi et al. 2006), demonstrating the necessity for correct apical localisation of 
proteins during canalicular formation in the liver. Disrupted liver architecture and disruption 
of the bile ducts is a characteristic of many common liver diseases such as hepatitis and non-
alcoholic fatty liver disease. Better understanding of the molecular mechanisms underlying 
biliary development can be gained by the investigation of rare single-gene disorders, such as 
progressive familial intrahepatic cholestasis (Cagle 2010), disorders which are associated with 
bile duct hypoplasia.  
 
1.10.2 Apical hepatocyte transporters 
Apical and basolateral surfaces of the hepatocyte contain different transporters for uptake and 
secretion of bile constituents. Bile salt secretion occurs against a steep concentration gradient 
at the apical membrane, and relies on members of the ATP-binding cassette (ABC) 
superfamily (Nicolaou et al. 2012). ABCB11 (otherwise known as the Bile Salt Exporter 
Pump - BSEP) is a member of this superfamily and transports monovalent bile salts across the 
apical membrane. It is trafficked to the apical membrane via a Rab11a recycling endosomes 
(Wakabayashi et al. 2004).  
The apical ABC transporter Multidrug Resistance-associated Protein 2 (MRP2) transports 
products including organic anions and their conjugates (bilirubin)(Nicolaou et al. 2012). 
MRP2 contains a PDZ binding motif thought to aid its targeting to the apical membrane (C-
terminal phosphorylation). NHERF-1, a PDZ protein has been shown to influence the level of 
MRP2 at the apical membrane (Li et al. 2010). 
MultiDrug Resistance protein 1 (MDR1 - otherwise known as ABCB1) is also found on the 
apical membrane and transports drugs and xenobiotics into the bile (Cascorbi 2011). In 
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contrast to BSEP, MDR1 has been shown to be transported directly from the golgi to the 
apical membrane (Sai et al. 1999). 
MultiDrug Resistance protein 3 (MDR3) is a lipid floppase, transporting phosphatidylcholine 
from the inner to the outer leaflet of the canalicular membrane, where it is extracted by bile 
acids (Jacquemin 2001)(Davit-Spraul et al. 2009). It plays an important role in reducing the 
cytolytic action of bile acids (Elferink & Beuers 2011).  
ATP8B1 (FIC1) is a lipid flippase also found at the apical membrane and plays the opposite 
role to MDR3, (Groen et al. 2011) moving phosphatidlyserine from the outer to the inner 
leaflet, and is thought to counteract the destabilisation of the canalicular membrane when 
MDR3 flops phosphatidylcholine.  
 
1.10.3 Cholestatic liver disease 
Cholestatic liver disease is a term that describes any condition in which the flow of bile from 
the liver is disrupted. Cholestatic diseases can be divided into two main groups, extrahepatic 
cholestasis which occurs outside the liver (and is secondary to disrupted bile flow via bile 
ducts) and intrahepatic which occurs inside the liver and can occur due to maldevelopment of 
intrahepatic bile ducts and/or abnormal transport of bile out of hepatocytes across the 
canalicular membrane. Both groups of cholestatic disorders have many different causes such 
as infection, single gene disorders, congenital malformations and maternal drug exposure.  
One of the cardinal features of ARC syndrome is intrahepatic cholestasis.  
Genetic causes of intrahepatic cholestasis include mutations in many genes, some of which 
may have a known function in bile transport but the role of many others has not been 
delineated (Jansen & Sturm 2003). For example, Progressive Familial Intrahepatic Cholestasis 
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(PFIC) is a group of autosomal recessive diseases caused by mutations in various canalicular 
transporter proteins. PFIC Type 1 is caused by mutations in ATP8B1, encoding the lipid 
flippase at the canalicular membrane (Bull et al. 1997). PFIC type 2 by mutations in the 
ABCB11 gene (also known as BSEP)(Strautnieks et al. 1998) and type 3 by mutations in 
MDR3, the lipid floppase (de Vree et al. 1998). Due to the differences in the function of the 
affected genes, and differing severity dependent on the patient mutation, there is a large scope 
of clinical variability between patients.  
In addition to defects in apical proteins, mutations in tight junction proteins, Claudin-1 and 
ZO-2 have been shown to cause 2 forms of intrahepatic cholestasis. Neonatal sclerosing 
cholangitis-ichthyosis syndrome is an autosomal recessive disorder caused by mutations in 
claudin-1. Patients present with jaundice, itching and acholic (absent bile, pale in colour) 
stool. It is a severe condition characterised by inflammation and fibrosis of intra- and 
extrahepatic bile ducts (Hadj-Rabia et al. 2004) leading to liver cirrhosis and liver failure. 
Some patients however, were found to have intrahepatic biliary hypoplasia on liver biopsy, 
which a similar histological appearance to the patients with PFIC1 and PFIC2. The 
pathophysiology underlying this condition is unclear but it is believed that a loss of cell 
polarity and paracellular leakage of bile secondary to abnormal development of tight junction 
may result from loss of claudin-1, which is a tight junction constituent protein (Paganelli et al. 
2011)(Grosse et al. 2011).  
Patients with familial hypercholanaemia, an autosomal recessive disorder were found to 
contain mutations in ZO-2, which links transmembrane junctional proteins with actin 
cytoskeleton (Carlton et al. 2003).  The disease is characterised by elevated serum bile acids, 
itching and fat malabsorption (Carlton et al. 2003). Mutations in ZO-2 were also proposed to 
increase paracellular permeability to bile acids allowing movement from the bile to the blood 
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through the paracellular space. A variety of different possible mechanisms were proposed for 
this including the failure of claudin to anchor properly, or changes in the conformation of 
claudin pores (Carlton et al. 2004).  
 
1.10.4 ARC liver  
Lutz-Richner and Landholt in 1973 were the first to report ARC syndrome, and in 1979 a 
second family were reported by Nezelof et al. (Lutz-Richner & Landolt 1973)(Nezelof et al. 
1979). Due to the different histological observations made when examining the livers from 
these patients, they were considered to represent 2 different clinical disorders. The first group 
had paucity of intrahepatic bile ducts and giant cell transformation of hepatocytes, and the 
second had pigment deposition in hepatocytes and cholestasis. However, in 1994 Horslen et 
al. suggested that the phenotypes were a variation within a single syndrome. This was due to 
the identification of a patient presenting with the cardinal features of ARC syndrome, but an 
overlap between the 2 liver pathologies previously reported, with cholestasis, lipofuscin 
deposition and intrahepatic biliary hypoplasia observed (Horslen et al. 1994). 
One of the cardinal features of ARC syndrome is neonatal cholestastic jaundice. 14 out of 15 
ARC patients analysed in one study (Gissen et al. 2006) had non-excreting biliary isotope 
studies, suggesting biliary obstruction or severe intrahepatic cholestasis. Bilirubin is the end 
degradation product of haeme and is often used as a marker of abnormal biliary excretion. It is 
normally excreted into the bile by MRP2 (ABCC2), an apical protein (Trauner & Boyer 
2003).  When the liver is damaged or bile ductular system is occluded, bilirubin levels in the 
blood increase resulting in jaundice (Carlton et al. 2004).  ARC patients present with 
conjugated hyperbilirubiaemia. Bilirubin, a breakdown product of haeme, is delivered to the 
liver in its unconjugated form. Here it is conjugated with glucuronic acid making it water 
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soluble.  If uptake of bilirubin by the liver is impaired or there is a defect in bilirubin 
conjugation, unconjugated bilirubin levels in the blood are raised; if excretion from the liver 
is impaired, conjugated bilirubin levels are increased (Carlton et al. 2004). In the case of ARC 
syndrome the levels of conjugated bilirubin are increased in the blood suggesting a secretion 
defect.  Additional markers typically used to assess liver damage found that ARC patients 
show low gamma-glutamyl transpeptidase (gGT) activity and normal to slightly increased 
ALanine Transaminase (ALT) and ASpartate Transaminase (AST). gGT is a protein found in 
the membrane or many tissues, most notably the liver. Elevated serum gGT levels can be 
indicative of diseases of the liver, biliary system or the pancreas. ALT and AST are enzymes 
also found within liver cells, if cells are damaged these proteins are released into the blood, 
and are therefore also used to identify possible liver damage. 
As previously discussed, histological findings in ARC livers are variable. Paucity of the bile 
ducts (reduction in the number of interlobular bile ducts) was observed in 7 out of 16 ARC 
patients in one study (Gissen et al. 2006). Lipofuscin deposition (Di Rocco et al. 
1990)(Horslen et al. 1994) was observed in 5 of 16 ARC livers (Gissen et al. 2006). 
Lipofuscin deposits are yellow-brown pigment granules consisting of highly oxidized cross-
linked proteins. The deposition of lipofuscin is linked to several cellular processes including 
the rate of oxidative damage to proteins, the effectiveness of mitochondrial repair systems and 
the functionality and effectiveness of the lysosomal degradation (Jung et al. 2007). 
Multinucleate giant cell hepatitis has also been observed (Abu-Sa’da et al. 2005). 
Immunohistochemistry analysis of ARC liver biopsies has been conducted for several 
proteins found within the liver (Figure 1.7). The apical protein BSEP is mislocalised to the 
basolateral membrane, which may result in impaired bile acid secretion. CEA, also an apical 
protein was found to be mislocalised to the cytoplasm and basolateral surfaces. MRP2, a 
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protein which is directly trafficked to the membrane, remains correctly localised to the apical 
membrane in contrast to BSEP and CEA. The localisation of E-cadherin, a protein found at 
the AJC’s, was also investigated and found to be present in reduced levels (Gissen et al. 
2004)(Cullinane et al. 2010). 
Eastham et al. first suggested the two pathophysiological mechanisms that may underlie the 
clinical feature of cholestasis in ARC (Eastham et al. 2001). These include the numerical 
reduction of intrahepatic bile ducts and reduced bile secretion across the canalicular portion of 
hepatocyte membrane. Both defects have been seen in other syndromes with cholestasis, and 
the particular similarity with ARC is seen for the histological findings in PFIC type 2.   
Vps33b and Vipar zebrafish morpholinos have been used to model the ARC syndrome, and 
have been reported as compatible with a partial ARC syndrome phenocopy (Matthews et al. 
2005)(Cullinane et al. 2010) as discussed in section 9.1.2. Cholestasis and bile duct paucity 
were reported. The features of the newly-developed murine model of liver Vps33b deficiency 
is described in chapter 5. 
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Figure 1.7 Staining of apical proteins in control and ARC liver 
CEA is localised to the canalicular membrane in control patients, typical apical staining 
indicated by arrows. In ARC liver CEA is mislocalised throughout the plasma membrane and 
is also cytoplasmic. E-cadherin is correctly localised however levels are reduced.  Adapted 
from (Gissen et al 2006) and (Cullinane et al 2010). 
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1.11 Platelets 
Platelets are small anuclear membrane fragments, approximately 2-3µm in size, that circulate 
in the blood.   They originate from their precursor cells, megakaryocytes, and have an average 
lifespan of 10 days in human and 5 days in mice (Ren et al.  2008)(Grozovsky et al. 2010).   
Platelets circulate in the bloodstream in a quiescent state and undergo rapid activation when 
the blood vessel is damaged.  In this way they are able to perform their primary function, to 
aggregate and form a vascular plug in order to prevent further blood loss and occlude the site 
of damage (Watson & Harrison 2007).  There are several stages of platelet activation:  
 
Tethering – This phase involves the tethering of platelets to the site of damage, creating a 
monolayer of activated platelets.  Upon damage to the vascular endothelium, extracellular 
matrix components are exposed including collagen, fibronectin and laminin.  In the low shear 
environment of the venous system, platelet adhesion involves binding to these extracellular 
matrix components.  In the high shear conditions of arteries and arterioles, platelet tethering is 
dependent on von Willebrand Factor (VWF) which binds to exposed subendothelial collagen 
fibres (Savage et al 1998)(Jackson et al 2003).  The bound VWF undergoes a conformational 
change (Siedlecki et al.  1996)(Schneider et al.  2007) which permits rapid binding to platelet 
GPIb-IX-V and therefore platelet capture.   This association is however transient due to a fast 
off-rate thereby allowing platelet translocation along the exposed subendothelial matrix. 
 
Stabilisation and activation – The deceleration of the platelets permits binding to the low 
affinity collagen receptor GPVI which initiates powerful activation of integrins αIIbβ3 and 
α2β1 and stabilisation through binding to VWF/fibrinogen and collagen, respectively (Watson 
& Harrison 2007).  The signals from GPVI synergise with those from GPIb-IX-V and the  
[47] 
 
two integrins mediate platelet spreading, secretion of α- and dense-granules, and de novo 
production and secretion of TxA2.  ADP from dense granules and TxA2 provide a positive 
feedback mechanism for activation of platelets. 
 
Further platelet recruitment and aggregation – Aggregation is mediated through cross-
linking of activated platelets via binding of fibrinogen to integrin αIIbβ3.  This is mediated 
through binding of VWF to integrin αIIbβ3 on activated platelets and tethering (or capture) of 
new platelets through binding of VWF to GPIb-IX-V.   VWF is present in the plasma and in 
platelet α-granules (Rand et al. 1987), and both sources are required to facilitate platelet 
aggregation under high shear (Kulkarni et al, 2000).   Thus α-granule secretion is required for 
thrombus growth. 
 
1.11.1 Platelet storage granules 
Platelets contain 4 types of storage vesicle, α-, dense, lysosomes and peroxisomes (figure 1.8).    
Dense granules 
Dense granules have a mean diameter of 150nm and are present at quantities ranging from 5 
to 9 dense granules per platelet.  They contain pro-aggregating, non-protein molecules 
including ADP, ATP, Ca2+, polyphosphate and serotonin (Rendu & Brohard-Bohn 2001).  
Visualisation by EM reveals a characteristic opaque dense core with clear space and single 
membrane (Figure 1.8).  
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α-granules 
α-granules are 200-500nm in diameter and are the most numerous storage granule in the 
platelet, with approximately 80 per platelet- a 10-fold greater level than that of dense granules 
(King & Reed 2002).   A proteomics study in 2003 identified 300 proteins released by 
platelets upon stimulation with thrombin, the contents of α-granules, dense- granules and 
lysosomes (Coppinger et al. 2004).   Subsequently, a proteomic study of purified α-granules 
by mass spectometry identified 284 non-redundant proteins (Maynard et al.  2007). α-granules 
contain a diverse set of proteins that participate in haemostasis and other vascular processes 
including tissue repair, angiogenesis, inflammation and host defence.   
 
• Fibrinogen, fibronectin and von Willebrands Factor (VWF) participate in haemostasis 
by supporting platelet-matrix and platelet-platelet interactions leading to adhesion and 
aggregation (Ruggeri & Mendolicchio 2007)  
• Growth factors such as Platelet Derived Growth Factor, Insulin-like Growth Factor-1, 
Vascular Endothelial Growth Factor and basic Fibroblast Growth Factor are 
implicated in angiogenesis and wound healing.    
• Fibrinolytic agents, such as Plasminogen activator inhibitor-1 and plasminogen, 
mediate clot remodelling and enhance cell/matrix interactions (Anitua et al. 2004).    
• Chemokines attract and activate leukocytes, modulating the production of 
inflammatory molecules and regulating an immune response (Ren et al. 2008).    
• Several transmembrane proteins become exposed on α-granule fusion with the plasma 
membrane.  These proteins include P-selectin, which promotes chemokine deposition 
and thus monocyte recruitment (Schober et al. 2002) and integrin αIIbβ3 which 
supports aggregation. 
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Lysosomes 
Lysosomes are intermediate in size, at 175-250nm and their contents are released upon 
platelet activation (Ciferri et al. 2000). They have a density similar to α-granules but the 
density is uniform throughout the granule (Rendu & Brohard-Bohn 2001). They contain a 
number of digestive enzymes required for elimination of proteins and metabolites not required 
in the platelet.  
Peroxisomes 
Peroxisomes are single membrane organelles found in most eukaryotic cells (Gabaldón 2010). 
Peroxisomes are involved in a number of metabolic pathways, with a general feature of 
peroxisomes being fatty acid catabolism through beta-oxidation (Wanders & Waterham 
2006).
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Figure 1.8 Electron microscopy images of platelets 
A. A representative mouse platelet showing an α-granule, a dense-granule and mitochondria 
B. A control human patient with α-granules marked with white arrow heads, and an ARC 
platelet with no α-granules. Small abnormal dense bodies are marked with white arrow heads. 
Adapted from (Lo et al. 2005). 
ARC platelet Control human platelet 
α-granule Mitochondria Dense granule A 
B 
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1.11.2 α-granules and platelet function 
α-granules contain a diverse set of proteins which must undergo a complex packaging 
procedure within megakaryocytes and during platelet maturation in order to create mature α-
granules (Rendu & Brohard-Bohn 2001). α-granules develop from the TGN within the 
megakaryocyte (Blair & Flaumenhaft 2009) and must mature before they become fully 
formed granules with distinguishable morphological zones (Rendu & Brohard-Bohn 2001).   
The maturation process involves the transport of proteins to α-granules.   Most proteins are 
synthesised early within the maturing megakaryocyte and transported from the rough ER, 
transported to the golgi and subsequently to the TGN where they are sorted and packaged into 
vesicles (Harrison & Cramer 1993)(Rendu and Brohard 2001). From here proteins are 
trafficked directly to the immature α-granules or indirectly via multivesicular bodies (MVBs). 
MVBs are intermediate sorting vesicles for granules and contain both dense and α-granule 
constituents (Youssefian & Cramer 2000).    
Several proteins are also transported to the α-granules following endocytosis from the plasma 
(Rendu & Brohard-Bohn 2001). IgG and albumin are taken up passively by fluid-phase 
endocytosis and are found at low concentrations. Proteins which are found in a higher 
concentration in platelets than in the plasma are taken up by receptor-mediated endocytosis 
(Rendu & Brohard-Bohn 2001).   For example, plasma fibrinogen is primarily synthesised in 
hepatocytes and is actively transported into megakaryocytes or circulating platelets from the 
plasma by endocytosis of integrin αIIbβ3 (Handagama et al. 1993) either via a clathrin-coated 
vesicle or by a clathrin independent endosome/lysosome route (King & Reed 2002).   
Endocytosis may occur at the stage of the megakaryocyte or when the platelet is in 
circulation.   
 
[52] 
 
1.11.3 Storage pool diseases linked to defective trafficking and vesicle fusion 
Patients with platelet storage pool disorders (SPDs) have absent or diminished granules or 
granule contents and are separated into 3 groups; α-, dense or αδ-SPDs. Dense granule storage 
is often affected along with other lysosomal related organelles including melanosomes which 
give rise to characteristic pigment disorders (Huizing et al. 2008). 
Hermansky Pudlak Syndrome (HPS) is a dense granule storage pool disease and was first 
described in 1959. It is an autosomal recessive disorder, rare worldwide but the most common 
genetic disorder in Puerto Rico with a prevalence of 1 in 1800 (Shotelersuk and Gahl, 1998).   
9 causative genes HPS-1 to HPS-9 have been identified to date in man and 15 in mice (Wei 
2006)(Cullinane et al. 2011). HPS1-9 are involved in several protein complexes named 
Biogenesis of Lysosome Related Organelle Complexes -1, -2, and -3 (BLOC-1, -2 and -3) and 
AP3. BLOCs are a group of proteins which together are involved in the formation and 
trafficking of lysosome related endosomes (Huizing et al. 2008). BLOC-1 has been implicated 
as being involved in SNARE mediated membrane fusion by interaction of its protein 
components with syntaxin 13 and SNAP-25/23 (Falcón-Pérez et al. 2002)(Starcevic & 
Dell’Angelica 2004). Oculocutaneous albinism and absent platelet dense granules are defining 
features of HPS and a bleeding tendency is associated with poor platelet aggregation due to 
the lack of dense granules. The buff mouse, with a missense mutation in Vps33a, described in 
section 1.9.1 has been suggested as a HPS model, however no human mutations have been 
identified in VPS33A to date (Suzuki et al. 2003). In total 15 mouse models of HPS have been 
reported (Wei 2006). 
 
Chediak Higashi Syndrome (CHS) is a severe autosomal recessive syndrome dense granule 
storage pool disease caused by mutations in LYSosomal Trafficking regulator 
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(LYST)(Barbosa et al. 1996)(Nagle et al. 1996). When CHS platelets were studied by EM in 
1983 a large reduction in dense granules was reported (Rendu et al. 1983). Bleeding diathesis 
is often mild and includes easy bruising and gum/mucosal bleeding.   A prolonged bleeding 
time with a failure of platelets to aggregate has been observed (Salles et al. 2008). LYST 
contains a BEACH domain (Domain named after Beige mouse, and Chediak Higashi 
Syndrome), a HEAT (Huntington, Elongation Factor 3, PR65/ATOR) domain and several 
WD domains in its C-terminal region (Kaplan et al. 2008). Yeast two-hybrids have revealed 
several LYST interacting proteins which regulate vesicle docking and fusion including Q-
SNAREs and R-SNAREs, HRS- a SNARE complex protein, and the signalling protein 14-3-
3δ (Tchernev et al. 2002)(Ward et al. 2003). A proteomic study comparing the lysosomal 
contents from the liver of the beige mouse, a Chediak-Higashi model, found that the 
lysosomal contents revealed no major differences but that the membrane had decreased levels 
of lysosomal membrane proteins such as Lamp1, Lamp2 and Niemann-Pick type C1. There 
was also an increase in endoplasmic reticulum membrane proteins, for example cytochrome 
P450. It was suggested that LYST may play a role in preventing the incorporation of 
inappropriate proteins into the lysosomal membrane, or have a role in membrane 
recycling/maturation (Zhang et al. 2007). In 2010, Hammel et al. found that secretory 
granules retained the ability to fuse randomly with other secretory granules no matter the size 
in the beige mouse. The role of LYST as a negative regulator of granule-granule fusion in 
mice was suggested (Hammel et al. 2010).    
ARC platelets have been described as having a Grey Platelet Syndrome (GPS) appearance 
(Deal et al. 1990). GPS was first described by Raccuglia in 1971 (Raccuglia 1971). It is a rare 
congenital syndrome, primarily associated with the grey appearance of platelets when viewed 
under light microscopy. Diagnosis of GPS is often due to mild symptoms such as easy 
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bruising or more obvious problems, for example excessive bleeding after operations 
(Hayward 1997). 
GPS platelets have been found to be highly variable in their size and structure (Mori et al. 
1984). EM reveals that in Grey platelets α-granule numbers are significantly reduced (White 
1979) whereas the number of dense granules, lysosomes and peroxisomes is within the 
normal range. GPS platelets often have characteristic large vacuoles, which are made up of α-
granule membranes identified by specific antibodies such as P-selectin, an α-granule 
membrane protein. These empty α-granules redistribute and fuse with the platelet cell surface 
membrane upon activation reinforcing the idea that GPS is not a secretion problem but a 
storage deficiency disorder (Rosa et al. 1987). 
Protein deficiencies of α-granule proteins differ from patient to patient. Immunogold labelling 
has found traces of soluble α-granule proteins such as VWF and fibrinogen in ‘empty’ α-
granules and in smaller granules resembling lysosomes (Cramer et al. 1985).  Other α-granule 
proteins obtained by endocytosis such as albumin and IgG are present and secreted in 
significant quantities from GPS α-granules (Rosa et al. 1987). Albumin was localised to the 
‘small’ residual α-granules by EM (Maynard et al. 2010). Endogenously produced soluble 
proteins stored in α-granules are severely deficient in GPS including Platelet Derived Growth 
Factor, thrombospondin and fibronectin (Hayward et al. 1996). This observation suggests that 
GPS is caused by a problem in the targeting and packaging of endogenously synthesised 
proteins and proteins obtained by endocytosis. 
GPS patients show great heterogeneity in platelet function. Bleeding times vary, ranging from 
normal to prolonged (Hayward 1997) and aggregation studies have shown that some patients 
have normal platelet aggregation (Falik-Zaccai et al. 2001) while others do not.   
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Morphological studies on control and Grey platelets identify significant differences in 
appearance during aggregation (Mori et al. 1986). Grey platelets are only loosely cross-linked, 
resembling the early phase of aggregation that is seen in normal platelets (Nurden & Nurden 
2007). This may be explained by the absence of secretion of key adhesive proteins from the α-
granules such that platelets cannot progress to the secretion-dependent phase of platelet 
aggregation (Nurden & Nurden 2007).    
GPS is in most cases assumed to be an autosomal recessive disorder, as familial studies have 
shown siblings but not parents to be affected (Bolton-Maggs et al. 2006). There has however 
been one large Japanese family identified with an autosomal dominant form of the disease 
(Mori et al. 1984). In 2011, mutations in NBEAL2 (neurobeachin-like 2) were identified in 
15/25 GPS patients with the autosomal recessive subtype (Gunay-Aygun et al. 2011)(Kahr et 
al. 2011)(Albers et al. 2011). Five missense, three nonsense, four frameshift and three splice 
site mutations were identified in NBEAL2 (Gunay-Aygun et al 2011). The heterogeneity in 
GPS may therefore be partially due to the wide variety of mutations seen in these patients, 
and the resultant effect on NBEAL2 structure. The function of this protein in megakaryocytes 
is not known, but it has been shown to be localised to the dense tubular system in platelets 
(Gunay-Aygun et al. 2011).    
NBEAL2 contains 3 domains: WD40, ARM-type and a BEACH domain, which are highly 
conserved and necessary for protein-protein interactions, membrane dynamics and vesicle 
trafficking (Gunay-Aygun et al. 2011).   The BEACH domain and WD40 domains are also 
found in LYST, mutations in which cause CHS. Both diseases involve impaired formation 
and trafficking of platelet vesicles.    
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1.11.4 ARC syndrome platelets  
A defect in platelet morphology in ARC was first described in 1990 in a patient whose 
platelets resembled those of GPS (Deal et al. 1990). They lacked α-granules and had low 
levels of the α-granule proteins β-thromboglobulin, Platelet Factor 4 (PF4) and 
thrombospondin. Furthermore, 7 out of 16 ARC patients who underwent organ biopsy 
experienced severe life threatening haemorrhaging consistent with a platelet defect (Gissen et 
al. 2006).    
Eastham et al. reported that the blood films of 4 ARC patients had abnormally large platelets 
with a mean platelet diameter of up to 10µm compared to the average of 3µm (Eastham et al. 
2001). Structural abnormalities were observed in Wright-Giemsa blood films and resembled 
platelets from patients with GPS with the platelets being large, pale and agranular (Deal et al. 
1990). Lo et al. performed transmission EM on two ARC patients and reported the complete 
absence of α-granules in comparison to control platelets containing an average 5.5 granules 
per platelet. They also lacked α-granule membranes in contrast to GPS platelets. On the other 
hand, small ‘densities’ were identified in ~50% of the ARC platelets which were absent in 
controls and could represent primitive granules that are capable of release (Lo et al. 2005). In 
2010, a study of 12 ARC patients confirmed the findings of Eastham and Lo, that the majority 
of the platelets were large and agranular, and all lacked α-granules (Kim et al. 2010). The 
grey appearance of platelets is therefore also a cardinal feature of ARC.  Quantitation of α-
granule proteins within ARC platelets by immunoblotting revealed deficiencies in the 
endogenously synthesised and secreted α-granule proteins, PF4, VWF, β-thromboglobulin 
and Thrombospondin-1, as well as  fibrinogen derived from the plasma and α-granule 
membrane protein P-selectin (Lo et al. 2005).   Song also reported severe VWF deficiency in 
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ARC pIatelets (Song et al. 2003). In megakaryocytes, the level of PF4 was also found to be 
severely deficient (Lo et al. 2005).     
The number of dense granules was increased in ARC platelets with an average of 6.5 per 
ARC platelet in comparison to 1.4 per control platelet observed by whole mount EM (Lo et al. 
2005).   Only 2 patients however were analysed, therefore it is difficult to draw any 
conclusions from this data. In contrast to the findings of Lo et al, Kim et al. did not identify 
abnormalities in dense granules, although the data was not shown (Kim et al. 2010).  
Due to the rarity of ARC syndrome, the young age of patients and the severity of phenotype, 
blood for functional studies is very limited. As a result, studies on ARC platelet function are 
incomplete. Reduced aggregation to arachidonic acid and absent secondary aggregation wave 
to ADP have been reported when using platelet rich plasma (PRP)(Lo et al. 2005). In a 
separate study, one patient presented without a secondary aggregation wave in response to 
collagen and ADP but a normal response to epinephrine (Song et al. 2003), however details 
about experimental procedure were not provided. To draw any conclusions from this work it 
must be known if PRP or washed platelets were used as fibrinogen is present in plasma as 
well as α-granules.  
 
1.11.5 Vps33b in megakaryocytes 
Vps33b is not present in platelets suggesting that it plays a critical role at the level of the 
megakaryocyte (Lo et al. 2005). In ARC megakaryocytes grown in culture, numerous 
vacuole-like structures present suggesting a defect in megakaryocyte maturation. The 
localisation of Vps33b in megakaryocytes has been investigated using antibodies for    
Vps33b and various vesicle markers (Lo et al. 2005). These experiments revealed that Vps33b  
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Figure 1.9 Immunofluorescence localisation of VPS33B with vesicle/organelle markers 
VPS33B partially co-localised with von Willebrand factor (VWF) an MVB and α-granule 
marker. It also partially co-localises with LAMP-1, a marker for late endosome/lysosomes, 
but not with CD63 which is found in MVBs, dense granules and lysosomes. VPS33B is also 
absent from cis-golgi (GM130) membranes. Adapted from (Lo et al. 2005) 
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co-localises partially with VWF, a MVB and α-granule marker. It also partially co-localises 
with LAMP-1, a marker for late endosome/lysosomes, but not with CD63 which is found in 
MVBs, dense granules and lysosomes suggesting that Vps33b is absent from lysosomes.   
Vps33b is also absent from cis-golgi (GM130) membranes (figure 1.9). Vps33b therefore co-
localises with α-granules and late endosomes, but not with lysosomes, cis-golgi or dense 
granules.   
1.12 Thesis Aims 
The molecular mechanisms underlying ARC pathogenesis remain unknown. In order to begin 
to elucidate the proteins and pathways involved in this severe syndrome two different 
strategies have been adopted in this study.  
1. By modelling patient mutations, insights into the effect of the mutation on protein 
interaction/localisation may be gained. Therefore, the aim of the first approach is to 
identify novel mutations in VPS33B and VIPAR by screening putative ARC patients. 
By modelling a variety of mutations, the aim is to learn about how mutations may 
disturb correct cellular function.     
2. Whilst VPS33B and VIPAR function has been studied in knockdown cell lines and 
model organisms including Drosophila and C. elegans, study in mammals is limited to 
what can be learnt from ARC patients. However, due to the severity of ARC 
syndrome, patient material for study is incredibly limited.  Therefore the aim of the 
work presented is to develop a murine model of ARC syndrome in order to investigate 
the effect of Vps33b deficiency in specific cell types and organs, such as 
megakaryocytes/platelets and the liver. It is the hope that a Vps33b deficient mouse 
will also provide a model for development of treatments for ARC syndrome in the 
future.	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CHAPTER 2 – MATERIALS AND METHODS 
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All reagents are from Sigma-Aldrich, Poole, UK unless otherwise stated.   
 
2.1 ARC-LOVD Database 
An online locus-specific ARC database (https://grenada.lumc.nl/LOVD2/ARC) was compiled 
using the Leiden Open Source Variation Database (LOVD) software system. To establish the 
database all relevant data from HGMD (www.hgmd.org) was added and a literature search 
was performed. The terms ‘VPS33B’, ‘VIPAR’ and ‘ARC syndrome’ were entered into 
PubMed (http://www.ncbi.nlm.nih.gov/sites/entrez?db=PubMed) and abstracts and full-text 
articles retrieved were screened for descriptions of sequence variants. The database also 
contains variants taken from dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP)(Sherry et al. 
2001).  Any mutations found in patients referred for diagnostic analysis also have been 
included in the database.  
 
2.2 Protein structure predictions of VPS33B and VIPAR  
Predictions of protein secondary structure, globularity and disorder were performed using 
GlobPlot (http://globplot.embl.de/), FoldIndex (http://bip.weizmann.ac.il/fldbin/findex), 
IUPred (http://iupred.enzim.hu/), RONN (http://www.oppf.ox.ac.uk/RONN/), and HHPRED 
(http://toolkit.tuebingen.mpg.de/hhpred). 
 
2.3 Patients and controls  
Informed consent was obtained from all participating families; research ethics committees 
from all participating institutions approved the study. Primary skin fibroblasts from patients 
were cultured in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal calf 
serum, 2 mM L-glutamine, MEM Non-Essential Amino Acid solution.  
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2.4 Extraction of DNA from cells and tissue 
The Qiagen DNeasy blood and tissue kit (Qiagen, Crawley UK) was used to extract DNA 
from patient cultured fibroblasts. A water control was always carried out to monitor for 
contamination. Fibroblasts cultured in 75cm2 flasks were washed twice with PBS and scraped 
into 200µl of PBS. 180µl buffer ATL supplemented with 20µl proteinase K was added to the 
patient cells to allow direct cell lysis overnight at 56°C. 200µl Buffer AL and 200µl ethanol 
(96%-100%) were added to allow selective binding of DNA to the DNeasy membrane. Next, 
the sample was placed in a DNeasy spin column and centrifuged at 6000 x g for 1 minute. 
The supernatant was discarded and subsequent washing steps with 500µl Buffer AW1 and 
then 500µl Buffer AW2 were carried out to remove contaminants and enzyme inhibitors. The 
samples were eluted into 30-50µl water by centrifuging at 6000 x g for 1 minute. 
 
2.5 Polymerase Chain Reaction (PCR) 
PCR was carried out to amplify patient’s 23 VPS33B and 19 VIPAR exons with flanking 
intronic sequence using previously designed primers (Appendix 1). PCR was also used to 
genotype the offspring of mouse matings (Appendix 1). The ThermoPrime PCR kit 
(ThermoScientific, Kent); Taq, dNTPs, reaction buffer and MgCl2 was used. A standard 
reaction mixture of 25µl was prepared, the reagents and volumes found below. 
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Reagent Volume (per reaction) 
DNA  1µl 
Primers (10µM) 0.5µl per primer 
10x Reaction Buffer 2.5µl 
MgCl2 (25mM) 1.5µl 
dNTP mix (10µM) 1.25µl 
Taq 0.2µl 
Milipore Water Make up to 25µl 
Total 25µl 
 
The following conditions were applied 
96°C 96°C 60°C 72°C 72°C 
3 minutes 45 seconds 45 seconds 45 seconds 10 minutes 
 35 cycles  
 
The taq used for these reactions works at up to 74°C, incorporating approximately 1000bp per 
minute. Therefore, the extension time was adjusted depending on how large the expected PCR 
product was. The annealing temperature was dependent upon the primers, which were 
designed to have annealing temperatures of 58°C. 
 
2.6 Agarose gel electrophoresis 
In order to determine if the PCR reaction had been successful and to determine the size of the 
products produced, gel electrophoresis was carried out.  A 2% agarose gel was made by 
dissolving 2% w/v agarose (Bioline, London) in 1 x TBE (90mM Tris base, 90mM Boric 
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acid, 2mM EDTA, pH8) and adding 10ngml-1 Ethidium Bromide. The buffer used was 1 x 
TBE, and 10µl of PCR product with 2µl 6x loading buffer (2 mM EDTA, 50% glycerol and 
0.1% orange G) was loaded. 100bp ladder (New England Biolabs, Hitchin, UK) was most 
commonly used with the 1kb plus ladder used for large products. Dependent on the size of the 
gel and the degree of separation required, gels were run at 90-140V, for 20-50 minutes. 
 
2.7 Sequencing of DNA 
2.7.1 Exo-SAP reaction 
In order to purify the PCR products for downstream processing the ExoSAP-IT PCR Clean-
up Kit (GE healthcare, UK) was used. This contains two enzymes, Exonuclease 1 which 
removes unwanted primers, and Shrimp Alkaline Phosphatase (SAP) which dephosphorylates 
any unused dNTPs. The concentration of the PCR product determined the volumes of 
reagents used. 
Reagent Volume  Reagent Volume 
DNA 8.5µl OR DNA 4.25 µl 
ExoSAP 1.5 µl  Milipore water 4.25 µl 
   ExoSAP 1.5 µl 
Total 10 µl  Total 10µl 
 
The following conditions were applied: 
 
37°C 80°C 
45 minute incubation 15 minute enzyme inactivation 
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2.7.2 Sequencing reaction 
To sequence patient DNA, the di-deoxy chain termination method was used. The DNA was 
sequenced bi-directionally therefore a reaction was carried out for both forward and reverse 
primers independently. The following reaction mixture was used (Applied Biosystem, Life 
Technologies, California). 
Reagent Volume 
5x sequencing buffer 2µl 
PCR product 4.4µl 
Primer – forward or reverse (10µM) 1.6µl 
Big Dye 1µl 
Nuclease free water 1µl 
Total 10µl 
 
The following conditions were applied 
 
96°C 96°C 50°C 60°C 12°C 
30 seconds 30 seconds 15 seconds 4 minutes forever 
 Repeat 30 times  
 
2.7.3 Sample precipitation 
In order to remove the unincorporated fluorescent ddNTPs and impurities from the DNA for 
automated sequencing, a precipitation reaction to clean the sample was carried out. 1µl 0.25M 
EDTA was firstly added to each sample followed by 32µl 95% ethanol. The sample was left 
to stand for 10 minutes then centrifuged at 4000 rpm, 4°C for 30 minutes. The ethanol was 
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removed and 125µl 70% ethanol was subsequently added. A further spin at 4000 rpm, 4°C for 
30 minutes was carried out and the ethanol was again removed. The samples were then left to 
stand at room temperature for 10 minutes to allow the remaining ethanol to evaporate and 
10µl HiDi Formamide used (Applied Biosystem, Life Technologies,California), a sample 
resuspension solution was added. The samples were then incubated at 95°C for 5 minutes to 
denature the DNA, and subsequently placed on ice. 
2.7.4 Sequencing analysis 
Denatured DNA was sequenced by ABI 3730 capillary sequencer (Applied Biosystems, 
California) and subsequently analyzed using BioEdit Sequence Alignment Editor. The 
sequence traces were firstly analysed by sight to identify any heterozygous changes. The 
sequence was then compared against control sequence using the ClustalW function to identify 
any homozygous sequence changes. If any changes were found they were checked against a 
SNP database (http://www.ncbi.nlm.nih.gov/projects/SNP). 
 
2.8 RNA extraction 
To isolate RNA from fibroblasts the reagent RNA-Bee (AMS Biotechnology Europe ltd, 
Abingdon UK) was used. Cells were firstly homogenized by scraping confluent fibroblast 
cells in a 75cm2 flask into 0.5ml RNA-Bee, and adding a further 0.5ml RNA-Bee. For the 
separation into aqueous and organic phase, 0.2ml chloroform was added to the homogenate, 
shaken vigorously to mix, incubated at room temperature for 5 minutes and then centrifuged 
at 12,000 x g for 15 minutes at 4°C, this spin removes DNA and protein from the aqueous 
phase. To precipitate the RNA the aqueous layer was isolated and 0.5ml of isopropanol was 
added. It was left to incubate for 5 minutes at room temperature and the RNA was 
subsequently pelleted by centrifuging at 12,000 x g for 15 minutes at 4°C. The RNA pellet 
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was washed with 1ml 75% ethanol and centrifuged at 7,500 x g for 15 minutes at 4°C. Finally 
the RNA was solubilised by removing the ethanol, air-drying the pellet for 1 hour and 
dissolving the RNA in water. 
 
2.9 DNA and RNA quantification 
In order to quantify and assess the purity of RNA extracted for the reverse transcription 
reaction, and DNA for real-time applications, quantification was carried out using a Nanodrop 
ND-1000 Spectrophotometer. 1µl of sample was placed on the detector and a reading was 
taken. 
 
Absorbance values were taken at 260nm and 280nm and the ratio 260nm:280nm calculated. A 
ratio of ~1.8 is accepted as “pure” for DNA and a ratio of ~2.0 is accepted as “pure” for RNA. 
For RNA 
[RNA] (mgml-1) = Absorbance at 260 nm x Dilution Factor x 40 
              1000 
For DNA 
[DNA] (mgml-1) = Absorbance at 260 nm x Dilution Factor x 50 
              1000 
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2.10 RNA analysis 
2.10.1 Reverse Transcription 
The Promega reverse transcription system (Promega UK, Southampton UK) was used to 
produce cDNA from the previously extracted RNA. The reaction mix can be found below. 
Reagent Volume 
10x Reaction Buffer 2µl 
MgCl2 (25mM) 4µl 
dNTP (10mM) 2µl 
Random primers or polydT primers 2µl 
Reverse transcriptase 0.8µl 
RNA 1µg 
H20 Make up to 20µl 
Total 20µl 
 
The following conditions were applied: 
42°C 96°C 
1 hour 5 minutes 
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2.10.2 Sequencing of cDNA 
Sequencing of cDNA was carried out as in section 2.4 except that the primers were designed 
for exonic sequence. Primer sequences for both VPS33B cDNA and VIPAR cDNA can be 
found in Appendix 1. 
 
2.11 Techniques for identification of complex mutations 
2.11.1 Platinum Taq 
Platinum Taq (Life technologies, California) is a hot start Taq which is attached to an enzyme 
which inhibits it until heated to 96°C which increases specificity and yield. It was used when 
amplification of DNA proved difficult with ThermoPrime Taq. 
Reagent Volume 
DNA 1µl 
Primers (10µM) 0.5µl (per primer) 
10x Reaction Buffer 2.5µl 
MgCl2 (50mM) 0.75µl 
dNTP mix (10mM) 1.25µl 
Platinum Taq 0.2µl 
Milipore water make up to 25µl 
Total 25µl 
The following conditions were applied 
94°C 94°C 60°C 72°C 12°C 
3 minutes 45 Seconds 45 Seconds 1 minute forever 
 Repeat 35 times  
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2.11.2 Gel extraction 
Extraction of DNA from bands separated by agarose gel electrophoresis was carried out using 
the Qiagen QIAquick Gel Extraction Kit, spin column protocol (Qiagen, Crawley UK).  
Firstly, the bands were cut from the gel and 3 volumes of buffer QG were added to one 
volume of agarose gel. The gel was then melted at 50°C for 10 minutes. 1 volume of 
isopropanol was then added to increase DNA yield. The solution was then applied to a 
QIAquick column and centrifuged at 17,900 x g for 1 minute, allowing the DNA to bind and 
waste to pass through. The supernatant was discarded and an additional 0.5ml QG buffer was 
added to the column and centrifuged to remove any remaining agarose, and the supernatant 
discarded. 0.75ml Buffer PE was then added to the column to wash, and centrifuged and 
supernatant discarded. The column was spun for a further minute to remove any residual 
ethanol and the DNA was eluted by adding 30µl water and spinning for 1 minute, collecting 
the DNA in an eppendorf. 
2.11.3 Long range PCR 
Long range PCR using 5-PRIME PCR extender system (5PRIME, Nottingham UK) was 
required to amplify genomic DNA too large for standard PCR. The reaction mix can be found 
below. 
Reagent Volume (per reaction) 
5 PRIME PCR Extender enzyme mix 0.3µl 
5 PRIME Tuning buffer 5µl 
dNTP mix (100µM)  0.8µl 
DNA 1µl 
Primer (100µM) 0.5µl per primer 
Milipore water Make up to 50µl 
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Total 50µl 
The following incremental conditions were applied in order to maximize the amount of PCR 
product produced. 
95°C 95°C 68°C 95°C 68°C 68°C 12°C 
2 minutes 30s 3 min 30s 30s 3 min 30s 
– increase 
20s every 
cycle 
15 
minutes 
forever 
 Repeat 11 times Repeat 26 times   
 
The extension time was adjusted depending on the size of the PCR product, approximately 
1000bp per minute as a guide. 
2.11.4 Nested primers 
In order to sequence across a deletion found in a patient nested primers were designed. This 
was necessary as the PCR product was too long to sequence with one forward and one reverse 
primer. As the PCR product was clean due to gel extraction only the sequencing reaction and 
precipitation was required prior to sequencing. 
2.11.5 3’-RACE  
To determine the functional implications of a splice site mutation, OligodT primers with 
adapter sequence attached from the 3’-RACE kit (Roche Diagnostics, West Sussex) in place 
of the normal OligodT primers were used for reverse transcription of patient RNA. VPS33B 
cDNA was then amplified using the 3’-RACE adapter primer and 3F VPS33B cDNA primer. 
Nested PCR was then carried out to further amplify specific product. 0.5µl of the PCR 
product was used in the reaction and the 4F VPS33B cDNA primer and 3’-RACE adapter 
primer were used. The PCR products were analysed using agarose gel electrophoresis. 
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2.11.6 Quantitative Real-time PCR using genomic DNA 
PCR primers were designed for VPS33B and two house-keeping genes, actin and GAPDH. 
Using Primer3 the primers were designed to amplify approximately 200bp and have a melting 
temperature of 60ºC. As the purpose of this experiment was to identify exon deletions, the 
primers were placed in the intronic sequence flanking the exons being studied. The primer 
sequences generated were put through nBLAST to check for specificity. The primers were 
then optimised to eliminate primer-dimers that would skew results as SYBR green binds to 
double stranded DNA. To do this different primer concentrations from 1 to 0.05µM were used 
in standard PCR reactions at 60ºC, the products of which were electrophoresed on a 4% 
agarose gel for confirmation that only one product was produced and that primer-dimers 
weren’t present. A final concentration of 0.2µM for exon 4 and 0.1µM for actin and GAPDH 
were used.  
25ng of DNA per reaction was used and each reaction was carried out in triplicate, a blank 
was used to check for background signal and contamination. A master mix was made for each 
different primer pair, the reagents below and was aliquoted into a 96-well optical plate and 
sealed. SYBR green (Applied biosystems, California) was used to detect double stranded 
DNA production.  
Reagent Volume per reaction (µl) 
SYBR Green Master Mix (2x) 12.5 
Forward Primer 0.25 
Reverse Primer 0.25 
Nuclease Free Water 9.5 
cDNA 2.5 
Total 25 
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The reaction conditions are as follows 
50oC 95oC 95oC 60 oC 
2 minutes 5 minutes 15 seconds 90 seconds 
 40 cycles 
 
Amplimer levels were measured by an iQ5 BioRad instrument and Ct values were calculated. 
A dissociation curve analysis was carried out at the end of the assay in order to confirm that 
only one product was amplified. 
Utilising the Ct values, copy number could be calculated by using the 2 reference genes as a 
comparison. Firstly the value of the gene is transformed to a quantity relative to a calibrator – 
the calibrator in this case being a control sample.  
Q = E(calibratorCt-sampleCt) 
Q=quantity sample relative to the calibrator sample 
E= amplification efficiency  
The relative quantities were then divided by the geometric mean of the 2 reference gene copy 
numbers. 
A haploid copy number of 1 is expected for a normal sample and 0.5 for those with a deletion 
(Hoebeeck et al. 2005).  
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2.12 Cloning of Vps33b cDNA for sequencing 
2.12.1 Ligation reaction 
In order to sequence the gel extracted 3’-RACE PCR product, cloning was conducted using 
pGEM-T East Vector system (Promega, Southampton UK). Firstly a ligation reaction, found 
below, was carried out. 
Reagent Volume 
2x reaction buffer 5 µl 
PCR product 2 µl 
pGEM-T easy cloning vector (50ng/µl) 1 µl 
Water, nuclease free 1 µl 
T4 DNA ligase 1 µl 
Total 10 µl 
 
The reaction mix was vortexed briefly and incubated at room temperature overnight. This 
reaction mix was then used for bacterial transformation. 
2.12.2 Bacterial transformation 
The heat shock method was used to transform E. coli competent cells. 10µl of the ligation 
mixture was added to 50µl of competent cells and left on ice for 15 minutes. The cells were 
then subjected to heat shock, at 42°C for 45 seconds and were then transferred back to ice for 
2 minutes. Finally 500µl of SOC was added to the mixture and left to incubate at 37°C 
shaking at 220 rpm for 1 ½ hours. The mixture was then centrifuged at 3000rpm for 1 minute, 
the top 360µl of supernatant removed and the cell pellet resuspended in the remaining 
supernatant and plated onto Xgal and IPTG treated agar plates supplemented with 100µg/ml 
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ampicillin. 20µl XGal (50mg/ml) and 100µl IPTG (100mM) were added to the agar plate 30 
minutes before plating the bacteria. These were left to incubate overnight at 37°C. 
2.12.3 Colony Selection 
Xgal and IPTG treated agar plates allowed blue/white selection of colonies, white colonies are 
recombinant colonies containing an insert, blue are non-recombinant and do not contain an 
insert. White colonies were selected and transferred to 10ml Luria Broth supplemented with 
10µg/ml ampicillin and left to culture overnight at 37°C, shaking at 220 rpm.  
2.12.4 Miniprep 
To extract and purify the plasmids from bacteria the Qiaprep miniprep kit (Qiagen, Crawley 
UK), microcentrifuge protocol was used. Firstly the bacterial cells were pelleted by 
centrifuging at 3000 rpm for 1 minute. The supernatant was discarded and the bacteria were 
resuspended in 250µl Buffer P1. 250µl Buffer P2 was then added to lyse the cells. Next, 
350µl of Buffer N3 was added to adjust the conditions to that of high-salt for DNA binding. 
The cells were then centrifuged for 10 minutes at 17,000 x g in a microcentrifuge. The 
supernatant containing the plasmid was then removed and added to the spin column provided 
and centrifuged for 1 minute at 17,000 x g. The column was then washed to remove 
exonucleases by adding 0.5ml Buffer PB and centrifuging for 1 minute at 17,000 x g. The 
spin column was washed with 0.75ml Buffer PE to remove salts and centrifuged for a further 
1 minute at 17,000 x g. The flow-through was discarded and the column spun for another 
minute to remove any excess wash buffer. The plasmid was eluted by adding 50µl water to 
the column, leaving for 1 minute and then centrifuging for 1 minute at 17,000 x g and 
collecting the flow-through in a 2.5ml eppendorf.   
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2.12.5 Sequencing a plasmid 
Sequencing of the insert within the plasmid is carried out in the same way as in 2.4.2, with 
plasmid specific primers however, the volumes for the sequencing reaction are altered 
slightly.  
Reagent Volume 
DNA 1µl 
Primer – forward or reverse (10mM) 0.8µl 
Big Dye buffer 2µl 
Big Dye 1µl 
Milipore water 5.2µl 
Total 10µl 
	  
2.12.6 Site Directed Mutagenesis 
To introduce base pair changes into the wild type VPS33B and VIPAR constructs in order to 
model known mutations, two complementary primers were designed with the nucleotide 
change and 15 bp of correct sequence either side. The Stratagene site directed mutagenesis 
XL kit (Agilent Technologies, Germany) was then used to introduce the mutation. The first 
step was to introduce the mutation by PCR. 
Reagent Volume 
10× reaction buffer 5 µl 
dsDNA template 10 ng 
oligonucleotide primer #1 125 ng 
oligonucleotide primer #2 125 ng 
dNTP mix 1µl 
QuikSolution 3µl 
PfuUltra HF DNA polymerase 1µl 
ddH2O final volume of 50µl 
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The reaction conditions are specified below 
95ºC 95ºC 60ºC 68ºC 68ºC 
1 min 50 seconds 50 seconds 5 ½ mins 7 mins 
 
1µl of Dpn1 was then added to the reaction mix in order to digest any methylated parental 
DNA, and incubated at 37ºC for 1 hour. XL-1 blue cells were then transformed with 4µl of 
the reaction mix. Colonies were subsequently selected and screened for the inserted mutation 
by sequencing. Patient AB VPS33B-c.1225G>C construction was more complex several 
approaches were attempted in order to produce a construct with the mutated cDNA running 
into intron 16-17. Initially, it was attempted to clone the whole length of the cDNA, this 
however proved unsuccessful. Introducing novel restriction sites by site directed mutagenesis 
into wild-type VPS33B and the cloned patient cDNA, removing exons 16-23, and inserting 
the mutant cDNA into the cleaved wild-type construct was successful.  
 
2.13 Co-overexpression studies 
2.13.1 Cell Culture  
HEK293 cells were grown in growth medium consisting of Dulbeccos’s Modified Eagle’s 
Medium supplemented with 10% foetal bovine serum, 2mM L-glutamin, 1x MEM non-
essential amino acid solution and 1x penicillin-streptomycin. Cells were passaged through 
0.25% trypsin for 5 minutes after being washed twice with PBS and cells were diluted as 
required in growth medium for replating. Cells were grown at 37ºC with 5% CO2. 
[78] 
 
 
2.13.2 Transfection 
HEK293 cells were seeded onto coverslips in a 24 well plate and allowed to grow to ~70% 
confluence. On the day of transfection the medium was removed and 500µl of Opti-MEM I 
(Life technologies, California) without antibiotics was added. 0.8µg of plasmid DNA was 
added to 50µl of Opti-MEM I. Next, Lipofectamine 2000 (Life technologies, California) was 
added to 50µl of Opti-MEM I and left to incubate for 5 minutes. The DNA and lipofectamine 
solutions were then mixed and left to incubate for 20 minutes at room temperature. The 
resulting mixture was then added to the cells and incubated at 37oC with 5% CO2 overnight. 
The medium was changed 24 hours later to complete growth medium. 
2.13.3 Fixation and staining  
Cells were fixed in 4% paraformaldehyde in PBS for 4 minutes. The cells were then washed 3 
times with PBS and permeabilised with 0.1% Triton X100 in PBS for 4 minutes. Cells were 
washed 3 times in PBS and blocked for 30 minutes with 1% BSA in PBS. Coverslips were 
then transferred to parafilm and incubated with primary antibody for 1 hour. The coverslips 
were washed 3 times with PBS and again transferred to parafilm for incubation with 
fluorescently labelled secondary antibody for 45 minutes, antibodies listed in Appendix 1. 
Cells were again placed in the tray, washed 3 times with PBS and then incubated with TO-
PRO-3 (1:1000)(Invitrogen, Paisley, UK) for 2 minutes and washed with PBS 3 times. The 
coverslips were then mounted face down on microscope slides with 2µl Prolong gold antifade 
reagent (Life Technologies, California). 
2.13.4 Immunofluorescence confocal Microscopy 
Microscopic images were captured using an inverted Leica TCS SP2 AOBS confocal 
microscope (Leica, Milton Keynes, UK) with 63x oil immersion objective and the pinhole set 
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to 1 Airy unit. Optical sections were collected in the xy plane and merged to maximum 
projection images. 
 
2.14 Protein extraction 
Tissues extracted from mice were snap frozen in liquid nitrogen and stored at -80ºC until 
required. Tissue was crushed in a pestle and mortar using dry ice, and liquid nitrogen to 
maintain the frozen state of the sample. 2x RIPA lysis buffer (50mM Tris-HCl, 150mM NaCl, 
1mM EDTA, 1% Igepal CA630, 0.5% Sodium Deoxycholate, 0.1% SDS and complete mini 
protease inhibitor cocktail (Roche Diagnostics, Burgess Hill, UK)) was added to the crushed 
sample. Cultured cells were washed twice with ice-cold PBS and then were scraped into 250ul 
of MRC lysis buffer (50 mM Tris-HCl pH=7.5, 50 mM Sodium Fluoride, 5 mM Sodium 
Pyrophosphate, 1 mM Sodium Orthovanadate, 1 mM EDTA, 1 mM EGTA, 0.27 M Sucrose, 
1% Triton - X - 100 and complete mini protease inhibitor cocktail (Roche Diagnostics, 
Burgess Hill, UK)).  For megakaryocytes, 50µl per mouse of 2x RIPA buffer was added to 
lyse the cells. The solution was then centrifuged at 18,000 x g for 15minutes at 4oC to remove 
any cell debris, and the supernatant transferred to a clean tube. 
 
2.15 Western Blotting 
2.15.1 Protein quantification 
In order to determine the concentration of protein in the lysate, the BioRad Dc Protein Assay 
kit was used (BioRad, Hertfordshire, UK). A 2-fold serial dilution of 3µg/µl Bovine serum 
albumin (BSA) with lysis buffer was carried out for each assay, with lysis buffer alone used 
as blank. 10µl reagent S was added to 500µl reagent A, to make reagent A’. On a 96-well 
plate, in each well 5µl of standard or sample, 25µl of A’ and 200µl of reagent B was added 
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and left covered at room temperature for 15minutes to develop. The plate was then read at 
690nm for 1 second per well, and protein concentration for the samples extrapolated from the 
standard curve. 
2.15.2 SDS-PAGE 
To separate the proteins according to their mass, Sodium Dodecyl Sulphate PolyAcrylamide 
Gel Electrophoreses was carried out. The resolving gel was made first, and the percentage 
used was dependent on the proteins mass – the larger the protein the lower the percentage gel 
used. The recipe for 2 1mm gels may be found below. 
Volume Reagents 
10% 
polyacrylamide gel 
12% 
polyacrylamide gel 
15% 
polyacrylamide gel 
30% Acrylamide 3.3ml 4ml 5ml 
Water 3.9ml 3.2ml 2.3ml 
10% APS 0.2ml 0.2ml 0.1ml 
1.5M Tris pH 8.8 2.5ml 
10% SDS 0.1ml 
TEMED – added 
last 
8µl 
 
 
After the TEMED was added, the solution was applied to a 1mm glass plate up to the level 
where the comb sits (BioRad, Hertfordshire, UK). The gel was overlayed with isopropanol, 
left to set for 20minutes and then rinsed twice with water. The stacking gel was then prepared, 
as below, and applied to the top of the resolving gel and combs were added. This was left to 
set for 20 minutes.  
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Reagents Volume 
30% Acrylamide 1.0ml 
Water 3.4ml 
0.5M Tris pH 6.8 1.5ml 
10% SDS 60µl 
10% APS 90µl 
TEMED – added last 6µl 
 
Meanwhile, protein lysate with lamelli loading buffer was boiled for 10 minutes.  3µl of a 
known molecular weight ladder (Page Ruler, Fermentas, York) was used to determine the 
protein mass and 20µg of protein lysate was loaded per well. The SDS-PAGE was run at 
30mA for ~1hr in 1x SDS Running Buffer (192 mM Glycine, 250 M Tris-Base and 0.1% 
SDS) until the dye reached the bottom of the gel. 
2.15.3 Protein Transfer 
In order to carry out immunoblotting, the proteins were transferred from the gel to a PVDF 
membrane (GE Healthcare, Chalfont St Giles, UK). The membrane was activated by placing 
in methanol for 1 minute. All equipment required for the transfer was placed in 1 x Transfer 
Buffer (192 mM Glycine, 250 mM Tris-Base and 20% methanol). The equipment was the 
constructed as below, making sure there were no air bubbles between the gel and membrane. 
The transfer of protein from the gel to the membrane was carried out in 1 x Transfer buffer at 
100mA for 1 hour, with an icepack and stirring. 
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Anode Fibre Pad 
 Filter Paper 
 PVDF membrane 
 Polyacrylamide Gel 
 Filter paper 
Cathode Fibre Pad 
 
2.15.4 Immunoblotting 
Membranes were left to block overnight in 10% non-fat dried milk powder (Marvel) 
dissolved in PBS-Tween 0.1% (PBST) at 4°C, they were then left to incubate at room 
temperature for 1 hour on a roller with the primary antibody in 5% dried milk in PBST, 
antibodies and concentrations used may be found in the appendix. Membranes were washed 
by shaking in PBST for 5 minutes, this was repeated 3 times. The membrane was then 
blocked in 5% dried milk in PBST for 5 minutes before incubating with the secondary 
antibody in 5% dried milk in PBST for 1 hour on a roller. The membrane was subsequently 
washed 3 times in PBST. 
2.15.5 Detection 
For immunoblotting the secondary antibodies used were Horse Radish Peroxidase (HRP) 
conjugates and therefore the enhanced chemo-luminescence plus (ECL+) western blotting 
detection system reagents (GE Healthcare, Chalfont St Giles, UK) were used, 1ml of reagent 
A and 25µl of reagent B were mixed and added to the membrane for 10 minutes in the dark.  
The bands were detected using X-ray film (Kodak). 
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2.15.6 Stripping and Re-probing 
To strip the membrane of antibodies to reprobe to test for equal loading of protein, the 
membrane was placed face down in a beaker of boiling water for 20 minutes. The membrane 
was then blocked overnight in 10% dried milk in PBST and blotted as described in 2.12.4 and 
2.12.5. 
2.15.7 Densitometry 
Western blot films were scanned, and ImageJ (http://rsb.info.nih.gov/ij/index.html) was 
subsequently used to calculate relative quantites of protein by densitometry. Step by step 
instructions are described on the ImageJ website 
http://rsb.info.nih.gov/ij/docs/menus/analyze.html#gels. Each band was measured, and then the 
quantity normalised against β-actin measurements. In this way discrepancies in loading amounts 
were taken into consideration and allowed the comparison of different samples. 
 
 
2.16 Mouse strains 
Embryonic stem cells containing Vps33a gene trap were purchased from Bay Genomics. 
Chimeric mice were produced by injection of the ES cells into blastocysts by Andrea Bacon, 
The University of Birmingham. Those containing the allele within their germ cells were used 
to breed heterozygous mice, Vps33a+/- on a 129P2 background. Conditional Vps33b ES cell 
lines and subsequent mice with LoxP sites flanking Vps33b exons 2-3 were created by 
Artemis Pharmaceuticals, and Vps33b+/fl mice were provided for breeding. These were 
subsequently crossed in order to produce Vps33bfl/fl mice on a C57BL/6J background. Cre 
recombinase transgenic lines were selected for temporal or spatial control of Vps33b 
expression. A ubiquitous cre expressing line, Pgk-cre, utlilising a 3-phosphoglycerate (PGK-
1) promoter was used to remove Vps33b from all tissue (McBurney et al. 1994).  Pf4-cre 
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mice, utilizing the platelet factor 4 promoter were used to create megakaryocyte and platelet 
specific Vps33bfl/fl mouse (Tiedt et al. 2007). A liver specific Alb-cre line was selected which 
utilises the albumin cre promoter to create a liver specific Vps33b conditional knockout 
mouse (Postic et al. 1999). A second liver specific cre line was selected, Alfp-cre, which 
makes use of the albumin promoter and alphafetoprotein enhancers to induce cre expression at 
an earlier time-point in liver development (Kellendonk et al. 2000).  
 
2.17 Animal Husbandry 
Mice were fed standard laboratory mouse diet of grain pellets. A 12 hour uninterrupted light-
dark cycle was maintained for best breeding performance and litters were weaned at 3 weeks 
of age. Ear clipping was carried out after weaning for genotyping and individual mouse 
identification. The DNA was extracted from these ear clippings using 100µl DirectPCR Lysis 
Reagent (Viagen Biotech, Los Angeles, CA) and 20µl Proteinase K (Qiagen, Crawley, UK). 
Incubated overnight at 56ºC and then inactivated at 86ºC for 1hr. 1µl was subsequently used 
in a PCR reaction- see Appendix 1 for primer sequences. 
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2.18 Timed matings 
Mice were mated overnight and females were inspected for vaginal plugs the following 
morning. If plugs were identified, noon that day is considered stage E0.5.  
2.18.1 Embryo extraction and genotyping 
The uterus was extracted from a schedule 1 culled pregnant mouse at the appropriate time-
point. This was done by opening the body cavity and cutting across the cervix and 2 utero-
tubal junctions, placing the uterus on a clean surface. The uterus was then removed by 
inserting scissors into the hole created at the cervix and cutting up the length of the uterine 
horn. Embryos were removed and dissected as described in 2.15.2-2.15.3.  For genotyping the 
ectoplacental cone and Reichert’s membrane are maternally contaminated therefore care must 
be taken when selecting tissue for genotyping, the yolk sac was primarily used. The yolk sac 
was added to 150µl ATL buffer containing Proteinase K and incubated at 56ºC for 1 hour. 
140µl 100% isopropanol was then added to precipitate the DNA. The solution was spun at 
maximum speed in a centrifuge for 30 minutes at 4 ºC. The supernatant was then removed and 
discarded and the DNA pellet washed with 70% ethanol and spun for a further 10 minutes. 
Again the supernatant was removed and discarded and the pellet left to air dry for 10 minutes 
before being dissolved in 20µl H20. 5µl of the DNA was used per PCR reaction. If the first 
PCR did not allow successful genotyping a subsequent PCR from this reaction was carried 
out. The mice were genotyped using PCR, primer sequences found in Appendix1. 
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2.18.2 Dissection of E7.5 
Decidua were moved into fresh DMEM and were dissected using watchmaker forceps. The 
decidua was cut in half with the embryo remaining in one side. The embryo was then teased 
away from the remaining decidua. The trophoblast cells must be removed with careful use of 
forceps and subsequently the Reichert’s membrane must be removed by tearing it open by 
grasping it where it stands away from the underlying tissue at the embryonic pole with two 
pairs of forceps and pulling apart.  
2.18.3 Dissection of E8.5-9.5 
The decidua were removed into clean PBS and dissected using watchmaker forceps. The 
embryo can be found at the opposite end to the mesometrial pole. With one pair of forceps the 
decidua was secured at the mesometrial pole and then the decidual tissue was peeled back 
from the embryo. The yolk sac was then carefully removed, and images taken. 
 
2.19 Establishing ES cell lines from blastocysts 
2.19.1 Mouse Embryonic Fibroblast (MEF) feeder cell preparation 
Timed matings were carried out and the embryos were extracted at E14.5. The heart, liver and 
cerebellum were removed and the remaining tissue was added to 10ml 1x trypsin in PBS, and 
left to incubate at 37ºC for 30 minutes. 5ml of this solution was removed and added to 5ml 
DMEM (high glucose) and kept on ice. 5ml 1x trypsin was then added to the remaining 
solution and again incubated at 37ºC for 30 minutes. This process was repeated 6 times. The 
tubes containing cells were spun at 1200g for 4 minutes and the cell pellet plated in two 
150cm2 dishes with 40ml MEF growth media (Dulbeccos’s Modified Eagle’s Medium 
supplemented with 10% foetal bovine serum, 2mM L-glutamine, 1x MEM non-essential 
amino acid solution and 1x penicillin-streptomycin, 0.1mM β-mercaptoethanol) in each. The 
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cells were expanded. To stop the feeder cells from dividing they were irradiated with 40 Gy 
and frozen until required. 
2.19.2 E3.5 blastocyst extraction 
The uterus removed from an E3.5 pregnant female. The ovary from each uterine horn was 
removed and a needle used to flush the blastocyst from the uterus with DMEM. Using a 
dissecting microscope, blastocysts were removed from the petri dish by mouth pipette and 
placed in a 10cm 0.1% gelatin coated plate containing ES cell media (DMEM-KO, 1%  L-
Glutamine, 0.5% Pen/Strep (10,000 U/ml), 1% Non-essential amino acid, 15% Serum 
replacement, 0.1mM β-mercaptoethanol, 0.01% LIF 10^7 units, ESGRO LIF Millipore).  The 
blastocysts were incubated at 37ºC for 2-3 days until the blastocyst had attached then the 
media was changed.  
2.19.3 ES cell culture 
When a defined inner cell mass (ICM) outgrowth could be seen from 2.16.2, after 
approximately 5-6 days the outgrowth was manually picked using a pipette under 20x 
magnification on a light microscope. The cells were separated by pipetting the mixture and 
these were plated on gamma-MEFs in ES cell media. Media was changed daily and 
approximately 3-4 days after plating when ES cell colonies could be seen the cells were 
trypsinised (0.25 trypsin-EDTA) for 5 minutes. ES cell medium was then added to inhibit the 
trypsin and the cells plated on new gamma-MEFs plated a day previous. The cells were 
expanded as required and frozen down in freezing medium (20% DMSO, 30% ES cell media, 
30% serum replacement).  For genotyping cells were grown in a MEF free environment to 
prevent DNA contamination, and genotyped using the protocol used for genotyping the mice. 
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2.19.4 ES cell transfection with Cre-containing plasmid 
ES cells were expanded on MEFs until 3-4x10^6 ES cells (2x 6cm plate) were obtained. On 
day 1 the ES cell media was changed 2hr before transfection, and the media on the MEFs also 
changed to ES cell media. After 2 hours the ES cells were trypsinised as described in 2.16.3. 
The cells were counted and 3-4x10^6 cells were centrifuged at 1200RPM for 3 minutes and 
the cell pellet washed twice with PBS. The cells were electroporated using Amaxa 
Nucleofector Technology (Lonza, Basel, Switzerland). The pellet was resuspended in 100µl 
Nucleofector solution and added to a cuvette containing 10ug of plasmid (5ul of Cre-IRES-
EGFP plasmid) making sure there were no airbubbles. The cells were electroporated using 
Amaxa A-024 Nucleofector programme and then the sample was transferred into 500µl of 
pre-heated RPMI (37ºC) and incubated at 37ºC for 1 hour. The ES cells were then plated on 
MEFs by dropping solution over plate. New gamma-MEFs were plated on day 1. On day 3 
the media was changed to ES cell media on the gamma-MEFs. The ES cells were trypsinised 
as described in 2.16.3, and were centrifuged at 1200RPM and resuspended in 400µl ES 
media. The cells were filtered through a 50µm filter (Millipore, Billerica, MA) to get a single 
cell suspension. Cells were sorted using MoFlow High Speed Cell Sorter (Beckman Coulter, 
High Wicombe, UK), using a high purification threshold for GFP positive cells. These were 
then plated on gamma-MEFs and single colonies expanded as described in 2.16.3. Cells were 
grown in a MEF-free environment for genotyping, and were genotyped using the same PCR 
primers as for Vps33bfl/fl mice. 
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2.20 Analysis of Liver function 
2.20.1 Blood extraction for plasma protein analysis 
Blood samples were taken from the mice at ages specified. 100-150µl of blood was extracted 
from a mouse into a heparinised tube by nicking the tail with a needle and teasing the blood 
out. These blood samples were immediately taken to Birmingham Womens Hospital where 
their bilirubin and ALT levels were measured. 
2.20.2 Electrospray mass spectometry of bile acids 
A terminal blood sample was required for bile acid analysis, see section 2.18.5 for method. 
Plasma was isolated by centrifuging whole blood at 1000g for 5 minutes, and plasma removed 
from the top of the eppendorf into a clean tube. The samples were sent to Clinical Chemistry, 
Sheffield Children’s Hospital for electrospray analysis. 
2.20.3 Fixation and processing of liver samples 
Livers were immediately excised from schedule 1 culled mice. Small sections were taken and 
fixed in 4% formalin or snap frozen in liquid nitrogen for protein extraction. Subsequent, 
processing, paraffin embedding and sectioning was carried out by the histology service, 
Birmingham Women’s Hospital. 
2.20.4 Immunohistochemistry  
All immunohistochemistry specific reagents were obtained from Vector Laboratories, CA, 
unless otherwise stated. Liver paraffin sections were cleared with two 5 minute washes in 
histoclear (National Diagnostics, Atlanta, USA). Rehydration of tissue was carried out by 
progressive 5 minute washes through 100% ethanol (two times), 90% ethanol, 70% ethanol 
and 50% ethanol. The sections were then washed in water and antigen retrieval undertaken by 
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boiling for 5 minutes in 10mM Citrate buffer (citric acid monohydrate 2.1g in 1L water, pH6 
with 2M NaOH) two times. Samples were then cooled to room temperature and endogenous 
peroxidase blocked with 6% hydrogen peroxide for 15 minutes.  The sections were marked 
around with a DAKO pen and then blocked with 2% BSA-PBS-0.5% tween (PBST-BSA) for 
30 minutes. The sections were then incubated in 150µl of primary antibody diluted in PBST-
BSA tween for 1 hour. The slides were then washed 3 times for 5 minutes in PBST and 
incubated with 150µl of the secondary antibody (biotinylated) for 45 minutes. The sections 
were again washed 3 times in PBST and then incubated with ABC prepared 30 minutes 
previous, for half an hour. Slides were washed 3 times in PBST and then incubated with DAB 
for 2-10 minutes until colour developed. Slides were washed 3 times then counterstained with 
hematoxylin. The tissue was then dehydrated by passing through 90% ethanol, 100% ethanol 
and then histoclear before a 1,5 coverslip was placed over the sample using VectaMount. 
Slides were viewed using a Zeiss Axiovert zoom brightfield microscope, and imaged using 
AxoCam ICc1at 40x magnification, na 1,3. 
2.20.5 Immunofluorescent staining 
Sections were treated as in 2.17.4 up-to and including antigen retrieval in citrate buffer. 
Blocking of endogenous peroxidase was not required therefore this step was skipped, primary 
antibody incubation with chicken α-BSEP (1/300 dilution) and washing occurred as in 2.17.4. 
The secondary antibody, Goat α-chicken Alexa 488 (1/200) was used. Finally the sections 
were washed 3 times for 5 minutes in PBS and mounted using 1,5 coverslips with Prolong 
gold antifade reagent (Life Technologies, California) and imaged as described in 2.10.4. 
 
[91] 
 
2.21 Analysis of platelets and megakaryocytes 
2.21.1 Megakaryocyte culture 
To extract megakaryocytes, the rear legs of a schedule 1 culled mouse which had been kept on 
ice were removed, taking care not to break the head of the femur and placed in a Petri dish 
containing 70% ethanol. The femur and tibia were separated and cleaned to remove any tissue 
from the bones. Under a tissue culture hood the ends of the bones were cut and a 25g needle 
and syringe filled with complete DMEM media (DMEM media supplemented with 10% FBS, 
2mM Glutamine and 1% Pen/Strep) were used to flush out the bone marrow (~10ml per 
mouse). The cells were pelleted by centrifuging at 1200 rpm, 4°C for 5 min, and then 
resuspended in ACK buffer (0.15M NH4Cl; 1mM KHCO3; 0.1mM Na2EDTA pH7.3), 6ml 
per mouse and left for 5 minutes. Cells were filtered through a Millex-GP 70µm nylon mesh 
filter (Millipore, Watford, UK) then spun 1200 rpm, 4°C for 5 min to pellet. Cells were 
resuspended in 1ml complete DMEM media per mouse. Cells not required were depleted by 
incubating on ice with Anti-Gr-1, Anti-cd 11b, Anti B220, anti CD16/32 (3µl of each per 
mouse) (all from eBioscience, San Diego). 1ml of complete DMEM per mouse was added to 
the cells and spun at 1200 rpm, 4°C for 5 min to pellet and resuspended in 1ml complete 
DMEM per mouse. 50µl sheep anti-rat Dynabeads (Invitrogen, Paisley, UK) per mouse were 
prepared by washing 3 times in complete DMEM, and resuspended in 50µl complete DMEM 
per mouse. 50µl Anti-rat Dynabeads per mouse were added to the cells, spun at 1200 rpm, 
4°C for 5 min, and subsequently resuspended in their supernatant. Resuspension and spin was 
repeated and then a magnet was used to pull down the beads. The supernatant was removed to 
a separate tube, and 500µl of complete DMEM was added to the remaining beads and the 
beads were resuspended and pulled down, the supernatant pooled with that obtained 
previously. The cells were spun at 1200 rpm, 22°C for 5 minutes. The pellet was resuspended 
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in 1.5ml complete Stempro media (Stempro media, 2mM L-Glutamine, Stempro Nutrient 
Supplement) per mouse supplemented with 20ng/ml stem cell factor (SCF)(Peprotech, NJ, 
USA) placed in a 6 well plate and incubated for 48 hours at 37°C, 5% CO2. Next the cells 
were resuspended in 1.5ml complete Stempro media per mouse supplemented with 20ng/ml 
SCF and 50ng/ml murine TPO (Peprotech, NJ, USA) and left to incubate for a further 3-4 
days. In order to separate the megakaryocytes from the undifferentiated stem cells a BSA 
gradient was prepared for each mouse (4ml of 3% BSA on bottom, 4ml of 1.5% BSA on top), 
cells were resuspended in their medium and layered on top of the gradient and left for 45 
minutes. The top 8ml was removed for a second round of culture, and the bottom 2ml was 
centrifuged at 1200 rpm, 22°C for 5 minutes. The supernatant was removed and the pellet 
resuspended in 1ml PBS, centrifuged at 1200 rpm, 22°C for 5 minutes and then lysed with 
50µl RIPA buffer (50mM Tris-HCl, 150mM NaCl, 1mM EDTA, 1% Igepal CA630, 0.5% 
Sodium Deoxycholate, 0.1% SDS and complete mini protease inhibitor cocktail (Roche 
Diagnostics, Burgess Hill, UK)).  
2.21.2 Bleeding time tests 
Mice were anaesthetised with the inhalation anaesthetic isofluorane (Abbott, Maidenhead) 
and transferred to mask. They were then given 0.05ml buprenorphine by intraperitenial 
injection. 2mm was removed from the tail tip using a razor blade, and the drops of blood were 
counted and collected. Bleeding was measured for a maximum of 10% blood loss, 20 minutes 
or was stopped if no blood had fallen for 5 minutes. Blood droplets were assumed to be 30µl 
from previous normalisation. The tail was then cauterised in order to prevent further bleeding, 
and animals were left to recover. 
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2.21.3 Platelet count and Mean Platelet Volume  
Platelet count and mean platelet volumes were measured in whole blood by ABX Pentra 60 
whole blood counter. 
2.21.4 Spleen measurement 
Mice were weighed before the procedure and their spleens were removed after the terminal 
bleed. The spleen length was measured and the weight recorded. These values were then 
normalized to body weight. 
2.21.5 Mouse platelet preparation 
Mice were culled by anaesthetising deeply with isofluorane (Abbott, Maidenhead) and then 
CO2 for cessation of breathing. Blood was drawn by performing a laparotomy and blood was 
drawn from the inferior vena cava into 200µl acid citrate dextrose (ACD)(Sodium Citrate 
25g/L, Glucose 20g/L, citric acid 15g/L). Cervical dislocation was then performed. The 
needle was then removed to prevent platelet shearing and the blood was added to 200ul 
Modified Tyrodes Hepes buffer (134mM NaCl, 2.9mM KCl, 0.34mM Na2HPO4.12H2O, 
12mM NaHCO3, 20mM HEPES, 1mM MgCl2, 5mM glucose)  pH 7.3 in a 1.5ml eppendorf. 
Blood was spun at 2000 rpm for 5 minutes using a microfuge. The top 70% of blood was 
removed into a new 1.5ml eppendorf and centrifuged at 200g for 6 minutes at room 
temperature. Platelet Rich Plasma (PRP) was removed and 200µl Modified Tyrodes Hepes 
buffer was added to the remaining cells to extract more PRP and centrifuged again at 200g for 
a further 6 minutes. For washed platelets further steps were carried out. 10µg PGI2 was added 
to the PRP and then centrifuged at 1000g for 6 minutes room temperature to pellet the 
platelets. Platelets were resuspended in 200µl Modified Tyrodes Hepes buffer pH 7.3. Cells 
[94] 
 
were counted using a Coulter Particle Counter and size analyser and were adjusted to the 
required concentration with Modified Tyrodes Hepes buffer.  
2.21.6 α-granule secretion analysis by Flow Cytometry 
One-colour analysis of α-granule secretion was conducted using 5µl rat anti-mouse CD62P-
FITC conjugated antibody (Emfret analytics).  Platelets were diluted to 2 x 107 and 50µl of 
this platelet sample was subsequently stimulated with 1U/ml thrombin 10 minutes at 37°C. 
5µl of rat anti-mouse CD62P-FITC conjugated antibody was added and incubated in darkness 
at room temperature for 20 minutes. 200µl of MTH buffer was added and samples were 
analysed within 30 minutes. Flow cytometry analysis (using Becton Dickinson FACsCalibur) 
was performed on each sample, a total of 10,000 events per sample were collected and the 
platelet population was identified by forward and side scatter profile. Data were analysed 
using CellQuest software. 
2.21.7 Aggregometry and dense granule secretion 
0.3ml of 2 x 108 mouse platelets were analysed using a lumiaggregometer, Chrono-log 
Corporation Lumi-dual aggregometer. Aggregation was measured using light transmission 
under stirring (1200 rpm) conditions at 37°C. Platelets were preincubated for 3 minutes at 
37°C before stimulation with agonist. Each sample was allowed to aggregate for at least 2.5 
minutes. Dense granule release was monitored using the Chrono-Lume luciferin/luciferase 
reagent (Chrono-log corporation) to detect adenosine triphosphate (ATP) release. 10µl of 
luciferin/luciferase was added 2 minutes prior to addition of agonist. Following 2.5minutes of 
secretion/activation an ATP standard was added in order to calculate secretion. Aggregation 
and ATP release were monitored simultaneously.  
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2.21.8 In vitro flow assay 
Thrombi formation under shear conditions was observed by conducting an in vitro flow assay 
through collagen coated capillaries. The glass capillaries (1x0.1mm Camlab, Cambridge) 
were filled with 100µg/ml collagen by capillary action and left to rotate in an upright rotator 
at room temperature for 1 hour. A rubber tube was then attached to the end of the capillary, 
the collagen flushed out, and 5mg/ml FAF (fatty acid free) BSA was drawn up into the 
capillary and rotated again for 1 hour at room temperature in order to block the capillary. The 
capillary was then attached to a glass slide with superglue and tape to secure. Blood from the 
mouse was drawn by cardiac puncture under terminal anaesthesia into 100µl Modified 
Tyrodes Hepes buffer (recipe in 2.18.5) pH 7.3 supplemented with 40µmol P-PAC and 5U/ml 
heparin. The needle was then removed to prevent platelet shearing and the blood was added to 
a further 200µl Modified Tyrodes Hepes buffer pH 7.3 supplemented with 40µmol P-PAC 
and 5U/ml heparin in a 1.5ml eppendorf and incubated at 37°C for 10 minutes before the flow 
experiment. The microscope slide-mounted capillary was then attached to the flow apparatus 
and washed with Modified Tyrodes Hepes buffer at the required flow rate of 1000/s 
(0.1ml/min) allowing it to normalize. 400µl of whole blood was then flowed through the 
capillary for 4 minutes, and a subsequent wash for~5minutes with Modified Tyrodes Hepes 
buffer was carried out.  
The capillary for imaging was flushed with 100µl 3.7% paraformaldehyde, left for 30 minutes 
and then rinsed 3 times with PBS, and left at 4°C until it was required. Imaging was carried 
out using a Zeiss Axiovert zoom DIC microscope, with AxioCan ICc1 and Slidebook 
software. 3 images were captured at x20magnification (na 0,4) and 5 images at x63 oil 
emersion magnification (na 1,4) at different sections of each capillary for visual analysis. 
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The capillary for quantification of platelet adhesion was washed 3 times with 50µl Modified 
Tyrodes Hepes buffer. The capillary was then washed with 50µl NP-40 lysis buffer (150mM 
NaCl, 10mM Tris, 1mM EGTA, 1mM EDTA, 1% NP-40, 2.5mM Na3VO4, 1mM AEBSA, 
5µg/ml leupeptin, 5µg/ml aprotinin, 1.25µg/ml pepstatin) and the lysate was collected in an 
eppendorf for further analysis. 
2.22.9 Platelet preparation for EM 
The platelets were prepared as described in 2.18.5 up to and including the pelleting stage. The 
platelets were then resuspended in 1ml 2.5% EM grade glutaraldehyde in PBS. 
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CHAPTER 3 – ASSOCIATIONS AMONG 
GENOTYPE, CLINICAL PHENOTYPE AND 
INTRACELLULAR LOCALISATION OF 
TRAFFICKING PROTEINS IN ARC 
SYNDROME 
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3.1 Introduction 
Arthrogryposis, Renal dysfunction and Cholestasis syndrome (ARC; MIM 208085) is an 
autosomal recessive multisystem disorder caused by mutations in VPS33B and VIPAR (Gissen 
et al. 2004)(Cullinane et al. 2010). Characteristic presentation of ARC syndrome includes 
neonatal cholestatic jaundice, renal tubular acidosis, arthrogryposis and severe failure to 
thrive. Most patients fail to survive past the first year of life (Gissen et al. 2006). 
VPS33B is a member of the Sec1/Munc18 family proteins, which directly interact with 
SNAREs and aid SNARE complex formation, thus facilitating membrane tethering and fusion 
(Hata et al. 1993)(Yamaguchi et al. 2002)(Dulubova et al. 2003). VPS33B and VIPAR are 
homologues of yeast Vps33p and Vps16 respectively. In yeast these proteins along with 2 
other class C vps proteins (Vps11 and Vps18) make up the core of HOPS and CORVET 
complexes responsible for the maturation and control of vesicular trafficking from early to 
late endosomes and vacuoles (Peplowska et al. 2007). Study of the subunit organisation of 
HOPS and CORVET showed that Vps16 is required for Vps33p association with Vps11 and 
Vps18 (Reider and Emr, 1997), more specifically residues 451-595 at the C-terminal domain 
in yeast Vps16 mediates binding to Vps33 (Pulipparacharuvil et al. 2005). Vps18 has a crucial 
role in the assembly of HOPS and the removal of Vps18 prevents the co-immunoprecipitation 
of all other subunits with Vps11 (Plemel et al. 2011). Mammalian equivalents of HOPS have 
been studied by several groups (Kim et al. 2001)(Nickerson et al. 2009)(Zhu et al. 2009). In 
metazoans there are 2 homologues of yeast Vps33p, VPS33A and VPS33B. It is probable that 
VPS33A in metazoans is a part of the HOPS complex  (Sriram et al. 2003), but the conditions 
in which the VPS33B-VIPAR complex may be involved in HOPS are unknown (Cullinane et 
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al. 2010)(Zlatic et al. 2011). At present it is unclear whether there is a mammalian equivalent 
of the yeast CORVET complex (Zlatic et al. 2011).  
It has been reported that VPS33B forms a complex with VIPAR and that together they 
partially co-localise and co-immunoprecipitate with Rab11a. Rab11a is a small GTPase 
associated with apical recycling endosomes, thus implicating a role for the VPS33B-VIPAR 
complex in the apical recycling pathway (Cullinane et al. 2010). Furthermore, mislocalisation 
of apical membrane proteins in the liver and kidneys of ARC patients (Gissen et al. 
2004)(Cullinane et al. 2010) and structural and functional abnormalities in the apical junction 
complex (AJC) in mIMCD3 cells with VPS33B and VIPAR stable knockdown support a role 
for VPS33B-VIPAR complex in the maintenance of apical-basolateral polarity (Cullinane et 
al. 2010).  
3.2 Aims and methodology 
The role of the VPS33B-VIPAR complex in apical-basolateral polarity has not been 
delineated. Identification of disease-causing mutations which modify the structure of wild-
type protein can advance understanding of protein interactions and ultimately of their roles in 
intracellular processes. Therefore, in order to learn more about VPS33B and VIPAR, patient 
mutations identified by genetic screening- both published and novel, have been compiled in a 
LOVD database for ARC. Additionally, cell-based assays have been used with the aim to 
determine the effect of various mutations that occur in ARC patients on VPS33B-VIPAR 
complex formation. The interactions of wild-type VPS33B and VIPAR with the HOPS 
complex protein, VPS18, were studied to detect any possible functional evidence of the 
interaction of VPS33B-VIPAR with the HOPS complex.  
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3.3 Results 
3.3.1 ARC-LOVD Database Construction 
In collaboration with Ekaterina Gogolina, an online locus-specific ARC database 
(https://grenada.lumc.nl/LOVD2/ARC) was compiled using the Leiden Open Source 
Variation Database (LOVD) software system (Fokkema et al. 2011). 
To establish the database, relevant data from the Human Gene Mutations Database 
(www.hgmd.org) was added, and any mutations identified by literature search were included. 
The database also contains 188 unique variants taken from dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP) (Sherry et al. 2001) and the most up to date 
information from the 1000 Genomes Project (http://www.1000genomes.org/), including 
information on frequency.   
20 previously unpublished pathogenic variants were identified when patients with classical 
ARC phenotype were referred for molecular diagnosis and all coding exons and intron-exon 
boundaries were screened for mutations in VPS33B and VIPAR. One patient was screened for 
mutations in VPS33B by Prevention Genetics (http://www.preventiongenetics.com). These 20 
mutations were included in the database.  
Variants were named according to HGVS nomenclature guidelines (http://www.HGVS.org) 
and numbered using the VPS33B reference sequence (NG_012162.1, NM_018668.3) and the 
VIPAR reference sequence (NG_023421.1, NM_022067.3). Previously published mutations 
were renamed accordingly and all annotations were checked using Web-based Mutalyzer 
software linked to LOVD (Wildeman et al. 2008). 
VPS33B and VIPAR each have a gene homepage which provides general information about 
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the gene. In the “variants” section are variant-specific fields for each gene (exon, 
pathogenicity, template/technique used for detection, DNA/RNA/protein change, frequency, 
number of times reported, database ID, phenotype, and reference). Records describing 
variants per individual patient can be accessed, along with information on patient phenotype 
and ethnic/geographic origin. 
3.3.2 New Variants 
The database includes 15 novel variants in VPS33B that have been classed as ‘pathogenic’ 
(Table 3.1). Of the disease-causing variant types, most common are substitutions (n=11: 9 
splice-site and 2 nonsense). The effect of the splicing mutations was predicted by 
bioinformatic analysis using the BDGP Splice Site Prediction software NNSPLICE 
(http://www.fruitfly.org/seq_tools/splice.html). 3 deletions which are predicted to result in 
frameshift and premature termination of transcription are included, as well as one whole-gene 
deletion. A variant of particular interest is the splicing mutation c.1225+5G>C, as it is 
associated with an attenuated ARC phenotype (see section 3.3.4 and 3.3.7).  
In the database 5 novel mutations in VIPAR are included (Table 3.1), including substitutions 
(n=3: 2 missense and 1 nonsense), a deletion which is predicted to result in frameshift and 
premature termination of transcription, and a splicing mutation. All are classed as 
‘pathogenic’ or ‘probably pathogenic’.  
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Table 3.1 Novel Pathogenic VPS33B and VIPAR variants listed in ARC database 
Nucleotides are numbered from the A of the ATG initiation codon. Del, deletion; Fs, 
frameshift; i, intron; *, stop; Δ, whole exon deletion;ap.(?) effect of the variant upon the 
protein is unknown. bp.(0?) no protein product is predicted 
 
 
Database ID 
 
 
Gene 
 
Exon 
 
DNA Change 
 
Protein Change 
 
VPS33B_00221 VPS33B 1 c.67C>T p.(Arg23*) 
VPS33B_00223 VPS33B 1i c.97-2A>C p.(?)a 
VPS33B_00231 VPS33B 2i c.178-2A>C p.(?) 
VPS33B_00224 VPS33B 2i c.178-1G>C p.(?) 
VPS33B_00225 VPS33B 10 c.711del p.(Phe237Leufs*2) 
VPS33B_00226 VPS33B 11i c.853-3C>G p.(?) 
VPS33B_00227 VPS33B 13i c.1030+5G>T p.(?) 
VPS33B_00230 VPS33B 16i c.1225+5G>C p.(?) 
VPS33B_00229 VPS33B 17 c.1261_1262del p.(Gln421Valfs*8) 
VPS33B_00228 VPS33B 20 c.1498G>T p.(Glu500*) 
VPS33B_00232 VPS33B Δ4 c.240-577_290-156del p.(Leu81Serfs*5) 
VPS33B_00233 VPS33B 3i c.240-1G>C p.(?) 
VPS33B_00234 VPS33B 21i c.1657+1G>A p.(?) 
VPS33B_00226 VPS33B 11i c.853-3C>G p.(?) 
VPS33B_00235 VPS33B 1-23 c.(?_-354)_(*431+d127_?)del p.(0?)b 
VIPAR_00023 VIPAR 9 c.638T>C p.(Leu213Pro) 
VIPAR_00021 VIPAR 6 c.463_464del p.(Trp155Glufs*4) 
VIPAR_00022 VIPAR 6 c.484C>T p.(Arg162*) 
VIPAR_00019 VIPAR 13 c.1021T>C p.(Cys341Arg) 
VIPAR_00020 VIPAR 11i c.837-1G>T p.(?) 
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3.3.3 Database Analysis  
As of January 2012, the ARC database contained 235 unique variants in VPS33B and 23 in 
VIPAR. Forty-six variants in VPS33B have been classed as ‘pathogenic’ or ‘probably 
pathogenic’ due to their predicted effect on the protein and the clinical presentation of the 
patients in whom they were found. Most of these are substitutions (n=32; 20 splice-site, 10 
nonsense, and 2 missense). There are also deletions (n=9; including 1 whole gene deletion), 
duplications (n=2), insertions (n=1), and indels (n=1), all of which are predicted to result in 
frameshift and premature termination of transcription. There are 9 recurrent variants, of which 
3 are more prevalent; a splice site mutation, c.403+2T>A (reported in 11 individual patients, 
all of Korean origin), a nonsense mutation, c.1312C>T (reported in 9 patients; 8 of Pakistani 
origin and one Arabic), and a nonsense mutation c.1519C>T (reported in 7 patients; 3 
Portuguese, 1 Korean, 1 Hispanic, 2 unknown ethnicity) (references are provided within the 
database).  
There are 11 ‘pathogenic’ variants in the VIPAR gene, most of which are substitutions (n=8; 6 
nonsense and 2 missense). There also are 2 deletions (resulting in frameshift) and one splice-
site mutation. There are two recurrent variants; a nonsense mutation, c.658C>T (reported in 2 
patients; of Italian and Turkish ethnic origins) and nonsense mutation, c.808C>T (reported in 
2 patients; Pakistani and Arab-Israeli).  
The distribution of variants is relatively uniform within VPS33B; no obvious mutational 
hotspots were identified (Figure 3.1). Protein structure predictions for VPS33B and VIPAR 
suggest that both proteins contain globular regions with well-defined secondary structure 
elements. VPS33B contains a Sec1 domain spanning almost the entire protein, amino acids 
31-611. A large disordered protein segment has been consistently identified by multiple 
structure prediction software at the N-terminus of VIPAR (Figure 3.1). At present, with the  
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Figure 3.1 ARC-LOVD database content analysis.  
VPS33B Gene map of distribution of ‘pathogenic’ and ‘probably pathogenic’ variants in 
VPS33B. The boxes represent the exons (not to scale). All variants are described at the DNA 
level. Variants below the genogram represent intronic mutations, affecting splice-sites. 
Variants above the genogram represent mutations in exons. Purple pointers indicate 
substitutions; → indicates a nonsense mutation, —• indicates a missense mutation. Orange 
pointers indicate deletions/duplications/indels; → indicates a deletion, —• indicates a 
duplication, and —♦ indicates an indel.  
VIPAR Gene map of distribution of ‘pathogenic’ and ‘probably pathogenic’ variants in 
VIPAR. The boxes represent the exons (not to scale). All variants are described at the DNA 
level. Variants above the genogram represent mutations in the exons. Purple pointers indicate 
substitutions; → indicates a nonsense mutation, —• indicates a missense mutation. The 
orange pointer → indicates a deletion. 
[105] 
 
exception of a single pathogenic mutation in the start codon, the N-terminal part of VIPAR is 
devoid of mutations. This might suggest that this region of VIPAR is dispensable for 
VPS33B-VIPAR interaction. 
3.3.4 Identification of patients with an attenuated ARC phenotype 
Patients with the suspected diagnosis of ARC were referred for molecular diagnosis.  Patient 
AB was referred for mutation screening at 2 ½ years with what appeared to be an attenuated 
phenotype of ARC. AB is a son of non-consanguineous Peruvian and Puerto Rican descent. 
His clinical features included failure to thrive, developmental delay with sensorineural 
hearing loss, renal loss of protein and amino acids, bilateral talipes with osteopenia and mild 
cholestasis. The MRI scan of the brain showed dysmorphic ventricles with coaptation of the 
occipital horns and irregular contour along the margins of the lateral ventricles. There was 
also mild confluent hyperintense T2 signal in the periventricular white matter consistent with 
early in utero ischaemic injury. He had very troublesome ichthyosis, which was associated 
with increased serum concentrations of bile acids and was not responsive to conventional 
therapy. Clinical management with supplemental feeds via gastric-tube achieved steady 
growth along 0.3 percentile for his weight and height. Pruritus responded to cutaneous biliary 
diversion performed at age 3 years (Figure 3.2A-D). 
At the age of 5.5 AB is attending kindergarten and a special school for children with hearing 
impairment. He is making slow progress in his development, such as learning to say two-
syllable words. AB has difficulties with using sign language due to severe hyperkeratosis and 
lichenification of the skin on his hands. He is able to walk on his own. He likes to play with 
other children particularly basketball, when he likes to dribble and shoot baskets. He is able to 
ride his bicycle with training wheels. Although thick, calloused hand skin (Figure 3.2C) 
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interferes with fine motor tasks, this problem seems to be responding to dermatological 
management. 
AB continues to have osteopenia with shortening of the proximal fibula, generalised amino-
aciduria and nephrotic range proteinuria, and recurrent episodes of epistaxis associated with 
the absence of platelet α-granules (personal communication, Dr R Romero). 
 
Patient CD was referred for a clinical opinion at the age of 12 months with the features of 
possible ARC. She was found to have arthrogryposis and failure to thrive at two weeks of age. 
Further investigations identified renal tubular defect, mild cholestasis, hyperpigmented 
lichenified skin, bilateral hip dislocations, decreased muscle bulk and sensorineural hearing 
loss (Figure 3.2E-I). She was not jaundiced but had hypercholanaemia. Magnetic resonance 
imaging at 14 months showed a thin corpus callosum and diffuse paucity of white matter. 
However, she continued to progress in her development with appropriate socialisation. Speech 
improved after a hearing aid was fitted. Pruritus improved with rifampicin, phenobarbitone 
and ursodeoxycholic acid treatment. CD continues to fail to thrive despite supplementary 
feeds. At age 3 years she underwent corrective surgery for hip dysplasia; she is starting to 
walk. Additional clinical problems include abnormal dental composition with weak enamel 
and easily chipped teeth (Figure 3.2E) (personal communication, Dr R Chang).  
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Figure 3.2 Patients with attenuated ARC syndrome. 
A-D Patient AB. Aged (A) 3 years and (B) 5 years. Hyperkeratosis and lichenification of 
palm of right hand (C) and sole of left foot (D). 
E-I, Patient CD. Facies aged 3 (E); in plaster after corrective hip surgery (F). Hyperkeratosis, 
dorsum of right foot (G). Radiographs of right foot showing vertical talus (H) and of pelvis 
showing hip dislocation (I). 
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3.3.5 Mutation identification in Patient AB 
Sequencing of VPS33B identified a heterozygous splice donor mutation c.1225+5 G>C in 
intron 6, also identified in the father (figure 3.4A). A single heterozygous mutation however 
is insufficient for diagnosis of ARC syndrome. Amplification of the first 5 exons of cDNA by 
PCR identified wild type length cDNA and cDNA approximately 50bp shorter. Sequencing of 
this fragment found that exon 4 was absent from the cDNA (figure 3.3B), resulting in a 
frameshift and premature stop codon, p.Ser81Valfs*5. Subsequent long-range PCR and nested 
sequencing allowed characterisation of the second heterozygous mutation identified in patient 
AB, a 983bp deletion, g.8164_9176del983 also present in the mother (figure 3.3A). The 
patient therefore was compound heterozygous for mutations in VPS33B.  
In the case of Patient AB, an exon deletion could be identified due to the availability of 
patient fibroblasts for RNA and protein analysis. However, when patient fibroblasts are not 
available, a heterozygous deletion of an exon is not detected by standard sequencing. An 
alternative method to using RNA analysis to detect exon deletions would therefore be useful. 
Quantitative real time PCR on genomic DNA was used in order to calculate exon 4 copy 
numbers in patient AB and family members. A haploid sample would give the value 1 once 
normalised against reference genes and 0.5 for those with a heterozygous deletion (Hoebeeck 
et al. 2005). Patient AB and the mother were found to have the deletion, the control and father 
not. There are patients referred for ARC syndrome screening found to have a single 
heterozygous mutation by standard sequencing. ARC syndrome diagnosis cannot be 
confirmed with a single heterozygous hit therefore these patients may benefit from the 
analysis of exon copy number within VPS33B and VIPAR. Subsequent to this work, whole 
exon deletions in further ARC patients have been identified by Birmingham Women's 
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Hospital by alternative methods including microarray confirming the need to look for whole 
exon deletions in suspected ARC patients.  
 
3.3.6 Mutation identification in Patient CD 
VPS33B sequencing, carried out by Prevention Genetics, found the patient to be compound 
heterozygous for c.1261-1262delCA, predicted to result in a frame-shift and premature 
protein termination (p.Gln421Valfs*8), and c.1225+5G>C, the splice donor site mutation 
identified in patient AB.  
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Figure 3.3 Characterisation of the heterozygous deletion mutation in Patient AB  
(A) Electropherogram identifying the location of the 983bp delection c.240-277_290-156del 
in VPS33B and an electropherogram (B) of the resultant cDNA lacking exon 4. The deletion 
results in a frameshift and premature stop codon in VPS33B. (C) PCR products using primers 
flanking the deletion indicate that maternal DNA contains the deletion but DNA from father 
does not. qRT-PCR results using genomic DNA (D) confirm this finding. Exon 4 is 
normalized against GAPDH and actin. Samples containing 2 copies of the exon will give the 
result 1, and those containing one copy due to a heterozygous deletion will give the result 0.5. 
Samples from the mother and Patient AB contain only one copy of exon 4. 
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3.3.7 Characterisation of the donor splice site mutation in Patient AB and Patient CD 
Although the mutations present were predicted to yield a severe phenotype, both AB and CD 
had an attenuated form of ARC. This finding merited further investigation. Immunoblotting of 
protein obtained from AB’s fibroblasts indicated the presence of VPS33B protein product 
shorter than control (figure 3.4C). When 3’-RACE was used to amplify the VPS33B transcript 
of unknown composition resulting from the splice site mutation, 114bp of intron 16 were 
found integrated into the VPS33B transcript before termination with a polyA tail (figure 
3.4B). The predicted protein composition therefore includes 12 additional amino-acid 
residues, encoded by this intronic sequence, before a stop codon. Exons 17-23 are absent from 
the cDNA thus resulting in a predicted protein length of 420aa in comparison to the wild-type 
617aa (figure 3.4D).    
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Figure 3.4 Characterisation of the heterozygous splice site mutation in Patient AB  
Electropherograms showing (A) the c.1225+5G>C mutation and (B) the difference in VPS33B 
cDNA composition between wild-type and patient; 114bp of intronic sequence after exon 16 
was integrated into the VPS33B transcript before termination with a polyA tail. (C) VPS33B 
immunoblot using protein obtained from control fibroblasts (lane 1), patients with c.1312C>T 
(lane 2), c.1594C>T and c.1225+5G>C (lane 4) identifies a smaller protein product in lane 4. 
(D) A diagram showing the predicted protein composition of mutant (MUT) VPS33B in 
comparison to wild type (WT) including 12 additional aminoacid residues encoded by the 
intronic sequence before a putative stop codon. Exons 17-23 are absent.  
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3.3.8 Genotype-phenotype correlation, VPS33B-VIPAR complex formation 
Most known VPS33B and VIPAR mutations result in complete absence of the protein product 
(Cullinane et al. 2009). Mutations predicted to result in an expressed protein from patients 
with phenotypes assessed as severe (VPS33B p.Leu30Pro and VIPAR p.Leu213Pro) and 
moderate (VPS33B c.1225+5G>C) phenotypes were selected for modelling to gain further 
insight into VPS33B and VIPAR function.  
Overexpression of VPS33B and VIPAR within HEK293 cells has found that these 2 proteins 
strongly co-localise to defined spots, and that these partially co-localise with RAB11A, a 
marker for recycling endosomes (Cullinane et al. 2010). 
Transfections of epitope-tagged constructs were used to investigate whether patient mutations 
in VPS33B or VIPAR disrupt the interaction between these proteins when overexpressed in 
HEK293 cells using co-localisation studies. Whilst wild-type VPS33B and VIPAR co-
localised (Figure 3.5A), co-overexpression of VPS33B and VIPAR(L213P) mutant did not 
result in co-localisation; a cytoplasmic distribution for both proteins was observed (figure 
3.5B). Similarly, co-overexpression of VPS33B(L30P) mutant with VIPAR (figure 3.5C) also 
resulted in cytoplasmic distribution for both proteins. The severe clinical phenotype 
associated with these mutations confirms the importance of VPS33B-VIPAR complex 
formation for the function of these proteins. Finally, when VPS33B(c.1225+5G>C) mutant 
(known to be associated with an attenuated clinical phenotype, see sections 3.3.4 and 3.3.7) 
was co-overexpressed with wild type VIPAR (figure 3.5D), specific fluorescent spots 
containing both proteins were observed. In addition aggregates containing only VPS33B 
could be seen. Thus it appears that the c.1225+5G>C VPS33B mutant retains partial ability to 
interact with VIPAR.  
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To investigate the sites of co-localisation of VPS33B and VIPAR in ultrastructural detail 
cryo-immunogold electron microscopy (EM) of HEK293 cells overexpressing different 
combinations of constructs was performed in collaboration with Romain Galmes, Utrecht. 
This showed that the wild-type proteins co-localised on endosome-associated tubular-
vesicular membranes also positive for transferrin receptor (figure 3.6A and 3.6B). The 
morphological and molecular characteristics of these membranes, including the presence of 
RAB11A as seen by immunofluorescence, identifies them as recycling endosomes (Sachse et 
al. 2002). When VPS33B(c.1225+5G>C) mutant was co-transfected with VIPAR, the 2 
proteins co-localised mainly in electrondense cytoplasmic clusters that contained no 
membranes (Figure 3.6C). Interestingly however, some staining for VPS33B(c.1225+5G>C) 
could be detected on vesicles found at the rims of these cytoplasmic aggregates. Thus, the 
VPS33B(c.1225+5G>C) mutation seems to affect the ability of the complexes to co-localise 
properly on tubular-vesicular recycling membranes, which is likely to abrogate at least 
partially its cellular functioning. 
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Figure 3.5 VPS33B and VIPAR interaction 
Confocal fluorescence photomicrographs of HEK293 cells co-transfected with wild-type and 
mutant constructs of YFP-tagged VPS33B and Myc-tagged VIPAR. Wild-type YFP-VPS33B 
and Myc-VIPAR co-localised (A). However, constructs modelled on severe-phenotype 
mutant proteins (B) Myc-VIPAR(L213P) and (C) YFP-VPS33B(L30P) resulted in a 
disruption of VPS33B-VIPAR interaction. (D) Transfection for YFP-VPS33B(c.1225G>C), 
modeling an attenuated phenotype, resulted in partial co-localisation. Myc-VIPAR was 
immunostained with mouse monoclonal antibody anti-myc (Sigma) at a 1:400 concentration 
and anti-mouse ALEXA-568 conjugate secondary antibody (Invitrogen) at a concentration of 
1:400. Nuclei are stained with TO-PRO-3. Scale bars, 10µm, n=3.  
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Figure 3.6 Ultrastructural localisation of VPS33B, VPS33B(c.1225+5G>C), VIPAR and 
VPS18 constructs. 
Transmission electron micrographs of ultrathin cryosections of HEK293 cells. (A and B), 
Cells co-transfected with YFP-tagged VPS33B and Myc-tagged VIPAR were immunogold-
stained with anti-GFP/YFP (15 nanometer gold) and anti-Myc (10 nanometer gold) (A), or 
anti-GFP/YFP (15 nanometer gold) and anti-TfR (10 nanometer gold) (B). Co-localisation 
was observed on endosome (E)-associated tubular-vesicular membranes typical of recycling 
endosomes, which was confirmed by the presence of TfR (arrows in B). (C) Cells co-
overexpressing YFP-VPS33B(c.1225G>C) and Myc-VIPAR were immunogold-labelled for 
anti-GFP/YFP (15 nanometer gold) and Myc (10 nanometer gold). The two proteins co-
localised in cytosolic aggregates with partial staining of VPS33B(c.1225G>C) on nearby 
vesicles (arrows). (D) Cells co-overexpressing YFP-tagged VIPAR (labelled with antiGFP; 
10 nanometer gold) and Myc-tagged VPS18 (labelled with anti-Myc, 15 nanometer gold) 
showed co-localisation in cytosolic aggregates. E: endosome, N: Nucleus, PM: Plasma 
Membrane. Scale bars, 200nm. 
Performed in collaboration with Romain Galmes, University Medical Centre, Utrecht 
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3.3.9 Interaction of VPS33B and VIPAR with the core HOPS complex protein VPS18 
To identify whether VPS33B and/or VIPAR may interact with the mammalian HOPS, their 
co-localisation with human VPS18 protein, which has a central role in HOPS subunit 
interactions was studied (Ostrowicz et al. 2010)(Plemel et al. 2011). 
When VPS18 was co-overexpressed with VPS33B, the 2 proteins did not co-localise (Figure 
3.7A): VPS33B was cytoplasmic and VPS18 formed small spots. When transfected 
independently, VPS18 has a small punctate distribution (data not shown), however, when co-
transfected with VPS33B it forms larger spots. This maybe an induction of VPS18 aggregate 
formation secondary to VPS33B overexpression, however the reason for this is unknown. 
When VPS18 was co-overexpressed with VIPAR there was co-localisation in large 
fluorescent spots (Figure 3.7B). However, by immuno-EM these spots were identified as 
cytoplasmic aggregates, without any membranes associated (figure 3.6D). 
Interestingly, when all 3 constructs were co-transfected into HEK293 cells (figure 3.7C), 
VIPAR co-localised and formed clusters with VPS33B, whilst VPS18 was cytoplasmic. 
These interactions were confirmed by co-immunoprecipitation experiments: HA-VIPAR 
could pull down members of the HOPS complex, especially VPS18 where a strong interaction 
was seen (Appendix 2). However, when this experiment was repeated in the presence of 
overexpressed YFP-VPS33B this strong interaction diminished considerably, confirming the 
immunofluorescence findings (Appendix 2). 
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Figure 3.7 VPS33B and VIPAR interaction with VPS18.  
Confocal fluorescence photomicrographs of HEK293 cells co-transfected with (A) YFP-
VPS33B and Myc-VPS18 found these proteins do not co-localise. However, (B) mCherry-
VIPAR and Myc-VPS18 do co-localise in clusters in the absence of YFP-VPS33B. If all three 
proteins were co-transfected, then YFP-VPS33B and mCherry-VIPAR formed clusters and 
Myc-VPS18 assumed independent cytoplasmic distribution (C).  Myc-VPS18 was 
immunostained with mouse monoclonal antibody anti-myc (Sigma) and anti-mouse ALEXA-
568 conjugate secondary antibody (Invitrogen), both at a concentration of 1:400. Scale bar, 
10µm, n=3 
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3.4 Conclusions  
Mutations in VPS33B and VIPAR have typically resulted in a severe ARC phenotype causing 
death within the first year (Gissen et al. 2004)(Cullinane et al. 2010). Previously reported 
mutations plus 20 novel mutations were collated to form an online database 
(https://grenada.lumc.nl/LOVD2/ARC). Mutations are distributed throughout the length of 
VPS33B, consistent with the Sec1 domain spanning the length of the protein (Carim et al. 
2000), whereas mutations in VIPAR are only present at the C-terminal globular region of the 
protein.  
3.4.1 VPS33B and VIPAR co-localisation is disrupted when severe ARC phenotype 
mutations are modelled 
The mutated proteins VPS33B(L30P) and VIPAR(L213P), which are associated with a severe 
ARC phenotype, did not co-localise with their respective wild type partners. The mutation 
L30P, modelled using bioinformatics analysis (Gissen et al. 2005), is predicted to disrupt an 
alpha-helix in VPS33B. Predicted secondary structure of wild type VIPAR includes an 
extended disordered region at the N-terminus (residues 1-150) followed by a 100% alpha-
helical domain that extends to the C-terminus (residues 105-491). A Leu213Pro substitution 
in VIPAR is predicted to result in the disruption of an alpha helix in the core of a folded 
region of VIPAR structure. Both VPS33B(L30P) and VIPAR(L213P) mutations might affect 
the overall folding of the protein and thus their interaction with wild-type VIPAR or VPS33B 
respectively and/or other potential binding partners. 
3.4.2 Identification of an attenuated phenotype, and partial VPS33B-VIPAR co-
localisation 
Two patients with an attenuated ARC phenotype were identified. They have a c.1225+5G>C 
splice site mutation in VPS33B in common. This mutation generates a truncated form of 
VPS33B (residues 1-420) that still partially co-localises with VIPAR (Figure 3.5D). From this 
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evidence and also the electron microscopy experiments it can be affirmed that truncation of 
the C-terminal region of VPS33B, as seen with the c.1225+5G>C splice mutation, may alter 
the overall interaction between VPS33B and VIPAR and the localisation of the complex. 
However, the attenuated clinical phenotype and the presence in cell culture of VPS33B- and 
VIPAR-containing clusters suggest that some of the function of the VPS33B-VIPAR complex 
may be retained. The finding that clusters containing VPS33B(c1225+5G>C) and VIPAR are 
mainly cytoplasmic suggests that the expected interaction of SM protein VPS33B with 
transmembrane SNAREs might be important for the proper localisation and function of the 
complex. In addition, interaction with SNARE proteins might be possible only after VIPAR 
binding to VPS33B, since overexpression of VPS33B alone is not sufficient to localise 
VPS33B on recycling endosomes.  
3.4.3 VPS33B and VIPAR interaction with the HOPS complex protein, VPS18 
Co-overexpression studies in HEK293 cells suggest that VIPAR may interact with VPS18 
only in the absence of VPS33B. Therefore, the VPS33B-VIPAR complex is unlikely to be 
involved in HOPS interaction. However, VIPAR may interact with VPS18 in cells with 
mutant VPS33B, implying that this interaction might be involved in ARC pathogenesis. 
 
This work highlights the importance of VPS33B-VIPAR co-localisation at membranous 
organelles, typical of recycling endosomes, for the correct cellular functioning of this 
complex. It also suggests that this complex may not be involved in HOPS complex 
interaction. 
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CHAPTER 4 - Vps33a AND Vps33b MOUSE 
MODELS 
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4.1 Introduction 
Multiple model organisms have been used to investigate the function of the two homologues 
of yeast Vps33p, Vps33a and Vps33b, and the homologue of yeast vps16, Vipar, described in 
section 1.9. Vps33a models include, a carnation mutant in Drosophila and the buff mouse, 
with missense mutation in Vps33a (Sevrioukov et al. 1999)(Suzuki et al. 2003)(Akbar et al. 
2009).  C. elegans Vps33b knockdown using RNAi, and Zebrafish morpholino (Matthews et 
al. 2005)(Zhu et al. 2009)(Matthews et al. 2005) have been developed to study Vps33b. 
Finally, Vipar models include C. elegans spe-39 mutant, a fob Drosophila homozygous null 
allele and a zebrafish morpholino (Zhu et al. 2009)(Cullinane et al. 2010)(Akbar et al. 2011).  
When creating a disease model the choice of organism should be considered carefully as each 
has its own advantages and disadvantages, a good summary found in Model Organisms- A 
historical perspective (Müller & Grossniklaus 2010). The mouse was selected to create 
knockout models of Vps33a and Vps33b deficiency, as 1) no mammalian models of ARC 
syndrome have yet been reported and 2) the buff mouse may not represent the true deficiency 
of a constituent HOPS complex component protein. 
Mice have been widely used to model human disease due to the striking homology between 
the two genomes (Chinwalla et al. 2002) with the percentage of mouse genes without a human 
homologue and vice versa at less than 1%. As a result of this homology, mice are similar to 
humans in many ways ranging from anatomy and physiology to cell biology.  The blood for 
example can be analysed in the same way as human blood to characterise defects in organ, 
immune or platelet function. They have an advantage over other mammals as they are small 
and therefore cheaper to maintain, and have quick gestation period of 19-21 days. Another 
advantage is that they are available as inbred strains, where littermates have been crossed for 
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at least 20 generations, in this way on average 96.8% of the loci are homozygous. Some 
strains have been bred for 150 generations and are essentially entirely homozygous and 
genetically identical, therefore a genetic profile of the strain can be carried out by looking at 
an individual mouse (Beck et al. 2000). This has the advantage that transplantation such as 
bone marrow and liver transplantation may be carried out without rejection due to their MHC 
antigens being identical (Coico & Sunshine 2009).  In addition, different strains are more 
suitable for different applications, for example senescence-accelerated mice display 
accelerated ageing (Takeda et al. 1997). 
One of the major benefits of using mice as a model for genetic disorders is our ability to 
perform gene knockouts in laboratory mice via ES cells, a tool that has been successfully used 
for the past 2 decades (Collins et al. 2007) making it a widely used model for human disease.  
Targeted gene disruption, utilises the process of homologous recombination which occurs 
during cell division. It requires individual vectors for each gene to be produced and thus is 
low throughput (Thomas & Capecchi 1987). A construct is made containing flanking 
sequences homologous to the gene of interest, and a central deleterious mutation such as a 
truncating mutation which is inserted into the construct (Bockamp et al. 2002). By 
introducing this construct into ES cells the deleterious construct can be introduced into the 
gene of interest by homologous recombination thus creating a null allele or ‘knockout’. 
Reporter genes, such as GFP or neo (neomycin resistance) may also be inserted allowing 
enrichment of successful recombination events – a low frequency event (Kent 2007). As 
targeted homologous recombination is a low throughput process, random insertion of 
‘genetrapping’ vectors into the genome, and subsequent identification of the disrupted gene 
by sequencing the cDNA by use of an identifying marker has allowed the production of a 
large volume of commercially available ES cells available for research (Stryke et al. 2003). 
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The ES cells produced by both of these approaches are injected into the blastocoel (open 
cavity) of an E3.5 wild-type blastocyst and implanted into a surrogate mother. Chimeric 
offspring are subsequently produced and mice containing the mutated allele in their germ cells 
are bred to create mice heterozygous and eventually homozygous for the genetrap.  
Since 15% of gene knockouts result in embryonic lethality 
(http://www.genome.gov/12514551) a method for selective removal of the gene of interest 
temporally or spatially is required. Two major systems have been utilised in transgenic mice, 
the phage based system using Cre/loxP (Sauer 1998), and a prokaryotic-based system using 
the tet operon (Furth et al. 1994).  
The Phage based system utilises targeted gene targeting and requires 2 elements. A vector 
containing loxP elements flanking an area of the gene of interest (termed floxed DNA) is 
constructed. This is inserted into ES cells by homologous recombination which are then used 
to produce chimeric mice by injection of the ES cells into blastocysts, and subsequent 
heterozygous and homozygous mice by breeding. LoxP elements are 34bp elements, 
consisting of two 13bp inverted repeats separated by a central 8bp spacer, the consensus 
sequence for cre-recombinase binding (Yamamoto et al. 2001). Once mice homozygous for 
this vector are created, they can be crossed with mouse lines containing specific promoter 
driven cre-recombinase lines. Cre-recombinase is a site specific DNA recombinase of the 
integrase family isolated from the P1 bacteriophage (Sternberg & Hamilton 1981). In the cells 
where the cre-recombinase is produced, two cre-recombinase molecules bind to each LoxP 
site, these then form a tetramer to bring the two sites together excising the floxed DNA and 
allowing the genomic DNA to recombine (Yamamoto et al. 2001). This process may be 
temporally or spatially controlled by controlling the expression of cre-recombinase and thus 
DNA excision. Various cre-recombinase lines have been engineered with promoters active in 
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select cells to allow the expression of cre in various tissues at different timepoints. This 
allows the gene to be turned on or off in a controlled manner (Jaisser 2000). For example, use 
of the albumin promoter allows expression of cre-recombinase in the liver. Cre-recombinase 
expression may also be controlled temporally by using cre- recombinase fused to the ligand 
binding domain of nuclear receptors, preventing cre from accessing the floxed DNA. The 
ligand binding domains are mutated in order to recognise only exogenous ligands, e.g. 
tamoxifen. When the ligand is added, the fusion protein is able to translocate into the nucleus, 
where the cre-recombinase can carry out its excision (Sauer 1998)(Metzger & Feil 1999). 
A prokaryotic based system was developed by the Herman Bujard laboratory (Furth et al. 
1994). It utilises the transposon-10 specified tetracycline-resistance (tet) operon of E.coli  
(Yamamoto et al. 2001), and relies on 2 components, a tetracycline-controlled transactivator 
(tTA), and a tTA dependent promoter that controls expression of the gene of interest. In the 
absence of tetracycline or its derivative doxycycline, tTA is constitutively active and able to 
bind to the tTA dependent promoter allowing the gene of interest to be expressed. In the 
presence of tetracycline or doxycycline however, tTA is no longer able to bind to its DNA and 
the gene is downregulated. This is known as a ‘Tet-OFF’ system (Gossen & Bujard 
1992)(Furth et al. 1994). A ‘Tet-ON’ system is also available (Kistner et al. 1996), this is 
where a mutant tTA termed rtTA is used. rtTA is not active until doxycycline is administered, 
the opposite function of tTA. The tet system has been widely used for the induced expression 
of transgenes in order to study subjects such as prion disease and memory (Tremblay et al. 
1998)(Mansuy et al. 1998). One of the advantages of the tet system is that the effects are 
reversible by stopping treatment with doxycycline, therefore the reversibility of the effects of 
knockdown or overexpression may be studied. 
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Although a Vps33a mouse mutant, the buff mouse has been reported, the creation of a Vps33b 
or Vipar deficient mouse model has not. Therefore the aim of this work was to create and 
phenotype a ubiquitous Vps33b deficient mouse and its homologue, a Vps33a deficient 
mouse. In this way the roles of Vps33b and its homologue Vps33a can be investigated in a 
model system closely resembling human physiology.  
4.2 Methodology - Developing Vps33a and Vps33b deficient mice 
The Vps33a knockout mouse was created using a genetrap method, with stem cells purchased 
from BayGenomics. The stem cells were originally created by BayGenomics using random 
insertion of a genetrap vector into intronic DNA (Stryke et al. 2003).The gene into which the 
genetrap was inserted was identified by cDNA sequencing, in this case Vps33a. Chimeric 
mice and subsequent heterozygous mice were created at the University of Birmingham, 
(figure 4.1). 
Since 1/3 of ‘knockout’ mice have been reported to be embryonically lethal, a cre/loxP vector 
for Vps33b was created by Taconic Artemis.  In this way if the ubiquitous Vps33b knockout 
mouse was embryonically lethal, tissue specific Vps33b conditional knockout mouse could be 
created. Using tissue specific Vps33b conditional knockout mice is also a good way to 
determine the contribution of each tissue to the ARC phenotype. The vector used allowed the 
insertion of loxP sites before exon 2 and after exon 3 of Vps33b. This mouse was then crossed 
with a ubiquitous cre- recombinase line with Phosphoglycerate kinase (Pgk) promoter in order 
to produce a mouse with Vps33b excision in all tissues. When cre-recombinase is introduced, 
exons 2 and 3 are spliced out resulting in a frameshift and premature termination of protein 
production, figure 4.1.  Additional methods for development of a genetically modified mouse 
strain are found in sections 2.13-2.16.  
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Figure 4.1 Murine Vps33a and murine Vps33b inactivation in the mouse germline.  
Vps33a Genetrap. Genomic organisation of Vps33a and gene inactivation strategy: the 
genetrap vector was constructed such that a splice acceptor site and β-geo identification 
marker were inserted into intron 5 of the Vps33a allele subsequently truncating the cDNA and 
protein. 
Vps33b Vector. Genomic organisation of Vps33b and gene inactivation strategy: the targeting 
vector was constructed such that homologous recombination resulted in exons 2 and 3 being 
flanked by LoxP sites allowing subsequent removal of these exons by Cre recombinase, 
resulting in frameshift preventing production of functional Vps33b.  
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4.3 Results 
 
4.3.1 Ubiquitous Vps33a-/- and Vps33bfl/fl-PgkCre mice are embryonically lethal 
The crossing of Vps33a+/- mice resulted in 28 litters consisting of 33 Vps33a+/+ mice and 59 
Vps33a +/- mice, no Vps33a-/- mice were found. Similarly, if only the offspring positive for the 
Pgk-cre recombinase are considered, the genotypes from Vps33b+/fl x Vps33b+/fl -PgkCre 
matings resulted in 29 Vps33b+/+ mice and 41 Vps33b+/fl mice from 23 litters, no Vps33bfl/fl 
mice were identified (Table 4.1). 
Targeted Gene Number of litters Wild-type Heterozygous 
Vps33a 28 33 59 
Vps33b 23 29 41 
Table 4.1 Genotypes of offspring from Vps33a+/- x Vps33a+/- matings and offspring 
positive for Pgk-Cre from Vps33b+/fl x Vps33b+/fl-PgkCre matings. Genotyping of 
offspring from heterozygous intercrosses reveals no homozygous mice  
 
From the number genotyped it can be deduced that removing Vps33a or Vps33b in the mouse 
results in embryonic lethality. Vps33a litters conformed to the mendelian mode of inheritance 
if removal of the gene is embryonically lethal. Confirmation that Vps33a-/- morulae were 
created was carried out by Ania Straatman-Iwanowska, Birmingham University. It was found 
at E3.5 that 2 of 7 morulae were Vps33a-/-.  
Vps33b litters suggest a close to mendelian mode of inheritance if removal of Vps33b is 
embryonically lethal. Heterozygous mice appear healthy, live as long as the wild-type 
counterparts and are fertile, therefore it is unlikely that viability is affected in Vps33b+/fl-
PgkCre embryos. 
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4.3.2 Determining time-point of lethality 
The average gestation period for a C57BL/6 mouse is 19-21 days. In order to determine the 
time-point of lethality, timed matings were carried out. The time-point E12.5 was selected as 
a start point and then earlier or later time-points in gestation were selected as necessary.   
Resorption sites were observed at E12.5 in both Vps33a and Vps33b pregnancies (Table 4.2 
and Table 4.3).  No Vps33a-/- or Vps33bfl/fl-PgkCre embryos were present at this stage and no 
embryonic remains could be identified. As resorption sites were observed it was assumed that 
the blastocysts implant into the uterus, a process which occurs at E4.5. Resorption sites were 
also observed at E10.5 in both mice, however at E9.5 digested remains of embryos could be 
genotyped without maternal contamination (Figure 4.3 and Figure 4.4). These were confirmed 
to be Vps33a-/- and Vps33bfl/fl-PgkCre embryos.  
Due to the level of degradation it could be determined that lethality in both cases most likely 
occurred between E7.5 and E8.5, a timepoint at which many developmental processes occur 
(Figure 4.2). Timed matings were carried out at E7.5 and no resorption sites were observed. 
All embryos were intact and not digested, however maternal contamination prevented 
accurate genotyping as all embryos appeared heterozygous for the wild type and transgenic 
alleles.  
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Figure 4.2 Murine development between E7-E9 
Many complex processes occur between E7 and E9. Highlighted areas on the embryo 
correspond to text above or below the image. ts – Theiler stage 
Figures adapted from the Edinburgh Mouse Atlas 
(http://www.emouseatlas.org/emap/home.html) 
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Gestation day 
(number in 
litter) 
Vps33a+/+ Vps33a+/- Vps33a-/- unable to genotype 
(resorptions) 
E12.5 (13) 3 10 0 (3) 
E10.5 (10) 1 2 0 5 (2) 
E9.5 (10) 4 4 1 (1) 
E9.5 (8) 2 3 2 1 
E9.5 (7) 3 2 0 (1) 
E8.5 (4) 1 1 1 1 
E8.5 (4) 2 2 0 0 
E8.5 (6) 1 3 0 2 
E3.5 (8) 2 4 2 0 
 
Table 4.2 Genotypes of offspring from Vps33a+/- x Vps33a+/- timed matings. 
Genotyping of offspring from Vps33a heterozygous intercrosses reveals embryonic 
lethality at approximately E8.5 when there was homozygous Vps33a inactivation. 
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Figure 4.3 E9.5 Morphology of Vps33a Embryos,  
A.Representative Vps33a+/+ wild-type littermate and B. Vps33a-/- digested remains,  
Scale bar = 100µm. At this time-point the decidua containing Vps33a-/- remains were smaller 
than Vps33a+/+ and Vps33a+/-. n=1 
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Gestation day 
(number in litter) 
Vps33b+/+ Vps33b+/fl Vps33bfl/fl Unable to 
genotype 
(resorptions) 
E16.5 (8) 1 3 0 (4) 
E12.5 (8) 1 5 1 (cre negative) (2) 
E10.5 (9) 4 3 0 1 (1) 
E9.5 (3) 1 1 0 (1) 
E9.5 (8) 0 5 1 (cre positive) 2 
 
Table 4.3 Genotypes of offspring from Vps33b+/fl x Vps33b+/fl- PgkCre timed matings. 
Genotyping of offspring from Vps33b heterozygous intercrosses reveals embryonic lethality at 
approximately E8.5 when there was homozygous Vps33b inactivation. 
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Figure 4.4 E9.5 Morphology of Vps33b Embryos,  
A.Representative Vps33b+/+ wild-type littermate and B. Vps33bfl/fl-PgkCre digested remains. 
Scale bar = 100µm. At this time-point the decidua containing Vps33bfl/fl-PgkCre remains were 
smaller than Vps33b+/+ and Vps33b+/fl littermates. n=1 
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4.3.3 Isolation of embryonic stem cells from knockout blastocysts 
It has been determined that both animal models are embryonically lethal at an early stage. To 
make use of these model systems, it was decided to establish embryonic stem (ES) cell lines 
from the blastocysts of Vps33a+/- x Vps33a+/- matings, and Vps33bfl/fl matings, see section 2.16 
for materials and methods.  
Figure 4.5 shows an example of an attached blastocyst 3 days after extraction. The brighter 
mass is the inner cell mass which was selected and expanded to create ES cell lines.  
 
4.4 Discussion  
Vps33a-/- embryonic lethality suggests that this protein plays an important role in 
development. This may explain why no human mutations in this gene have ever been 
identified. The buff mouse with missense mutation in Vps33a, has been suggested as a model 
for Hermansky Pudlak syndrome (HPS) (Suzuki et al. 2003).  Therefore, VPS33A has been 
screened in many HPS-like patients with unknown mutations but no mutation has been 
identified to date. The missense mutation in the buff mouse may allow the protein to retain 
partial functionality thus allowing embryo development and explain survival of this mouse. 
Lethality during development has been observed in Drosophila (Akbar et al. 2009).  
Embryonic lethality in the Vps33bfl/fl-PgkCre mouse was unexpected due to the survival of 
ARC syndrome patients born with mutations in this gene. The reason for ARC patient 
survival may only be postulated. It may be that patients are able to express alternative 
transcripts of VPS33B, which allows them to bypass embryonic lethality. The finding of an 
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alternative transcript in the patient with attenuated phenotype may support this hypothesis. It 
is also possible that the incidence of miscarriage is increased in families with ARC, however  
 
Figure 4.5 Blastocyst outgrowth 3 days after isolation.  
A representative Vps33bfl/fl blastocyst outgrowth isolated at E3.5 and grown for 3 days. The 
inner cell mass appears as a bright mass in the centre, which was isolated and trypsinised in 
order to establish embryonic stem cells. The outer cells are trophectoderm. In the case of 
Vps33bfl/fl ES cells, a Cre-recombinase containing plasmid was introduced to create Vps33b-/- 
ES cells.
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it is difficult to ascertain if this is the case. It may also be that VPS33A may be able to 
compensate for VPS33B during human embryo development. 
It can be concluded from this work that the removal of Vps33a or Vps33b results in 
embryonic lethality in the mouse at E7.5-E8.5.  Between these time-points many different 
processes occur. Major landmark processes include: the formation of the amnion to create 3 
cavity egg cylinder, formation of the allantois which grows out towards the ectoplacental cone 
and fuses with the developing chorion, formation of the mesodermal layer and the beginnings 
of development of the heart, and finally turning, where the embryo rotates on its body axis 
(figure 4.5)(Theiler 1989). These processes involve many different signalling pathways and 
molecules; the appropriate location of which guides correct development. 
At present the possible reasons for embryonic lethality can only postulated. It has been 
suggested from work in other model organisms that Vps33a plays a role in the biogenesis of 
lysosome related organelles and the fusion of autophagosomes with lysosomes in Drosophila 
(Akbar et al. 2009), as well as the fusion of uroplakin-degrading MVBs with lysosomes in 
mouse urothelium (Guo et al. 2009), resulting in defective degradation of proteins. Vps33b 
has been implicated in apical recycling of receptors, with apical proteins in the ARC liver 
being mislocalised to the basolateral membrane. In Vps33b knockdown mIMCD cells a 
similar observation was made with the P75 neurotrophin receptor protein which is normally 
restricted to the apical membrane (Cullinane et al. 2010). If receptors and signalling 
molecules are incorrectly trafficked or degraded, developmental cues including those 
dependent on correct orientation may not be properly interpreted, thus leading to a halt or 
defect in development. This may be the case in the Vps33a-/- or Vps33bfl/fl-PgkCre mice.  
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Supporting this hypothesis is the finding that disruption of the HOPS complex component, 
Vps39, has been found to cause embryonic lethality between E3.5-6.5 (Messler et al. 2011).  
It was originally identified as a protein that may be involved in TGF-β signalling due to  25% 
homology to TGF-β receptor associated protein-1 (TRAP-1), and subsequently found to bind 
to TGF-β receptors and Smad4 (Felici et al. 2003).  
TGF-β and the cytokines belonging to the TGF-β superfamily are important during 
embryogenesis for many processes including establishment of body axis and tissue 
differentiation (Harland 1994)(Neumann & Cohen 1997). TGF-β elicits intracellular 
signalling pathways through activation of the TGF-β receptors type I and type II, 
serine/threonine kinases which subsequently signal through phosphorylation of downstream 
effectors including those in Smad-dependent and Smad-independent pathways such as the 
Ras-MAPK Erk1/2 pathway (Moustakas & Heldin 2008). In the Smad dependent pathway 
Smads are phosphorylated by TGF-β RI, associate with Smad4 and subsequently translocate 
to the nucleus where they act as transcriptional regulators.  
For TGF-β signalling in many cell types, internalisation of the type I receptors to early 
endosomal antigen (EEA) 1-positive endosomes is required (Di Guglielmo et al. 2003). TGF-
β receptors also consitutively recycle in a Rab11 dependent manner (Mitchell et al. 2004). It 
was proposed by Felici et al. that Vps39 may direct activated TGF-β receptors from the 
plasma membrane to Smad3-containing endocytic subdomains to facilitate formation of 
Smad3/4 complexes (Felici et al. 2003). This is consistent the requirement of Vps39 for 
vesicular trafficking in yeast for biogenesis of the vacuole (Nakamura et al. 1997) and it has 
been hypothesised that the phenotype observed in Vps39 deficient mice is a result of defective 
trafficking (Messler et al. 2011). 
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Further investigation of embryonic lethality and protein function of Vps33a and Vps33b may 
use a similar approach to that used in the study of CHMP5 (Shim et al. 2006). CHMP5 is 
homologous to Endosomal Sorting Complex Required for Transport-III (ESCRT-III) complex 
proteins, and when absent causes embryonic lethality at approximately E10. It was suspected 
that CHMP5 may play a role in regulation of endocytosis or lysosomal transport of receptors 
involved in signal transduction. Primary embryonic cells from E8.5 embryos were cultured 
and ES cell lines were established. These were used along with stable knockdown cells to 
establish that it was endocytosis of receptors such as NF-κB that was disrupted. As a result, 
processes involved in embryonic development were disrupted. This was found to be due to 
incorrect regulation of receptors important in embryogenesis at this stage, such as 
Transforming Growth Factor-β (TGF-β) receptors. 
With the establishment of Vps33b-/- ES cell lines this work is now possible. In addition, full 
morphological analysis of embryos at E7.5 and E8.5 should be undertaken. This could 
indicate the exact stage at which lethality occurs and may include whole mount staining or 
paraffin embedding and sectioning.  
As a cre-lox system was used in order to create the ubiquitous Vps33bfl/fl mouse, selection of a 
different cre recombinase line will allow production of a tissue specific Vps33bfl/fl conditional 
mouse in order to avoid embryonic lethality. In chapter 5 and 6 the development of tissue 
specific Vps33b deficient mice is described. These models are particularly valuable for 
investigation of the role of Vps33b in specific cell types.  
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CHAPTER 5 - A LIVER-SPECIFIC Vps33b 
CONDITIONAL KNOCKOUT MOUSE 
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5.1 Introduction and overview 
Intrahepatic cholestasis is a cardinal feature of ARC syndrome.   In PFIC types 1, 2 and 3 it 
has been shown to be caused by mutations in genes located at the apical membrane involved 
in transport across the apical membrane. Mutations in tight junction proteins have also been 
shown to cause intrahepatic cholestasis thought due to loss of cell polarity and paracellular 
leakage between the hepatocytes.   At present the molecular mechanisms that result in 
cholestasis in ARC syndrome are unknown. Staining of patient livers has however found the 
apical proteins CEA and BSEP are mislocalised, and E-cadherin and claudin-1 levels are 
reduced. Further investigation is required to understand the pathways involved. 
Technical problems have slowed progress in the understanding of hepatocyte polarity and 
cholestasis. Loss of structural polarity in primary hepatocyte culture and the mixing of 
membranes made poor models for the study of apical-basolateral polarity. Difficulties 
prompted the use of secondary hepatocyte cell lines such as HepG2 cells, however these too 
have disadvantages. They express many liver specific genes but have a low polarity index 
making them unsuitable for morphologic study  (Arias et al. 2009). Development of models of 
liver disease is therefore very important to help understand these processes and thus improve 
the clinical outcome of liver diseases such as intrahepatic cholestasis.   
 
5.2 Aims 
As ubiquitous removal of Vps33b in the mouse results in embryonic lethality, the aim is to 
develop a suitable mammalian model of the ARC syndrome liver for future use in 
experimental work to understand the molecular mechanisms of ARC and help aid future 
patient treatment. 
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5.3 Results 
5.3.1 Developing a liver-specific Vps33b conditional knockout mouse  
In order to create a liver specific knockout mouse, a cre-recombinase with albumin promoter 
was selected as albumin expression is restricted to hepatocytes (Pinkert et al. 1987). The 
number of births from Vps33bfl/fl x Vps33bfl/fl-AlbCre matings was 26 Vps33bfl/fl and 24 
Vps33bfl/fl-AlbCre mice, conforming to the mendelian mode of inheritance. Vps33bfl/fl-AlbCre 
mice thrived with no obvious ill effects. They were aged and removal of Vps33b in the liver 
had no obvious adverse effect on livelihood at 1 year of age. No signs of jaundice were 
observed.  
Protein lysates obtained from crushed livers extracted at 15 weeks from control Vps33bfl/fl 
mice and Vps33bfl/fl-AlbCre mice were immunoblotted for Vps33b (figure 5.1A). The 
percentage expression of Vps33b when normalised again β-Actin in Vps33bfl/fl-Albcre was 
reduced by approximately 71% when compared to Vps33bfl/fl controls (figure 5.1B). Total 
removal of Vps33b was not expected due to the presence of a mixed population of cells in the 
liver (Pinkert et al. 1987). Hepatocytes make up approximately 70% of the liver mass, and 
60% of the cellular number, therefore when using crushed liver the protein from other cell 
types are included in the lysate produced. For example, the liver is highly vascularised, and 
the endothelium  of these blood vessels do not produce albumin, therefore Vps33b expression 
in these cells would not be affected as cre-recombinase is not produced. 
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5.3.2 Vps33bfl/fl-AlbCre liver function tests  
In order to fully characterise the liver, tests for liver damage were carried out (figure 5.1C and 
D). In the clinic, ALT and bilirubin levels are tested for initial assessment of liver 
damage/dysfunction. Due to blood sampling restrictions, 10% of the total mouse blood 
volume every month is permitted to be taken, therefore ALT and bilirubin levels were 
checked once every 5 weeks, from 10 weeks of age. ALT levels were not elevated in 
Vps33bfl/fl-AlbCre mice, indicating there is no significant liver damage.  
One knockout mouse was observed to be very itchy from 10 weeks onwards, and as a result of 
scratching had patchy fur and broken skin. Therefore bile acid levels within the blood were 
checked (figure 5.1D).  Results were very variable, with the 'itchy' mouse having 10 times the 
level of tauro-trihydroxycholanoate than the control animals. The other knockout mice had 
levels equivalent to control or up to 3 times that of control, the difference was not statistically 
significant due to the variation between animals. 
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Figure 5.1 Vps33bfl/fl-AlbCre Liver characterisation 
(A) Immunoblot of kidney and liver protein lysates using primary rabbit anti-VPS33B, 1:500 
dilution and secondary HRP-conjugated goat anti-rabbit 1:500 dilution. β-Actin used as a 
loading control. Kidney immunoblot was carried out to check for Alb-cre liver specificity. 
n=3. (B) Densitometry of Vps33b immunoblot, Vps33b is normalised against β-actin. Vps33b 
is reduced by 72% in comparison to control. n=3 (C) ALT plasma protein levels measured at 
10-20 weeks, no significant difference was observed. n=3. (D) Bilirubin plasma levels at 10 
and 15 weeks, no significant difference was observed. n=3. (E)Plasma levels of taurocholate 
by electrospray mass spectrometry identified no significant difference, n=3. Data from graphs 
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B-E were analysed using a two-tailed Student t test and the mean data points and standard 
error of mean error bars are presented.  
 
5.3.3 Developing a second liver specific Vps33b conditional knockout mouse 
Since the Vps33bfl/fl-AlbCre mouse produced variable results and it was reported that the 
expression of Alb-Cre was low prenatally (Postic & Magnuson 2000), it was decided to try a 
variation of the Alb-Cre line, AFP-albumin cre. This line contains the albumin promoter but 
also additional alpha-fetoprotein (AFP) enhancers, and is referred to as the Alfp-Cre line. Alfp-
Cre has been shown to be expressed at much higher levels prenatally then Alb-Cre 
(Kellendonk et al. 2000) and therefore was expected to produce a more consistent phenotype 
in ARC model. This is because at least some of the liver defect is likely to be due to abnormal 
prenatal liver development. Vps33b levels were again assessed at 15 weeks in Vps33bfl/fl-
AlfpCre mice by immunoblot. The percentage expression of Vps33b when normalised against 
β-Actin was reduced by approximately 76% when compared to Vps33bfl/fl controls (figure 
5.2A-B).  
5.3.4 Vps33bfl/fl-AlfpCre liver function tests  
Identical tests were performed for ALT, bilirubin and bile acid levels as for the Vps33bfl/fl-
AlbCre mice. These tests were performed at 15 weeks of age. There was no significant 
difference observed between control Vps33bfl/fl and Vps33bfl/fl-AlfpCre mice in ALT and 
bilirubin levels (figure 5.2C-D), as found in the Vps33bfl/fl-AlbCre mice. Bile acid tests 
however show a consistently significant increase in the levels of tauro-trihydroxycholanoate 
(figure 5.2E), in contrast to the Vps33bfl/fl-AlbCre mice. Levels were elevated by at least 8 
times and up to 18 times that of the mean level of control.  
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Figure 5.2 Vps33bfl/fl-AlfpCre Liver characterisation 
(A) Immunoblot of kidney and liver protein lysates using primary rabbit anti-VPS33B, 1:500 
dilution and secondary HRP-conjugated goat anti-rabbit 1:500 dilution. β-Actin used as a 
loading control. Kidney immunoblot was carried out to check for Alfp-cre liver specificity. 
n=3. (B) Densitometry of Vps33b immunoblot, Vps33b is normalised against β-actin. Vps33b 
is reduced by 76% in comparison to control. n=3 (C) ALT plasma protein levels measured at 
15 weeks, no significant difference was observed. n=3. (D) Bilirubin plasma levels at 15 
weeks, no significant difference was observed. n=3. (E) Plasma levels of taurocholate by 
electrospray mass spectrometry identified a significant increase, n=3. Data from graphs B-E 
were analysed using a two-tailed Student t test and the mean data points and standard error of 
mean error bars are presented.  
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5.3.5 Localisation of liver proteins in Vps33bfl/fl-AlfpCre mice 
Histological analysis of hemotoxylin and eosin stained liver sections identified no 
abnormalities such as bile duct paucity or lipofuscin granules. Immunostaining of Vps33bfl/fl-
AlfpCre liver sections found CEA to be mislocalised to the cytoplasm and both apical and 
basolateral membrane (figure 5.3). The localisation of E-cadherin, an adherens junction 
protein, and ZO-1, a tight-junction associated protein were not disrupted by Vps33b 
deficiency. Immunostaining for BSEP, the primary bile acid transporter on the canalicular 
membrane identified apical staining; however it appeared reduced with fewer ‘branched’ 
stainings visible (figure 5.4). Immunofluorescent staining again showed reduced apical 
staining in the Vps33bfl/fl-AlfpCre mice, but also revealed an increased number of hepatocytes 
with punctate cytoplasmic staining when compared to control. This suggests there may be a 
defect in the trafficking of BSEP to its correct canalicular location. 
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Figure 5.3 Immunohistochemical analysis of protein localisation in mouse liver  
5 micron sections of paraffin embedded liver were immunostained for CEA, E-cadherin and 
ZO-1, antibody information in Appendix 1, sections were counterstained with hematoxylin, 
scale bar- 25µm. Apical staining is indicated with an arrow in control CEA staining. CEA was 
found mislocalised throughout the cytoplasm and plasma membrane in Vps33bfl/fl-AlfpCre 
livers. E-cadherin and ZO-1 were correctly localised. n=3 
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Figure 5.4 Immunohistochemical and immunofluorescent analysis of BSEP localisation 
in mouse liver  
Top row: 5 micron sections of paraffin embedded liver were immunostained for BSEP, 
antibody information in Appendix 1, sections were counterstained with hematoxylin. Typical 
canalicular staining is indicated with an arrow in control Vps33bfl/fl livers. Vps33bfl/fl-AlfpCre 
livers also show canalicular staining indicated with an arrow, however staining appeared 
reduced. 
Bottom row: Immunofluorescent staining for BSEP, antibody information in Appendix 1, 
found the same canalicular staining as by immunohistochemistry, but also revealed an 
increased number of hepatocytes in the Vps33bfl/fl-AlfpCre liver containing punctate 
intracellular staining, magnified 4 times in bottom right image .Scale bar - 50µm, n=3  
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5.4 Discussion 
An Alb-cre line was selected as albumin expression is exclusively restricted to hepatocytes 
(Meehan et al. 1984). Albumin is expressed early during mouse development at 7-8 somites 
(Gualdi et al. 1996) therefore the use of an albumin promoter to drive cre recombinase 
expression was deemed suitable for our use. It is a widely used cre-promoter and has proven 
useful in cre-dependent excision in adult hepatocytes (Postic et al. 1999). Only a mild 
phenotype was found in the liver specific Vps33b knockout developed this way. One mouse 
was identified as being itchy and high blood bile acid levels were observed, with bile acid 
results ranging from equivalent to control mice levels to the level 10 times higher than control 
mouse levels (the itchy mouse). It has been reported that recombination due to cre excision 
with Alb-Cre transgene is progressive over time, with recombination being 40% at birth 
progressing to full recombination at 6 weeks shown by southern blotting (Postic & Magnuson 
2000). In the same publication use of a ROSA26 reporter mouse showed 99% of hepatocytes 
had undergone recombination at 12 days. It was hypothesised that expression of cre is below 
the threshold level necessary to cause rapid recombination in hepatocytes. Subsequently 
however, this finding was disputed, with the hypothesis that the alteration in recombination is 
due to a change in the ratio of hepatocytes:non-hepatocytes within the liver during juvenile 
development (Weisend et al. 2009). Since no further work was published on this topic and 
due to the varied results given by Alb-Cre in the Vps33bfl/fl mice, it was decided to develop a 
second liver specific line. The Alfp-Cre line contains albumin regulatory elements but also 
AFP enhancers. AFP is a fetal protein secreted in the liver during embryonic life. AFP 
enhancers are thought to influence albumin expression therefore this was done to mimic the 
organisation of the albumin gene (Kellendonk et al. 2000). The Alfp-Cre line was shown to 
produce cre-recombinase as early as E10.5. The Vps33b knockout mouse that resulted from 
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crosses with Alfp-Cre also produced a mild liver phenotype, but had less variable results 
during bile acid level analysis and therefore was used for further investigation. 
5.4.1 Is the Vps33bfl/fl-AlfpCre mouse a phenocopy of the ARC liver?  
ALT, a marker for liver damage was not increased in the Vps33bfl/fl-AlfpCre mice. In ARC 
patients it has been reported that ALT levels range from normal levels to just slightly raised. 
This test was carried out in order to confirm that the removal of Vps33b in the mouse liver did 
not result in a more severe phenotype or different presentation than the patient.  
Conjugated hyperbilirubinaemia is seen at some point in time in all severely affected ARC 
patients, although the levels may fluctuate (Gissen et al. 2006). Diseases that reduce the flow 
of bile or transport of bilirubin into the bile produce an increased level of conjugated bilirubin 
in the blood due to its reflux out of hepatocytes into blood (Iyanagi et al. 1998). Non-
excreting biliary isotope tests in ARC patients indicate reduced bile flow out along the bile 
duct and into the intestine. Total bilirubin was not increased in the Vps33bfl/fl-AlfpCre mouse, 
indicating a milder phenotype. Discoveries made in previous cholestatic mouse models 
identifying differences between human and mouse may help explain our findings. 
A BSEP knockout mouse (spgp) was created to model PFIC type 2. These mice developed 
intrahepatic cholestasis, but phenotype was less severe than PFIC type 2 (Wang et al. 2001). 
There was a dramatic decrease in the export of hydrophobic bile acids such as cholate into the 
bile (6% of wild-type) due to the lack of BSEP, however total bile acid output remained 30% 
of wild-type. Within the liver trihydroxylated bile acids were reduced (66% in males and 42% 
in females), and the atypical tetrahydroxy bile acid was present. The polarity of bile acids 
(hydrophobic or hydrophilic) is assumed to depend on the number of hydroxyl groups, 
therefore it was suggested that tetrahydroxy bile acids are more hydrophilic than the 
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trihydroxylated bile acids, resulting in reduced toxicity in the mouse liver (Perwaiz et al. 
2003). The bile acids secreted into the bile were normal hydrophilic bile acids and 
tetrahydroxy bile acids are not normally detected (Perwaiz et al. 2003). Biliary secretion of 
these bile acids suggested an alternative transport mechanism for hydrophilic bile acids in 
mice. The P-glycoprotein genes Mdr1a and Mdr1b were found to be upregulated in these 
mice (Lam et al. 2005).  Mdr1 was shown to have the ability to transport bile acids but at a 
lower affinity than BSEP (Lam et al. 2005). Triple knockouts were therefore produced 
(BSEP, Mdr1a and Mdr1b) (Wang et al. 2009). The knockout of these 3 genes led to a much 
more severe phenotype with impaired bile formation, jaundice and increased mortality. The 
conclusion was that mice have a compensatory mechanism which reduces the severity of 
cholestasis. This compensatory mechanism however was not enough to protect the BSEP 
knockout mouse (spgp) against cholestasis when fed a cholic acid diet, and severe intrahepatic 
cholestasis with jaundice, liver necrosis and high mortality was observed (Wang et al. 2003). 
Bile acid levels, specifically tauro-trihydroxycholanoate, were increased ranging from 8 to 18 
times that of control in the Vps33bfl/fl-AlfpCre mice. Increased plasma bile acids is a sign of a 
liver secretion defect and is suspected to be a causative factor of the itching (pruritis) 
experienced by ARC patients. Only one ‘itchy’ mouse, a Vps33bfl/fl-AlbCre mouse was 
identified. Tauro-trihydroxycholanoate has been found to be the best indicator along with total 
bile acid concentrations of cholestatic hepatobiliary disease in newborns (Mushtaq et al. 
1999). The increased level of tauro-trihydroxycholanoate in the blood of the knockout mice 
indicates a defect in secretion of bile acids.  
A mislocalisation of apical proteins was observed in the mouse. CEA is a glycoprotein 
involved in cell adhesion. It is a GPI-anchored cell surface glycoprotein that undergoes both 
N- and O- glycosylation, and is found on the apical surface of healthy hepatocytes (Ordonez 
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et al. 2007).  CEA is mislocalised in the Vps33bfl/fl-AlbCre mice, found throughout the plasma 
membrane and in the cytoplasm , phenocopying the distribution seen in ARC livers. BSEP is 
trafficked via a Rab11-positive endosome pathway. The localisation also resembled that of 
patients, with reduced apical staining and increased intracellular protein.  
In conclusion, it appears that in respect to protein localisation and plasma bile acid 
accumulation, the Vps33bfl/fl-AlfpCre mice are a good phenocopy of the ARC liver. The 
milder phenotype with regards to liver morphology may be induced by feeding a cholic acid 
diet. As a result these mice may be used in the future for further experiments to aid 
understanding of the ARC liver. 
 
[154] 
 
 
 
 
 
 
CHAPTER 6 - A MEGAKARYOCTYE AND 
PLATELET-SPECIFIC Vps33b 
CONDITIONAL KNOCKOUT MOUSE 
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6.1 Introduction and overview 
 
An α-granule defect in ARC platelets was first reported by Deal et al. in 1990 when it was 
identified that patient platelets resembled those of Grey platelet syndrome (Deal et al. 1990). 
Subsequently a bleeding diathesis was reported when >50% of patient liver biopsies resulted 
in severe life threatening haemhorraging (Gissen et al. 2006).  Deficiencies in both α-granule 
membranes and contents distinguish ARC platelets from the α-granule storage pool disease 
Grey platelet syndrome in which α-granule membranes appear intact. 
α-granules are predicted to play multiple functions, a result of the diverse and numerous 
proteins contained within these granules (Maynard et al. 2007). These roles include 
angiogenesis, wound healing and immune response activation (Ren et al. 2008).  It would 
therefore be of great interest to create a mouse severely deficient or completely lacking α-
granules and their contents in order to study their suspected wide reaching functions. 
Consequently, the aim is to create and characterise a megakaryocyte and platelet specific 
Vps33b conditional knockout mouse.  This is because most of the platelets in ARC patients 
completely lack α-granules, and have greatly reduced or absent levels of α-granule proteins. 
Creating a mouse with reduced Vps33b within its megakaryocytes may allow us to create a 
mouse severely lacking platelet α-granules. In addition to the exploration of different roles of 
α-granules, it would also allow us to investigate further the role of Vps33b in platelet 
formation, helping us to learn more about the proteins function.   
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6.2 Methodology 
A transgenic Pf4-Cre recombinase strain (Tiedt et al. 2007) was used in a conditional 
knockout strategy to target megakaryocyte lineage and therefore platelets. The Pf4-Cre 
transgene has been shown to partially excise floxed alleles in hematopoietic progenitors, 
however shows full excision in megakaryocytes (Coppinger et al. 2004). Therefore, this cre-
recombinase line was deemed suitable for our use.  
 
6.3 Results 
6.3.1 Megakaryocyte Vps33b levels in Vps33bfl/fl -Pf4Cre mice  
The offspring resulting from Vps33bfl/fl x Vps33bfl/fl-Pf4Cre matings resulted in a 1:1 ratio of 
Vps33bfl/fl and Vps33bfl/fl-Pf4Cre live births, thus indicating that the excision of Vps33b by 
Pf4-Cre recombinase does not affect embryo viability.  
As Vps33b is not present in platelets (Lo et al. 2005) it must function in the megakaryocyte. 
Analysis of Vps33b levels in megakaryocytes was undertaken using megakaryocytes 
differentiated from haemopoeitic stem cells of the control Vps33bfl/fl and Vps33bfl/fl -Pf4Cre 
mice. Immunoblotting of Vps33b and found that Vps33b levels were reduced by 
approximately 82% in the Vps33bfl/fl-Pf4Cre megakaryocytes in comparison to control 
Vps33bfl/fl megakaryocytes (figure 6.1A). A reduction and not complete loss of Vps33b may 
be observed due to the nature of the Pf4-Cre recombinase transgene discussed in section 6.4.3 
(Tiedt et al. 2007). The Cre-recombinase may not act early enough in megakaryocyte 
maturation to prevent production of Vps33b, thus explaining the low levels seen.  
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6.3.2 Analysis of platelet count, volume and spleen size 
Platelet count in the Vps33bfl/fl–Pf4Cre mouse whole blood was analysed using an ABX 
Diagnostics Pentra 60. There was no significant difference in platelet count observed (figure 
6.1B). There was an increase of in mean platelet volume by approximately 4.4% in the 
Vps33bfl/fl -Pf4Cre mouse platelets (figure 6.1C). In mice with platelet defects often an 
enlargement of the spleen can be observed, therefore the spleen was measured in 9 week old 
mice, with the spleen mass being normalised to body mass. No significant difference was 
observed (figure 6.1D). 
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Figure 6.1 Immunoblot for Vps33b, platelet count, mean platelet volume and spleen 
mass 
A. Immunoblot for Vps33b in megakaryocytes, mouse anti-Vps33b primary antibody 
(Proteintech) at a concentration of 1:500, and rabbit anti-mouse HRP-conjugated secondary 
antibody (Invitrogen) at a concentration of 1:500 was used. Loading was confirmed by 
immunoblotting for β-Actin, n=3. A graph displaying the densitometry of the Vps33b 
immunoblot, Vps33b is normalised against β-actin. Vps33b is reduced by 82% in comparison 
to control. n=3 
B. Platelet count in whole blood using the ABX Pentra 60 whole blood counter, no significant 
difference was observed, n=20.  
C. Mean platelet volume measured using the ABX Pentra 60 whole blood counter, a slight 
increase was in MPV was observed, n=19. 
D. Spleen mass normalised to body mass, aged 9 weeks, n=4. No significant difference was 
observed. 
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Data in B-D was analysed using a two-tailed Student t-test with mean and standard error of 
mean error bars presented.  
6.3.3 Electron microscopy of platelets  
Platelets were prepared for EM and sent for analysis to Walter Kahr, Hospital for Sick 
Children, Toronto. α-granules were present in the Vps33bfl/fl-Pf4Cre mouse platelets (figure 
6.2). To quantitatively determine if there was a difference in α-granule number between 
control Vps33bfl/fl and Vps33bfl/fl -Pf4Cre platelets, 50 platelets from each sample were 
counted. As platelet sections were analysed only a proportion of the total number of α-
granules within the platelets were counted.  Vps33bfl/fl -Pf4Cre platelets had 4.5±0.38 α-
granules per platelet section in comparison to 6.4±0.4 in Vps33bfl/flcontrol. Data was analysed 
using a two-tailed Student t-test and identified a significant reduction, p=0.0018.  
 
6.3.4 Bleeding time test 
In order to assess whether bleeding time was extended in the mice, bleeding time tests were 
carried out. Control Vps33bfl/fl mice and Vps33bfl/fl-Pf4Cre mice were tested using a standard 
bleeding time assay (see section 2.18.2 for methods). Blood loss was measured after removal 
of the tail tip. No significant difference was observed between the two groups of mice (figure 
6.3).  
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Figure 6.2 Ultrastructural analysis of platelets 
A. Electron microscopy images of control Vps33bfl/fl platelets, left- saggital image with α-
granules marked with yellow asterisks, centre-horizontal section and right-field of view. 
B. Electron microscopy images of Vps33bfl/fl-Pf4Cre platelets. left- saggital image with α-
granules marked with yellow asterisks, centre-horizontal section and right-field of view. No 
obvious morphological differences were observed. 
Images taken by Walter Kahr, Sick Kids, Toronto 
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Figure 6.3 Bleeding time test 
Total volume of blood lost in 20 minutes normalised to body mass. Test was 
stopped after 5 minutes if no droplet fell, n=10.  No significant difference was 
observed between control Vps33bfl/fl and Vps33bfl/fl-Pf4Cre mice. 
Data points for each mouse are presented, and the mean value depicted by a bar. 
Data was analysed using the Wilcoxon rank-sum test. 
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6.3.5 Flow cytometry to assess P-selectin expression 
 
P-selectin is a protein found on the membranes of platelet α-granules. Upon stimulation with 
thrombin, α-granules fuse with the platelet outer-membrane allowing the release of their 
contents. As a result, P-selectin is relocated to the outer membrane of the platelet and thus is 
used as a marker for α-granule presence and secretion. It must be noted that P-selectin has 
also been reported present on dense granule membranes (Israels et al. 1992).  A FITC-
conjugated anti-mouse CD-62 antibody was used to detect levels of P-selectin on the surface 
of the mouse platelets. No significant difference was observed between the Vps33bfl/fl and 
Vps33b+/+-Pf4Cre controls, data not shown. P-selectin levels were reduced by approximately 
44% in the Vps33bfl/fl-Pf4Cre mice compared to Vps33bfl/fl control (figure 6.4).  
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Figure 6.4 Flow cytometry to assess P-selectin expression on the platelet membrane 
A. Basal (unstimulated) platelets or stimulated platelets (1U/ml thrombin) were labelled with 
FITC-conjugated anti-mouse CD62P (P-selectin). Flow cytometry results, represented by a 
histogram, show fluorescence intensity against platelet count. Vps33bfl/fl-Pf4Cre platelets 
showed a reduced level of fluorescence and therefore reduced P-selectin expression on the 
platelet surface. 
B. Geometric mean fluorescence intensity of platelets was calculated from flow cytometry 
data, n=4.The mean value and standard error of mean error bars are presented. Data was 
analysed using a two-tailed Student t-test and a significant reduction in P-selectin levels on 
the Vps33bfl/fl-Pf4Cre platelets was observed. 
 [164] 
 
 
6.3.5 Aggregation and dense granule secretion 
In order to assess aggregation and dense granule secretion, low, threshold and high 
concentrations of thrombin, a strong platelet activator, were used to activate platelets. For 
aggregation in response to thrombin in washed platelets, fibrinogen, an α-granule protein, 
must be present to allow cross-linking of platelets via the integrin αIIbβ3 receptor. Platelets 
were washed twice to remove all plasma proteins, thus the only available fibrinogen would be 
within the platelet. Aggregation was followed by monitoring light transmission in a stirred 
platelet suspension.  No differences between the control Vps33bfl/fl mice, Vps33b+/+-Pf4Cre 
control mice (data not shown) and Vps33bfl/fl -Pf4Cre were observed in aggregation in 
response to thrombin or collagen (figure 6.4A and B).  
Dense granule secretion by thrombin stimulation was also monitored by measuring ATP 
secretion using the reagent Chronolume.  Chronolume contains luciferin, a pigment which is 
catalysed to oxyluciferin by the enzyme luciferase with a resultant emission of light. This 
energy for this reaction is provided by ATP, and the light given off is directly proportional to 
the quantity of ATP present. Therefore by recording luminescence ATP secretion from dense 
granules can be monitored. No significant difference was observed (figure 6.4C).  
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Figure 6.5 Aggregation and dense granule secretion in response to thrombin and 
collagen 
(A-B) Traces showing aggregation in response to different concentrations of (A) thrombin or 
(B) collagen, n=3. No difference was observed.  
(C) Graph showing ATP secretion in response to 0.3U/ml thrombin stimulation. ATP 
secretion from dense granules was monitored using Chronolume and measuring light 
emission. Data was analysed using a two-tailed Student t-test and the mean with standard 
error of mean error bars presented. No significant difference was observed, n=3.
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6.3.6 Shear assay to assess thrombus formation under stress  
Platelets are constantly exposed to shear forces due to the mechanical forces created by blood 
flow through the various blood vessels.  It is therefore necessary to test platelet aggregation 
under shear conditions using an in vitro flow-based platelet aggregation assay in addition to 
the standard method of studying aggregation in a stirred platelet suspension. It is a more 
representative assay for the function of mouse platelets in vivo due to the mimicking of 
physiological conditions experienced by the platelets upon vascular injury. Two variations of 
the shear assay were carried out, one without washing and one with 5 minutes of washing 
upon termination of blood flow over the capillary. In this way, aggregate formation and 
aggregate stability could be assessed. There was a trend towards reduced aggregate formation 
in the Vps33bfl/fl-Pf4Cre mouse (figure 6.6C) assessed by total protein obtained from the flow 
assay capillary, however the difference was not significant. When the capillary was washed 
for 5 minutes following the flow assay, aggregates appeared to be unstable and washed off in 
the Vps33bfl/fl-Pf4Cre samples (figure 6.6B), when compared to control (figure 6.6A). This is 
supported by the significant reduction of total protein by approximately 62% in Vps33bfl/fl-
Pf4Cre aggregates compared to control (figure 6.6D). These findings suggest that initial 
aggregate formation was not affected but that the aggregates formed were not stable, thus 
breaking down upon washing.  
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Figure 6.6 In vitro shear assay images and protein quantification 
A – Representative DIC images of Vps33bfl/fl control mouse platelet aggregations on collagen 
with 5 minutes wash, shear rate 1000s-1, 63x magnification, n=3 
B – Representative DIC images of Vps33bfl/fl-Pf4Cre  mouse platelet aggregations on collagen 
with 5 minutes wash, shear rate 1000s-1, 63x magnification, n=3, Scale bar = 50µm. 
Aggregates were much reduced in Vps33bfl/fl-Pf4Cre platelets after washing in comparison to 
Vps33bfl/fl control mouse platelets.  
C – Protein quantification on lysates collected from the capillaries of shear aggregation 
studies on mouse platelets from A and B, n=3.  
D - Protein quantification on lysates collected from the capillaries of shear aggregation studies 
without 5 minutes washing, n=3. 
Data from C and D was analysed using a two-tailed Student t-test, and the mean with standard 
error of mean error bars are presented.  
Flow assay carried out with Jocelyn Auger and Danai Bem 
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6.3.7 Immunoblotting for the presence of α-granule proteins 
In order to determine if α-granule contents within the platelet were altered the levels of α-
granule proteins PF4 and VWF were evaluated. Immunoblotting indicated that PF4 levels 
were reduced in Vps33bfl/fl –Pf4Cre mice (figure 6.7A). Densitometry revealed that there was 
a significant reduction of PF4 by approximately 56% compared to Vps33bfl/fl control levels. 
VWF was also shown to be reduced by immunoblotting (figure 6.7B) in the Vps33bfl/fl-Pf4Cre 
mice, and densitometry revealed a significant reduction of approximately 51% in comparison 
to control platelets. These results demonstrate that Pf4-cre mediated Vps33b excision in the 
mouse megakaryocyte results in the reduction of PF4 and VWF, α-granule proteins, in the 
mouse platelet.  
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Figure 6.7 Immunoblotting and densitometry of α-granule proteins. 
(A) Immunoblot for PF4 in platelets, rabbit anti-PF4 primary antibody (Accurate Chemical 
and Scientific Corp) at a concentration of 1:1000, and goat anti-rabbit HRP-conjugated 
secondary antibody (Invitrogen) at a concentration of 1:1000 was used. Loading was 
confirmed by immunoblotting for β-Actin, n=4. 
(B) Immunoblot for VWF in platelets, rabbit anti-VWF primary antibody (Santa Cruz) at a 
concentration of 1:500, and goat anti-rabbit HRP-conjugated secondary antibody (Invitrogen) 
at a concentration of 1:500 was used. Loading was confirmed by immunoblotting for β-Actin, 
n=4. 
Densitometry was carried out on immunoblots for PF4 and VWF and expression normalised 
to β-Actin. All data points are presented, the mean values represented as a bar and standard 
error of mean error bars plotted. Data was analysed using a two-tailed Student t-test.  
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6.4 Discussion 
6.4.1 Characterisation of the platelets from Vps33bfl/fl-Pf4Cre mouse 
The aim of this work was to develop a megakaryocyte and platelet-specific Vps33b 
conditional knockout mouse in the hope to create a model of ARC syndrome platelets. ARC 
platelets lack α-granules, therefore characterisation of the Vps33bfl/fl-Pf4Cre platelets and 
more specifically the α-granules was required. 
Platelet count was unaffected in the Vps33bfl/fl-Pf4Cre mouse. Morphologically the platelets 
also did not have any gross abnormality, with a small increase of 4.4% in MPV and only a 
marginally reduced α-granule count in comparison to control. The expression of P-selectin, an 
α-granule membrane protein, on the plasma membrane was measured by flow cytometry. 
Levels were found to be reduced by approximately 44% compared to Vps33bfl/fl control. A 
reduction in P-selectin platelet surface expression by flow cytometry could be indicative of 
several different platelet defects: a reduced number of α-granules, an α-granule secretion 
defect, or a reduction in P-selectin protein levels within the platelet. These defects are not 
mutually exclusive and the reason for P-selectin level reduction could be a combination of 
these. 
In vivo bleeding time test revealed that the mice did not suffer from a bleeding diathesis and 
aggregation experiments revealed no defect in aggregation or dense granule secretion when 
the platelets were stimulated with thrombin or collagen in stirred suspension. This suggests 
that fibrinogen is present within the platelet, as the platelets were washed twice for removal of 
all plasma proteins. Fibrinogen is required for platelets to aggregate in stirred suspension, as 
demonstrated by the use of fibrinogen-deficient mice (Suh et al. 1995) and in cases of 
afibrinoginemia (Xu et al. 2006).  
 [171] 
 
The most notable defect in platelet function was revealed by an in vitro shear assay, the most 
physiologically relevant assay for platelet aggregation. Platelet aggregates formed; however, 
when washing was carried out the platelets were removed indicating that the aggregates 
formed were not stable. The reason for this instability may be due to reduced VWF within the 
α-granules. The group of Dr  Shaun Jackson have demonstrated in shear assay tests using von 
Willebrands disease platelets, that platelets lacking VWF are unable to support platelet 
tethering and translocation under shear conditions, with only 20% platelet tethering in 
comparison to control despite normal plasma VWF levels (Kulkarni et al. 2000). In addition 
thrombus formation was affected with only small thrombi formed when von Willebrands 
disease platelets were passed over a monolayer of control platelets (thrombus formation was 
restored to 50% with addition of purified VWF). This suggests that VWF contained within α-
granules is important for normal thrombus formation. As the Vps33bfl/fl-Pf4Cre mouse platelet 
VWF levels are reduced by approximately 51% they may not be able to as efficiently support 
platelet tethering, translocation and thrombus formation. 
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6.4.2 Development of the mouse model - a good model for ARC platelets? 
The aim of this work was to produce a mammalian ARC platelet model. Therefore a Pf4-Cre 
mouse was used in order to model the disease.  It has been concluded that although the 
Vps33bfl/fl-Pf4Cre mouse had a mild α-granule defect demonstrated by the shear assay, P-
selectin expression and immunoblotting, it has not allowed generation of mice that are a 
model for ARC syndrome platelets. This may be due to the cre recombinase transgene 
selected, which is discussed in section 6.4.3. 
ARC patients have a severe bleeding diathesis due to most platelets being devoid of platelet 
α-granules. The Vps33bfl/fl-Pf4Cre mouse showed no such bleeding diathesis in bleeding time 
tests. Morphologically, Vps33bfl/fl-Pf4Cre mice do not resemble ARC platelets. ARC platelets 
are typically large and most platelets lack α-granules (Lo et al. 2005). Compared to control 
platelets, there was only a marginal increase of 4.4% in mean platelet volume in Vps33bfl/fl-
Pf4Cre platelets, and ultrastructural analysis revealed that α-granules are present if at slightly 
reduced numbers. The α-granule protein deficiency seen in ARC patients by immunoblotting 
indicates that PF4 and VWF are markedly reduced if not absent (Lo et al. 2005). In contrast, 
Vps33bfl/fl-Pf4Cre platelets showed reductions of approximately 56% and 51% in PF4 and 
VWF respectively, indicating only a partial defect. 
 
6.4.3 Why a mild phenotype in Vps33bfl/fl-Pf4Cre platelets? 
Recently it has been identified that α-granules are heterogeneous and that platelets contain 
different subsets of these granules, a controversial topic in the field of platelets. α-granules 
have been found to contain VEGF, a pro-angiogenic molecule, and endostatin, an anti-
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angiogenic molecule (Italiano et al. 2008). It was shown that they appear to be in different α-
granules and the secretion of these granules is different depending on the agonist used. One 
hypothesis for the partial α-granule defect observed may be that in mice that only one subset 
of α-granules is affected by removal of Vps33b.   
A more likely explanation for a partial defect may be the nature of the Pf4-Cre recombinase 
transgene. When testing the efficiency of Cre-mediated excision, Tiedt et al found that the 
Pf4-Cre x integrin β1fl/fl mice still had reduced but detectable levels of integrin β1 (Tiedt et al. 
2007). As Vps33b likely plays a role in α-granule synthesis in megakaryocytes, it may be that 
there is sufficient Vps33b produced in Vps33bfl/fl Pf4-Cre megakaryocytes for the formation 
of α-granules before the pf4 promoter is activated and the Cre recombinase can carry out its 
function. Work has now begun on using an inducible cre, CreERT2 to remove Vps33b at an 
earlier timepoint in megakaryocyte development. 
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CHAPTER 7 – DISCUSSION 
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7.1 Development of an ARC-LOVD database provides a central resource for researchers 
and clinicians 
An ARC-LOVD database has been developed to provide a central resource for ARC, allowing 
easy access to a central log of updated information, and to provide the opportunity to share 
data. It is the hope that as data is added, opportunities for epidemiological investigations and 
meta-analysis will increase. The identification of a range of phenotypic severity in ARC 
underlines the importance of such a database to help accurately advise patient families on 
prognosis. In addition, advances in knowledge of ARC pathogenesis and clinical course may 
lead to novel therapies and improved management of patients with ARC.  
 
7.2 Mutation analysis in VPS33B and VIPAR identifies a genotype-phenotype 
correlation 
For the first time patients with attenuated ARC phenotype have been identified and 
characterised as compound heterozygotes. Patients with attenuated phenotype have a common 
splice site mutation, VPS33B(c.1225+5G>C) which results in truncated VPS33B. VPS33B 
and VIPAR have previously been shown to interact (Cullinane et al. 2010), and this work 
demonstrates that in severe ARC syndrome mutations this interaction is disrupted, suggesting 
that VPS33B-VIPAR interaction is necessary for correct cellular functioning. VPS33B and 
VIPAR have been shown to co-localise with RAB11A positive endosomes (Cullinane et al. 
2010). In keeping with this finding, ultrastructural analysis confirmed that VPS33B and 
VIPAR co-localised on endosome-associated tubular-vesicular membranes also positive for 
transferrin receptor. It was noted that the attenuated VPS33B(c.1225+5G>C) and VIPAR 
remain able to interact but form cytoplasmic aggregates and no longer associate with 
membranes. It suggests that VPS33B-VIPAR interaction is necessary but not sufficient for its 
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correct cellular functioning, and that correct cellular localisation of the complex is also 
required. 
The yeast HOPS and CORVET subunit composition is well defined (Seals et al. 
2000b)(Peplowska et al. 2007) and the organisation of these subunits have recently been a 
topic of great interest. Work by Ostrowicz et al. and Plemel et al. have led to models of HOPS 
subunit organisation (Ostrowicz et al. 2010)(Plemel et al. 2011), with Vps18 and Vps11 
central to the interactions of the remaining subunits, and Vps33 interacting with these proteins 
via Vps16. At present the metazoan HOPS complex composition and structure is unclear. Zhu 
et al 2009 reported that Spe-39 (VIPAR homologue) in C. elegans interacted with both 
Vps33a and Vps33b (Zhu et al. 2009). Cullinane et al. and Pulipparacharuvil et al.  found that 
Vipar interacted with Vps33b but not Vps33a in HEK293 cells and Drosophila respectively 
(Pulipparacharuvil et al. 2005)(Cullinane et al. 2010). Work in this thesis is insufficient to 
determine the likely composition of the metazoan HOPS complex, however, results suggest 
that VIPAR may interact with VPS18 only in the absence of VPS33B. This suggests that the 
VPS33B-VIPAR complex is unlikely to be involved in direct HOPS interaction in a wild-type 
situation.  
It has been shown that patient mutations disrupt the interaction between VPS33B and VIPAR. 
However, it is not known how these two proteins interact. Future experiments should include 
the cloning of truncated VPS33B and VIPAR constructs. Co-transfection and subsequent co-
immunoprecipitation experiments with these constructs will help map the regions required for 
their interaction. Additionally, producing purified VPS33B and VIPAR in complex, 
crystallisation of these proteins could help identify how the proteins interact, and may allow 
more accurate prediction of how patient mutations would disrupt the structure. The 
recombinant proteins could be used for pull-down experiments to identify possible interacting 
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partners by mass spectrometry. This approach would help to identify the downstream 
pathways affected in ARC syndrome for further investigation.  
 
7.3 Vps33b and its homologue, Vps33a, are necessary for murine development 
Vps33a metazoan models have reported varying effects on development. In Drosophila, 
carnation is lethal at second instar stage (Sevrioukov et al. 1999). In contrast, the buff mouse 
with missense mutation in Vps33a, appear to develop normally and live to adulthood (Suzuki 
et al. 2003). In concordance with the findings in Drosophila, it has been determined that 
Vps33a is also required for murine development, and that a Vps33a deficiency results in 
embryonic lethality between E7.5 and E8.5. This highlights the importance of Vps33a in 
development and may help to explain why no mutations in human VPS33A have been 
discovered.  
In contrast to Vps33a, no Vps33b model organisms previously reported have displayed a 
lethal phenotype during development (Matthews et al. 2005)(Zhu et al. 2009)(Akbar et al. 
2011). By use of the ubiquitous Pgk-Cre recombinase it is shown that Vps33b is also required 
for murine development, and is also lethal at approximately E7.5-E8.5. Interestingly, the 
survival of ARC patients contradicts this finding. It suggests that humans are able to bypass 
lethality by a method that may only be postulated, for example by expressing alternative 
transcripts of VPS33B.  It may also be that VPS33A in humans can compensate for the 
absence of VPS33B during human development. 
At E7.5-E8.5 many important processes occur in murine development. In order to understand 
how Vps33a and Vps33b contribute to these processes full morphological analysis of embryos 
should be undertaken. Embryonic stem cells isolated from blastocysts of these mice could be 
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used to investigate pathways affected by Vps33a or Vps33b disruption, such as the trafficking 
of receptors required for signal transduction during development. 
 
7.4 Use of Alfp-Cre for removal of Vps33b from murine liver results in a suitable ARC 
phenocopy 
Intrahepatic cholestatic jaundice is a cardinal feature of ARC syndrome (Gissen et al. 2006). 
The molecular mechanism resulting in intrahepatic cholestasis is currently unknown. In this 
thesis, two liver specific Vps33b conditional knockout mice were developed using different 
Cre-recombinase transgenes in order to model the ARC liver. The mice with Alb-Cre 
recombinase transgene presented a more variable phenotype than those with the Alfp-Cre 
recombinase transgene, highlighting the importance of Cre-recombinase selection when 
considering the development of a disease model. The Vps33bfl/fl-AlfpCre mice present with a 
good ARC phenocopy with the apical proteins CEA and BSEP being mislocalised, as seen in 
ARC livers (Gissen et al. 2004)(Cullinane et al. 2010). Additionally the bile acid taurocholate 
is increased in the mouse, indicative of a defect in bile acid secretion. 
Morphological presentation of livers varies between ARC patients, as demonstrated by the 
original assumption that there were two different syndromes (Lutz-Richner & Landolt 
1973)(Nezelof et al. 1979). Bile duct paucity is observed in patients and Zebrafish models 
(Matthews et al. 2005)(Gissen et al. 2006). In contrast in the Vps33bfl/fl-AlfpCre mouse the 
reduced number of bile ducts was not detected so far. It has been suggested that bile duct 
formation is dependent on hepatocyte polarisation and correct apical trafficking of ABC 
transporters (Sakaguchi et al. 2008)(Wakabayashi et al. 2004). In mice it has been 
demonstrated that there is a compensatory mechanism for bile acid production when BSEP is 
absent (Wang et al. 2001), and may explain why the Vps33bfl/fl-AlfpCre does not show bile 
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duct paucity. Future experiments should include a supplemented diet cholic acid which I 
expect will induce a more severe phenotype. By feeding Vps33bfl/fl-AlfpCre mice a cholic acid 
diet, histological observations made in ARC patients’ livers such as giant cell transformation 
may be induced, in a response to increased conjugated hyperbilirubinaemia. Histological 
observations may be made with a wider variety of stains, a trichrome stain for example would 
indicate if there was fibrosis by inappropriate deposition of collagen. In addition, extraction 
and primary culture of hepatocytes from the liver of these mice using sandwich culture could 
therefore be used as a tool to investigate pathways affecting the trafficking in these cells by 
live cell imaging.  
 
7.5 A megakaryocyte and platelet specific Vps33b conditional knockout mouse results in 
a mild α-granule defect 
ARC platelets are large and agranular, and have been reported to be absent of α-granules (Lo 
et al. 2005). In contrast a mild α-granule defect, characterised by present α-granules at only a 
slightly reduced level, but reduced P-selectin levels (44%) by flow cytometry, reduced 
aggregate stability and reduced α-granule protein content (56% reduction of PF4 and 51% 
reduction of VWF) was identified in Vps33bfl/fl-Pf4cre mice. VWF deficiency and aggregate 
instability in the Vps33bfl/fl-Pf4Cre is consistent with the proposal that VWF stored within the 
platelet is necessary for stable aggregate formation under shear conditions (Kulkarni et al. 
2000). This may help to explain why ARC patients have a bleeding diathesis. 
A mild phenotype in the Vps33bfl/fl-Pf4Cre mice may be explained by the nature of the Cre-
recombinase transgene. Tiedtl et al. found detectable levels of their targeted protein, albeit at 
clearly reduced levels in cultured megakaryocytes. The suggestion was that it reflected a long 
half-life of their protein in megakaryocytes (Tiedt et al. 2007). This implies that although the 
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Cre-recombinase effectively reduces protein levels, excision may not occur early enough in 
the megakaryocyte to prevent the targeted protein from being produced. In the case of 
Vps33b, low levels of the protein may be sufficient for α-granule formation.  
 
7.6 Future Experiments 
The work presented provides many tools for the study of ARC syndrome and the proteins 
VPS33B and VIPAR. In addition to the further experiments discussed in sections 7.2-7.4, 
future experiments may include: 
• Development of an inducible Vps33b ubiquitous knockout mouse. This would allow 
the induction of Vps33b after E9.5 to circumvent embryonic lethality, and allow all 
cell types to be targeted. As a result a more complete mouse model of ARC syndrome 
may be obtained for study of Vps33b deficiency in all organs, gene therapy and drug 
treatment trials. 
• Platelet experiments should be repeated with the inducible Vps33b ubiquitous 
knockout mouse. Megakaryocyte precursors would express the Cre-recombinase 
allowing removal of Vps33b before the maturation to megakaryocytes. As a result a 
more accurate ARC platelet phenocopy may be observed due to the complete absence 
of Vps33b from megakaryocytes. 
 
7.7 Final thoughts 
Defining the roles of VPS33B and VIPAR is a complex undertaking. These proteins have 
wide reaching functions demonstrated by the severe phenotype and multiple systems involved 
in ARC syndrome. By identifying and modelling patient mutations, the requirement for 
VPS33B-VIPAR complex formation in correct cellular functioning has been established. By 
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developing mammalian models the requirement of Vps33b in murine embryonic development 
has been identified. This knowledge has allowed subsequent progression to tissue specific and 
temporal Vps33b removal in the mouse providing ARC models for development of gene 
therapy and drug treatments in the future with the aim to eventually aid progression to clinical 
trials. 
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APPENDIX 1 
 
Primer pairs for VPS33B sequencing 
Exon 
Forward primer Reverse primer 
Product Size 
1 CCTTCTCAGAACGAAGGGC GGAAGAAATGTGCATCCAATG 215 
2 CTGCGGAAGCTCATGTGAC TTGTTCATCAAAAGAAAAACTGC 196 
3 TCTTCGTGTCACACTTTGTGC AGATGAAAGGCAGACGTGC 202 
4 GAGACCTGTAGGGCAAATGG AGGGTCCTTATGGCCAAGG 237 
5 GCAGCTTCCCTGTTTCTAGC CCGGTCCTCAGTCCTGTTC 190 
6 TTGTCTTTCACTGGGTTCGG CCAGGAAAAGAAGGAGCTGG 276 
7 TTCCCTCTTAACGTGGAGC TGGTATTTCTAGCCCTCTGC 254 
8 CTAGGGCTAGCCACTTTCC CAGGGAAAACAGCGTCTGC 225 
9 GGAAGTATCACGTGGAAAGG TAGGGCTGAAAGATGACAGG 228 
10 AAGCTGCCCTTGGACATGC GTCCATCTTGCCAAGATGC 189 
11 GTAGGAGAAGTCCTCATTGG CCCACAGCCTGGTATAAGC 187 
12 GAACACCTGAGTACCCTTCC CTGAGGCAACAAAACAGAGG 217 
13 TGGTTTCTCGTGTCTGAGG GGAGTAATGGTCCTCTGGA 540 
14 AGAACCAGGAGTATGTCAGC TAGAAGCGTGGGCAGTAGC 156 
15-16 CCTGTTAGCATAGATGGCAGC TCACTTCTTCTGTCCCTAAGGC 378 
17 GTTCGTTGCTGGTTGATCTG TGCCCAATAACTGCCCTC 187 
18 TGACAGTACTAGATGCTCTTTGGAC ATGCTGCGTGTTGAGAGAAG 256 
19 CTGTCGTGTCCTGAATGGTG CTCCACAATGGAATGAACCC 212 
20 TTTAAAGGGTTAGGGAGCTGAG AAACATTGAGACACGCCAGG 239 
21 TGCTGTGCCCTTCCTTTCC AGGATCAGACCAGATTCAGC 246 
22 CCCTTCCTTTCCTAAGCCTG GCCCAGCTGACACTTTGTTAC 427 
23 TGGAGAGGCTCTATGGGTTG TGCATCTCACTGAGGAATGTG 211 
cDNA 1 CGGCCTTCTCAGAACGAA AGCCAATTTGTCAGCATTGA 409 
cDNA 2 GACCCCGCATCAAGAATATG GGAGCAAAGTGCTGTCACAA 489 
cDNA 3 GAAGGCCAGAGATTGGACAT TTCCTCAATGTAGCTGGTGCT 494 
cDNA 4 GCAGGATTTCCAGGAGCTAA CTTGGCCAGAGAACTGAAGG 370 
cDNA 5 TCACAGCCGTGGAGAGTAAA TGCTGTCGTCAGGAAAATGA 449 
cDNA 6 GCCTCATCTTGGTGGTGTTC AAAGTTGGAAGTGCGTGTCC 495 
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Primer Pairs for VIPAR sequencing 
Exon 
Forward primer Reverse primer 
1 CCAGAAAGGGGCAATGTATG GCCTAGTTACCCAGAATGCAA 
2 GAGCACCCTAGCCTTGTGTC TCTATCCCTGCCTAGGGACTC 
3 TGTCAAGGCTTTATTGTGCTAT GGACTTCCCTATCCATTTAAG 
4 CTTTAACCAAGCCTGGATGG GTCCCCATAACTCCCCAGAC 
5 GGAAGGAATGACAAGCAGGA GGAAAATCAAGCCAGGTAACA 
6 GGAGCGGGTATGCTGATAAA TTCCCTGTGTGAACAAGCTG 
7 TCCAGCAACAACAAAGGAATAAAGAA TGATTGGATTTTCAGAAACTAGTGA 
8 GGCATGACTCTGTGTTGGAA CGCCCTCAGAGAGTGATTT 
9 GGGAGACCAATTTCACACTTG TCCCTCAGAGTGCTTTGAAAC 
10 GGCACTCGATTTTGTGAGGT TGCCCAGCCTAGATTTCTGT 
11 GCATGGGAAGTTCAGTTAATCA CTTCCTGCCTATCCATTCCA 
12 ATGCTGGCGATTTGGTTTAG CCACGTGCAGAGCATAGAAA 
13 TTTTCTCCTGCCTCTACTCCA TTGTGCAATGAGAGTTTGTGG 
14 AGAGCTTGGGTGGTACTTGG CCCAAACTCATTCCTTTCCAA 
15 TTAAGCACCCCCATTGATGT AACCCTTCTGTCTCCCAAGG 
16 GTTGAGTGTGCCTGGCCTA GGGAAAACAAGAGCAGATCG 
17 TGTGCCTTATGGGTGTTTGA ACGGAGGACTCCCATTTCTT 
18 TGGGCAAAAAGAACCCTGTA CTGTCTCCTGAGCCTGCTG 
19 TGAGCCTTGTTTGTTGCAT TTTCACAGGCAGGAGAGGAG 
cDNA 1 CGCTGTCCTGAGAGGGAG 
 
CAGGAAGATACAGGTGAGGCTT 
 
cDNA 2 GGTAGATCCATGGCTTCCTG 
 
ATACTTCCCACAGGTTCCCC 
 
cDNA 3 TCGTGGATGATGATGACGAT 
 
AGCTTTTGGCAGGTGTGTCT 
 
cDNA 4 CCTACTCCCTGAGCAGCTTTT 
 
AACTGCAGTAATGACGTTTCCA 
cDNA 5 CCGCTCCTTACAGGACAAAC  
 
AATGGCAAACCAACACAGGT 
cDNA 6 ATTCAGGACCCTGACAAACG  
 
TCTACATCATTCCAGGCTCG 
cDNA 7 CCTGAAGAAGACATTTAAGATCCC 
 
ATTCTTCCATCGAATTTGCG 
cDNA 8 TTGATACCTACCGGGACCTG 
 
TGTCAAGAGTAGCTGGCACTG 
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Primers for genotyping of mice 
Gene/ 
transgene 
Forward Reverse Size 
Vps33b CCAACTGAATTGCTTGCTCAG GTGTGACTCAGTGATACAGC Wild-type 
~350bp 
Floxed 
~450bp 
Vps33b 
excised allele 
CCAACTGAATTGCTTGCTCAG GTCCTGGTTTGATCTCCTGC Cre + 
~1000bp 
Vps33a TCCTGCTCTTCCAGAG Ex 6R- 
GCATATGAGTGCAGTGACCAA 
Genetrap R- 
TCTAGGACAAGAGGGCGAGA 
Wild-type 
~200bp 
Genetrap 
~300bp 
Pgk-Cre F COMM- 
TCGTTGCATCGACCGGTAAT 
PGK F-GCGCATCCTCTTCCTC 
GACCAATGAAACGTGGGCG Wild-type 
~600bp 
Cre + 
~100bp 
Alb-Cre GTAGTTATTCGGATCATCAGCTA
CAC 
GCTGCCACGACCAAGTGACAGCA
ATG 
Cre + 
~400bp 
Alfp-Cre CCCGCAGAACCTGAAGATGTT CCTGATCCTGGCAATTTCGGC Cre + 
~200bp 
Pf4-Cre CCCATACAGCACACCTTTTG TGCACAGTCAGCAGGTT Cre + 
~400bp 
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Antibodies and dilutions used for immunoblotting 
Antibody Supplier Primary 
Dilution 
Secondary 
Dilution 
Primary 
Rabbit α-VPS33B Protein Tech 1/500 1/500 
Mouse α−β-actin Sigma 1/15000 1/20000 
Rabbit α-PF4 Accurate chemical 
and scientific group 
1/1000 1/1000 
Rabbit α-VWF Santa Cruz 1/500 1/500 
Secondary 
HRP-conjugated goat 
α-rabbit 
Dako   
HRP-conjugated 
rabbit α-mouse 
Dako   
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Antibodies and dilutions used for immunofluorescence microscopy 
Antibody Supplier Primary 
Dilution 
Secondary 
Dilution 
Primary 
mouse α-myc 9E10 Sigma 1/200 1/200 
Chicken α-BSEP Gift 1/300 1/200 
Secondary 
Goat α-chicken Alexa 
488 
Invitrogen   
Goat α-mouse Alexa 
633 
Invitrogen   
 
antibodies and dilutions used for immunohistochemistry 
Antibody Supplier Primary 
Dilution 
Secondary 
Dilution 
Primary 
Rabbit α-CEA Dako 1/100 1/100 
Mouse α-E-cadherin BD Transduction 
Laboratories 
1/100 1/100 
Mouse α-ZO-1 Invitrogen 1/100 1/100 
Chicken α-BSEP Gift 1/300 1/100 
Secondary 
Biotinylated goat α-
chicken 
Vector Labs   
Biotinylated goat α-
mouse 
Vector Labs   
Biotinylated goat α-
rabbit 
Vector labs   
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APPENDIX 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary figure 1. Co-immunoprecipitation of VIPAR with HOPS complex 
proteins. 
(A) HEK293 cells were co-transfected with HA-empty or HA-VIPAR and myc tagged 
VPS11, VPS18, VPS39 or VPS41.  Co-immunoprecipitation experiments revealed interaction 
between over-expressed VIPAR and HOPS complex proteins. More VPS18 than VPS11, 
VPS39 and VPS41 was pulled down.  Although these proteins were present in the lysates, 
none were pulled down together with HA-empty. 
(B) HEK293 cells were co-transfected with HA-empty or HA-VIPAR, YFP-empty or YFP-
VPS33B and myc-VPS18.  A co-immunoprecipitation experiment showed that VIPAR and 
VPS18 interacted when the over-expressed VPS33B was absent.  In presence of over-
expressed VPS33B substantially less VPS18 was pulled down. 
Work done by Andrew Cullinane 
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